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Abstract 
Many complementary approaches have been used to inactivate the HIV-1 nucleocapsid 
protein (NCp7) zinc finger for therapeutic use. The cysteine residues of NCp7 are some of the 
most nucleophilic of all zinc-bound thiolates found in proteins. Electron-rich metals such as 
Au(I) are particularly suitable for designing metal-based zinc ejectors because, as soft Lewis 
acid electrophiles, they have high affinity for Cys residues. Without the proper tridimensional 
folding granted by Zn coordination, NCp7 is inactivated and unable to further recognize specific 
nucleic acid sequences.  
A series of Au(I) complexes with the general structure [Au(L)(PR3)] (R=Et or Cy) was 
designed. The two aromatic residues in the structure of NCp7 (Phe16 and Trp37) are 
responsible for π-stacking with purine and pyrimidine bases found on RNA and DNA. The 
presence of these residues can be used for introducing an extra selectivity component in the 
designed compounds, as an aromatic L ligand can be used. We also examined for comparison 
the ‘standard” gold-phosphine compound auranofin which contains a thiosugar ligand 
coordinated to {Au(Et3P)}. The nature of the phosphine and the nature of L affect both the 
reactivity with the C-terminal NCp7 ZnF2 and the ‘full” NCp7 as well as the final coordination 
sphere of Au once incorporated into the protein. In this reaction, the first step is the electrophilic 
attack of the Au(I)-phosphine compounds on the Zn-coordinated residues, forming an 
heterobimetallic {R3PAu}-ZnF species.  Two alternative pathways open up from here on. In 
the most typical pathway, after Zn displacement the {R3PAu} moiety can remain coordinated 
to a Cys residue. Afterwards, the phosphine is lost and a Cys-Au-Cys gold finger (AuF) is 
obtained. In this mechanism, compounds with slower reactivity such as [Au(dmap)(Et3P)] allow 
us to probe the initial auration steps, with species as such as {Et3PAu}-apoNCp7 still being 
present. Longer incubation times or more reactive compounds such as the chloride precursors 
provide information on the final species, the gold finger itself.   In an alternative pathway, 
observed for the model compound auranofin, the {R3PAu} moiety coordinates to a His residue, 
and the final hypothetical AuF obtained from this pathway has Cys-Au-His coordination sphere. 
The Au(I-phosphine series had also its cytotoxic properties investigated. The compound 
[Au(dmap)(Et3P)]
+ demonstrated a cytotoxic selectivity >50 towards a tumorigenic T 
lymphoblast cell line (CEM) in comparison to a normal cell line (HUVEC). Compound 
[Au(dmap)(Et3P)]
+ caused apoptosis on the CEM cell line through a mechanism independent 
of p38 MAPK, as opposed to auranofin.  
  
Although Au(III) compounds are typically not very stable under biological conditions 
since Au(III) can be easily reduced and it has fast ligand exchange rates, many recent Au(III)-
containing compounds have been rationally designed by tailoring the ligands to stabilize 
Au(III). The Au(III) compounds evaluated so far as ZnF inhibitors undergo reduction to Au(I) 
with loss of all ligands, thus it is commonly accepted that the oxidation state of incorporated 
gold in AuFs is 1+. By handpicking the ligands, it is possible to fine tune the stability of Au(III) 
complexes, stabilizing the Au(III) oxidation state even in the presence of peptides with high 
cysteine content such as ZnFs. Here we explored the Au(III)(C^N) motif based on the 
organometallic compound [Au(2-bnpy)Cl2] (2-bnpy = deprotonated 2-benzylpyridine) in 
comparison to a series of Au(III) complexes with typical κ2N,N′ chelators (2,2’-bipyridine, 4,4’-
dimethyl-2,2’-bipyridine and 1,10-phenanthroline). The organometallic compound Au(2-
bnpy)Cl2 had a sui generis mechanism of zinc displacement, never reported before for any metal 
compound, which consists on the transfer of the 2-bnpy ligand to a Cys residue from the protein, 
leading to Au-catalyzed C-S coupling. 
Determining the actual coordination sphere of Au in the AuF obtained by interacting 
Au(I) and Au(III) complexes with ZnF proteins is an interesting challenge, and for that purpose 
we used two innovative approaches that allowed us to obtain structural information in solution. 
Travelling-Wave Ion Mobility (TWIM) coupled to Mass Spectrometry (MS) was used to 
evaluate the interaction of the Au(I) compound [AuCl(Et3P)] with two model ZnF proteins that 
differ on the Zn coordination sphere: NCp7 ZnF2 (Cys3His) and the human transcription factor 
Sp1 ZnF3 (Cys2His2). Furthermore, X-Ray Absorption Spectroscopy (XAS) was used in a 
“dual-probe” approach to monitor oxidation state, coordination sphere changes and geometry 
changes of both Au and Zn for the interaction of two series of compounds. In the first series, 
[AuCl(Et3P)] and auranofin were compared when interacting with NCp7 ZnF2 and Sp1 ZnF3. 
TWIM-MS and XAS data indicate that [AuCl(Et3P)] leads to the formation of a Cys-Au-His 
AuF when interacting with Sp1 ZnF3, as opposed to the {Et3PAu}-F species (observed by XAS) 
that evolves to the Cys-Au-Cys AuF (observed by TWIM-MS) identified for the interaction 
with NCp7 ZnF2.  Finally, XAS was used to compare the interaction of two [Au(dien)L]n+ 
compounds (dien = diethylenetriamine; L = Cl, n= 2; L=dmap, n=3) with the same two zinc 
fingers and demonstrated that [Au(dien)(dmap)]3+ retains the AuN4 coordination sphere and 
square planar geometry of Au(III) when interacting with NCp7 ZnF2, suggesting that the 
compound behaves as a non-covalent Zn ejector. MS data confirmed Zn displacement, and led 
to the identification of a non-covalent adduct between [Au(dien)(dmap)]3+ and the full-length 
NCp7 ZnF, supporting the non-covalent displacement hypothesis. 
  
Resumo 
Muitas abordagens complementares têm sido utilizadas para inativar a proteína zinc 
finger (ZnF) NCp7 do vírus HIV-1 para fins terapêuticos. As cisteínas que aparecem 
coordenados ao Zn no NCp7 fazem parte do grupo de resíduos mais nucleofílicos presente em  
ZnFs. Metais ricos em elétrons, tais como Au(I), são particularmente adequados para o desenho 
de complexos metálicos ejetores de zinco porque, como ácidos de Lewis moles, têm alta 
afinidade por resíduos de Cys. Sem a estrutura tridimensional adequada mantida pela 
coordenação tetraédrica do Zn, o NCp7 (e qualquer outro ZnF) é inativado e se torna incapaz 
de reconhecer sequências específicas de ácidos nucleicos. 
Uma série de complexos de Au(I) de estrutura [Au(L)(PR3)] (R = Et ou Cy) foi 
desenhada. Os dois resíduos aromáticos presentes na estrutura do NCp7 (Phe16 e Trp37) são 
responsáveis por interações do tipo π com purinas e pirimidinas de ácidos nucleicos. A presença 
desses resíduos permite a introdução de um componente de seletividade adicional nas estruturas 
dos compostos desenhados, já que ligantes L aromáticos podem ser usados. A auranofina, um 
composto ouro(I)-fosfina modelo que contém um tioaçúcar como ligante L, também foi 
avaliada por conter Et3P. A natureza da fosfina e do L afetam tanto a reatividade dos compostos 
com o NCp7 como também a esfera de coordenação final do Au incorporado à proteína. Nessas 
reações, o primeiro passo é o ataque eletrofílico dos compostos ouro(I)-fosfina ao resíduos 
coordenados ao Zn, formando uma espécie heterobimetálica {R3PAu}-ZnF. Duas vias 
alternativas se abrem a partir daqui. Mais comumente, após a ejeção do Zn a porção {R3PAu} 
permanece coordenada a um resíduo de Cys. Em seguida, há a perda da fosfina e formação do 
gold finger (AuF) de coordenação Cys-Au-Cys. Nesse mecanismo, compostos menos reativos 
como [Au(dmap)(Et3P)] permitem estudar as primeiras espécies formadas, como por exemplo 
{Et3PAu}-NCp7. Por outro lado, tempos de incubação mais longos ou a utilização de 
compostos mais reativos, como os precursores contendo cloreto, fornecem informações sobre 
as espécies finais destas reações (os próprios AuFs). Em uma segunda possibilidade, observada 
para a auranofina, {R3PAu} se coordena a um resíduo de His, levando a um AuF de esfera de 
coordenação Cys-Au-His. A série de compostos de ouro(I)-fosfina também foi investigada 
quanto ao potencial citotóxico. O composto [Au(dmap)(Et3P)]
+ apresentou seletividade >50 
contra a linhagem tumoral CEM (linfoblastoma de linfócitos T), em comparação à linhagem 
normal HUVEC (células endoteliais de cordão umbilical humano). Além disso, o composto 
[Au(dmap)(Et3P)]
+ causou apoptose na linhagem CEM através de um mecanismo independente 
de ativação de p38 MAPK, ao contrário do observado para auranofina. 
  
Embora compostos de Au(III) não sejam tipicamente estáveis em condições biológicas 
devido à facilidade de redução e à rápida troca de ligante, eles podem racionalmente desenhados 
pela escolha de ligantes que contribuam para a estabilização do estado de oxidação 3+. Os 
compostos de Au(III) avaliados até agora como inibidores de ZnF frequentemente sofrem 
redução a Au(I) com a perda de todos os ligantes, sendo comumente aceito que ouro(I) é 
incorporado à proteína  (AuF). Com os ligantes adequados, compostos de Au(III) podem se 
tornar estáveis mesmo na presença de peptídeos ricos em cisteína como ZnFs. O composto 
organometálico [Au(bnpy)Cl2] (bnpy = 2-benzilpiridina desprotonada) foi explorado em 
comparação a uma série de complexos de Au(III) com ligantes κ2N,N′ bidentados (2,2'-
bipiridina, 4,4'-dimetil-2,2'-bipiridina e 1,10-fenantrolina). O composto [Au(bnpy)Cl2] 
apresentou um mecanismo sui generis de ejeção de zinco, nunca antes relatado para qualquer 
composto metálico, que consiste na transferência do ligante bnpy para um resíduo de Cys da 
proteína alvo, levando a um acoplamento C-S. 
Determinar a esfera de coordenação do Au em AuFs obtidos pela interação de 
complexos de Au(I) e Au(III) com proteínas ZnF é um desafio interessante e, para esse fim, 
utilizamos duas abordagens inovadoras que permitem a obtenção de informações estruturais em 
solução. A técnica Travelling-Wave Ion Mobility (TWIM) acoplada à espectrometria de massas 
(MS) foi utilizada para avaliar a interação do composto de Au(I) [AuCl(Et3P)] com duas 
proteínas ZnF modelo que diferem quanto à esfera de coordenação do Zn: NCp7 ZnF2 
(Cys3His) e também o terceiro dedo do fator de transcrição humano Sp1 (Cys2His2). Além disso, 
a espectroscopia de absorção de raios X (XAS) foi utilizada em uma abordagem de "dupla 
sonda" para monitorar mudanças no estado de oxidação, esfera de coordenação e geometria do 
Au e do Zn em reações de compostos de Au(I) e Au(II) com ZnFs. Dois compostos de Au(I) 
([AuCl(Et3P)] e auranofina) foram comparados ao interagir com NCp7 ZnF2 e Sp1 ZnF3. Os 
dados de TWIM-MS e XAS indicam que o [AuCl(Et3P)] leva à formação de um AuF Cys-Au-
His ao interagir com Sp1 ZnF3, ao contrário da espécie {Et3PAu}-F (observada por XAS) que 
evolui para o AuF Cys-Au-Cys (observado por TWIM-MS) identificado na interação com 
NCp7 ZnF2. Finalmente, a técnica XAS demonstrou que o composto [Au(dien)(dmap)]3+ 
continua com a coordenação AuN4 após interação com NCp7 ZnF2, sugerindo que o composto 
se comporta como um ejetor de Zn não-covalente. Dados de MS confirmaram o deslocamento 
de Zn e a levaram à identificação de um aduto não-covalente entre [Au(dien)(dmap)]3+ e a 
proteína NCp7 completa, dando suporte à hipótese de ejeção não-covalente.  
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“an” ion peptide fragment observed by MS/MS and CID. Corresponds to a 
decarbonylated “bn” ion 
apopeptide  non-metallated protein 
ATD   Arrival Time Distribution 
“bn” ion peptide fragment observed by MS/MS and CID. Originate from the nth 
amino acid from the N-terminus.  
bipy   2,2’-bipyridine 
bnpy   2-benzylpyridine 
CCDC   Cambridge Crystallographic Data Centre 
CCS   Collision Cross-Section 
CEM T lymphoblast tumorigenic cell line, the associated disease is the acute 
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COSY   NMR experiment. Correlation Spectroscopy 
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DFT   Density Functional Theory calculations 
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One example of use is “AuF”, indicating that a Au ion is coordinated to 
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the protein.   
FP   Fluorescence Polarization 
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GAG core structural protein of HIV-1. After proteolytic processing, major 
viral proteins are obtained, such as the matrix (MA), capsid (CA) and 
nucleocapsid (NC). 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, an organic 
zwitterionic compound used as buffering agent 
HMBC NMR experiment. Heteronuclear Multiple Bond Coherence. 
HSQC NMR experiment. Heteronuclear Single-Quantum Coherence. 
HUVEC  Human Umbilical Vein Endothelial Cells 
IMS   Ion Mobility Spectrometry 
MS   Mass Spectrometry 
N-Ac-Cys  N-Acetyl-L-Cysteine 
NC   nucleocapsid 
NCp7    nucleocapsid protein 7 from HIV-1 
Full-length full-length nucleocapsid protein from HIV-1, comprising both the ZnF1 
and ZnF2 domains 
ZnF2  C-terminal ZnF domain of the nucleocapid protein from HIV-1 
Zn1F full-length nucleocapsid protein from HIV-1 containing Zn(II) in only 
one of its zinc finger domains 
Zn2F full-length nucleocapsid protein from HIV-1 containing Zn(II) in both 
zinc finger domains 
  
NEM   N-ethylmaleimide 
NMR   Nuclear Magnetic Resonance 
PDB   Protein Data Bank 
phen   1,10-phenantrholine  
ROS   Reactive Oxygen Species 
Sp1   human transcription factor, comprises three ZnF domains 
ZnF3  Third (C-terminal) ZnF domain of the human transcription factor protein 
Sp1 
TD-DFT  Time-Dependent DFT 
TWIM-MS  Traveling-wave Ion Mobility coupled with Mass Spectrometry 
XANES  X-ray Absorption Near Edge Structure 
XAS   X-ray Absorption Spectroscopy 
“yn” ion peptide fragment observed by MS/MS and CID. Originate from the nth 
amino acid from the C-terminus. 
ZnF   Zinc finger protein 
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Overview
Motivations
  
Zinc finger proteins were discovered recently, in 1982.1 The first representative of this 
class of proteins, know referred to as Transcription Factor III (TFIII) was identified by the study 
of Xenopus laevis oocytes. Zn binding was confirmed by X-ray absorption spectroscopy 
(XAS),2 an alternative technique to the classical single-crystal diffraction and NMR-based 
techniques. This research was pioneered by professor Aaron Klug, that combined the zinc-
binding information provided by XAS with the already known sequence of TFIII and came up 
with the idea of a finger-like structure, that established a new principle of nucleic acid 
recognition.  
Transcription factors are proteins involved in the process of converting, or transcribing, 
DNA into RNA. Transcription factors include a wide number of proteins, excluding RNA 
polymerase, that initiate and regulate the transcription of genes. One distinct feature of 
transcription factors is that they have DNA-binding domains that give them the ability to bind 
to specific sequences of DNA called enhancer or promoter sequences. Some transcription 
factors bind to a DNA promoter sequence near the transcription start site and help form the 
transcription initiation complex.3,4 Regulation of transcription is the most common form of gene 
control. The action of transcription factors allows for unique expression of each gene in 
different cell types and during development. 
Among the plethora of zinc fingers that have been discovered and studied so far, we 
chose the nuclecapsid protein (NCp7) from the human immunodeficiency virus (HIV-1) as the 
main protein target for the work discussed in this Thesis. One of the most remarkable structural 
and functional characteristics NCp7 is the presence of two -Cys-X2-Cys-X4-His-X4-Cys- zinc 
finger (ZnF) domains, typically found on nucleic acid binding proteins. The presence of ZnF 
domains is highly conserved among retroviruses5 and any mutation on the Zn-bound residues 
results in loss of biological function.6,7 On the infectious HIV-1, NCp7 appears closely and 
strongly associated to RNA on the viral core.8 The two major functions of NCp7 are RNA 
binding and viral encapsidation, but new evidence also suggests that NCp7 has a role in some 
other processes such as RNA dimerization, Gag-Gag interactions, membrane binding, reverse 
transcription and stabilization of the proteic complex pre-integration.5 The human transcription 
factor protein Sp1 (also known as specificity factor 1) was also investigated as a target, with 
the purpose of comparing the more reactive Cys2His2 ZnF motif with the Cys3His motif found 
in the structure of NCp7. The coordination sphere has also a direct effect on the zinc affinity of 
the protein, and the Cys3His motif was shown to bind zinc more tightly than the Cys2His 
motif.9,10 
  
Many complementary approaches have been used to inactivate the NCp7 zinc fingers 
for therapeutic use.11,12 In considering the zinc center as a target, an interesting suggestion to 
approach selectivity is that, based on the Lewis acid considerations for different zinc 
coordination spheres, zinc chelators may be effective for zinc coordination spheres with a labile 
catalytic site whereas electrophilic attack of zinc-bound thiolate may be more favored in cases 
of structural zinc where there are at least 2 Cys residues in the coordination sphere.13 This 
hypothesis to some extent reflects the historical situation where early attempts to inactivate the 
zinc center used compounds such as S-acyl 2-mercaptobenzamide thioesters.14,15 The cysteine 
residues on the NCp7 are some of the most nucleophilic of all zinc-bound thiolates in 
proteins.16,17 As such, they are substrates for alkylation by electrophiles such as maleimide and 
iodoacetamide.18 In cellular assays, N-ethylmaleimide (NEM) can inhibit retroviral infectivity 
in a concentration-dependent manner.19 Modification of cysteine residues by alkylating agents 
such as iodoacetamide, 4-vinylpyridine and acrylamide has also been used in mass 
spectrometric peptide mapping for protein identification.20 In this work, we make use of the 
Lewis acid electrophilic attack strategy, based on Au(I) and Au(III) coordination complexes. 
 
Part I Au(I) Complexes 
Chapter 1 Au(I)-phosphine series design 
  
Au(I)-phosphine 
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Introduction 
The zinc finger template is in general a ready source for metal ion replacement.21 Ions 
such as Co(II) and Cd(II) can be used as spectroscopic probes and it is axiomatic that metal-ion 
replacement may also result in inhibition of function due to alterations in tertiary structure when 
ions preferring square-planar geometry such as Pt(II) or Au(III) or linear geometry such as 
Au(I) replace tetrahedral Zn(II). Electron-rich metals such as Au(I) are particularly suitable for 
designing metal-based zinc ejectors because as thiophilic Lewis acid electrophiles they have 
high affinity for Cys residues. Without the proper tridimensional folding, NCp7 is inactivated 
and unable to further recognize specific nucleic acid sequences. This strategy is also interesting 
because it represents an alternative to the conventional reverse transcriptase HIV-1 inhibition 
widely available in the clinic. Few works have reported the zinc ejecting capabilities of Au(I) 
compounds. Larabee22 demonstrated the potential of aurothiomalate as a zinc ejector for the 
specificity factor Sp1 back in 2005. Despite the particularly suitable characteristics of Au(I) for 
designing zinc ejectors, our group was the first to report a series of Au(I) compounds rationally 
designed as potent zinc ejector.23  
Compounds of general structure [L-Au-A]n allow the modification of both the leaving 
ligand L and also the ancillary ligand A for fine-tuning the properties of the overall complex 
towards the desired biomolecular target. Phosphines and carbenes are particularly well suited 
to work as carrier (or ancillary) ligands when designing Au(I) complexes for they are able to 
form stable and strong bonds with Au(I) as well as good air and moisture stability of the formed 
Au(I) complexes.24,25The two aromatic residues in the structure of NCp7 (Phe16 and Trp37) 
are responsible for π-stacking with purine and pyrimidine residues on RNA and DNA.1,3,4 The 
importance of these residues in dictating reactivity can be explored by introducing aromatic co-
ligands with good π-stacking ability such as a purine or 4-dimethylaminopyridine (dmap) in the 
L position of [Au(L)(A)], leading to more efficient metal-based zinc ejectors.21 In this chapter 
we explore the basicity and steric hindrance of the phosphine as well as lability and donating 
properties of the co-ligand (N-heterocycle vs. Cl-) to design a series of Au(I)-phosphine 
complexes. This series of Au(I) compounds explores the analogy between the organic and the 
Lewis acid electrophiles, and we demonstrate that chemoselective auration is useful for probing 
the nucleocapsid topography. We also examined for comparison the “standard” gold-phosphine 
compound auranofin which contains a thiosugar co-ligand. The Au(I)-phosphine compounds 
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evaluated here are shown in Figure I-1.1, along with the structures of the zinc finger proteins 
selected as targets.  
 
Figure I-1.1. Designed gold(I) compounds (I-1, I-2, I-4 and I-5). Auranofin (I-3) was studied within the 
Et3P series due to structural similarities. Phosphine Tolman cone angle (in degrees) and pKa values are 
also given. Triphenylphosphine data (Ph3P) is also provided as comparison. Also shown are the 
structures of the full-length NCp7 zinc finger (with ZnF2 boxed)), highlighting the Zn-bound residues. 
Previous works have explored other classes of proteins as biomolecular targets for 
Au(I)-phosphine complexes. Glutathione-S-transferase was inhibited by auranofin.26 
[AuCl(Et3P)] was used for targeting the de novo designed coiled coil TRIL23C, binding to Cys 
residues.27 A series of Au(I)-triethylphosphine was shown to inhibit cytosolic and 
mitochondrial thioredoxine reductase.28 Bis(cyanoethyl)phenylphosphineAuCl was found to 
selectively inhibit lymphoid tyrosine phosphatase over other tyrosine phosphatases.29 
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Regarding specifically zinc finger proteins as targets, an Au(I)-triphenylphosphine with 
pyridylimidazole ligand was described to inhibit PARP-1 expression in A2780 cell extracts. 
Our group has also studied a series of Ph3PAuL (L=Cl or N-heterocycle) compounds, and we 
demonstrated that metalation of NCp7 ZnF2 happens with maintenance of the phosphine 
ligand.23  
Experimental 
Materials  
H[AuCl4], triethylphosphine (Et3P) were purchased from Acros. Tricyclohexylphosphine, 4-
dimethylaminopyridine (dmap), 2,2’-thiodiethanol and auranofin were obtained from Sigma-
Aldrich. Deuterated solvents are from Cambridge isotopes or Sigma-Aldrich. The target zinc 
finger proteins were obtained in their non-metallated forms (apo) from Invitrogen. Protein 
sequences: 
         10         20         30         40         50 
NCp7 ZnF2 KGCWKCGKEG HQMKNCTER 
full-length NCp7 MQRGNFRNQR KNVKCFNCGK EGHTARNCRA PRKKGCWKCG KEGHQMKDCT ERQAN 
Sp1 ZnF3 KKFACPECPK RFMSDHLSKH IKTHQNKK  
 
Synthesis 
Chloro(phosphine)gold(I). [AuCl(Et3P)] (I-1) was synthesized by an adaptation of a method 
already published.30 Summarizing, H[AuCl4] (0.50 mmol, 194 mg) was dissolved in 1.0 mL of 
distilled water and the resulting solution was cooled in an ice bath. 2,2’-thiodiethanol (1.17 
mmol, 117 L) was dissolved in 360 L of EtOH and added slowly (over ~4 hours, 10 L per 
addition) to the Au(III) solution. Throughout the addition, the solution changes from yellow 
(Au(III)) to colorless (Au(I)) and the brown-orange byproduct was filtered off. Et3P was 
dissolved in 360 L of EtOH and the resulting solution was cooled in freezer and then added to 
the Au(I) solution. A white crystalline solid was obtained immediately. The stirring was carried 
for further 30 minutes and the solid was isolated by filtration and purified by recrystallization 
from water/EtOH (1:1). Anal. Calc. for (C6H15AuClP) (%): C (20.56), H (4.31); Found (%): C 
(20.58), H (4.22). [AuCl(Cy3P)] (I-4) was synthesized following the same procedure described 
for [AuCl(Et3P)]. Anal. Calc. for (C18H33AuClP) (%): C (42.16), H (6.49); Found (%): C 
(41.62), H (6.04). 
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[Au(dmap)(Cy3P)]+ (I-5) was synthesized following the procedure previously reported by us 
for [Au(dmap)(Ph3P)]
23, but starting from [AuCl(Cy3P)]. Anal. Calc. for 
[Au(dmap)(Cy3P)](NO3), C25H43AuN3O3P (%): C (45.39), H (6.55). Found (%): C (44.19), H 
(6.02). The compound [Au(dmap)(Et3P)]+ (I-2) is light-sensitive in the solid state, but stable 
in solution. Many different methods were attempted to isolate the solid product, but it 
decomposes by reduction. In order to characterize this compound, the synthetic procedure was 
carried out in solution. For 1H NMR and 31P NMR experiments, 1 eq of the chloride precursor 
(1) and 1 eq. solid AgNO3 were mixed in deuterated acetonitrile. The suspension was stirred 
for 1 hour and the AgCl that precipitates was removed with a syringe filter. To the remaining 
solution 1 eq of dmap was added. The same procedure, using non-deuterated acetonitrile, was 
used for preparing the compound for MS assays. 
1H NMR data for compounds I-1, I-2, I-4 and I-5 are provided in Figure AI-1.1. 
NCp7 (ZnF2 and “full”) and Sp1 preparation. An adequate amount of apo-peptide was 
dissolved in water, followed by addition of 1.2 zinc acetate per zinc-binding domain mol/mol. 
The pH was adjusted to 7.2-7.4 using a diluted NH4OH. The solution was incubated for 2 h at 
37 °C prior to any other experiments. The ZnF formation was confirmed by circular dichroism 
and mass spectrometry. The overall CD profile and species distribution in MS were in 
agreement with data previously reported for all ZnFs studied here. Representative mass spectra 
of NCp7 ZnF2 (Figure AI-1.2), “full” zinc finger (Figure AI-1.3) and Sp1 F3 (Figure AI-1.4) 
are provided in Part I – Appendix 1.  
 
Ligand scrambling evaluation 
31P NMR 
A 10 mmol L-1 solution of compounds I-1 to I-5 were prepared in deuterated acetonitrile. 31P 
NMR spectra were recorded with 256 scans at 20, 27, 34, 41 and 48 °C.  
UV-Vis 
The [AuCl(Cy3P)] (4.3 x 10
-4 mol L-1) and [Au(dmap)(Cy3P)]
+ (1.7 x 10-4 mol L-1) solutions 
were prepared in acetonitrile. UV-Vis spectra were recorded in an HP 8453 spectrophotometer 
equipped with a diode array detector. The temperature was set to 20, 27, 34, 41, 48 and 55 °C 
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using a Peltier unit. After reaching 55 °C and acquiring the respective spectra for compounds 4 
and 5, the temperature was returned to 20 °C and the spectra were recorded once again.  
 
Interaction with Model Biomolecules 
Ligand displacement induced by N-acetyl-L-cysteine (N-Ac-Cys) 
NMR. 400 µL of a 10 mmol L-1 solution of each Au(I)-phosphine compound in CD3CN were 
mixed with 400 µL of a 10 mmol L-1 solution of N-Ac-Cys in CD3N. 
1H and 31P NMR spectra 
were acquired immediately after mixing and over time (after 1, 2, 24 and 96 hours) for each 
compound in the series. 
MS. A sufficiently small volume of a 14 mmol L-1 solution of each Au(I)-phosphine compound 
in acetonitrile was mixed with the same volume of a 14 mmol L-1 solution of N-Ac-Cys in 
water. Mass spectra were acquired immediately after mixing for each compound in the series. 
Tryptophan fluorescence quenching assay 
7.5 mmol L-1 stock solutions of the dmap-functionalized compounds (I-2 and I-5) were 
prepared. The quenchers were titrated into a cuvette containing 3.0 mL of 5 μmol L-1 solution 
of N-acetyl-tryptophan, from 1:1 up to 1:100 (N-Ac-Trp : quencher). Spectral window 
monitored: 300-450 nm, λex = 280 nm, detector voltage = 750 V, T = 20 °C, scan rate = 600 
nm/min. For the Stern-Volmer model, the linearized data was obtained at λmax 362.9 nm.  
 
Targeting NCp7 ZnF2 and the full-length NCp7 ZnF 
Circular Dichroism  
50 M samples of NCp7 ZnF2, apo-NCp7 F2, full-length NCp7 ZnF or apofull-length NCp7 
were used. For time-based measurements, 1.3 : 1 mol/mol of Au(I)-phosphine compound  per 
ZnF core were mixed and spectra were recorded immediately after mixing and over time (after 
1, 6 and 24 hours). For the concentration-dependent measurements, [Au(dmap)(Et3P)]
+ titrated 
into the ZnF solution in the molar ratio range ri=0.3–1.3. 
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Mass spectrometry 
1 mmol L-1 interaction products were obtained by mixing at room temperature a stock solution 
of the Au(I) complex with a ZnF stock solution (1:1 mol/mol Au complex per ZnF core in a 
water/acetonitrile mixture; the pH was adjusted to 7.0 with NH4OH if needed). The final 
solution was incubated for up to 24 h at room temperature. MS experiments were carried out 
on an Orbitrap Velos from Thermo Electron Corporation operated in positive mode. Samples 
(25 μL) were diluted with methanol (225 μL) and directly infused at a flow rate of 0.7 μL/min 
using a source voltage of 2.30 kV. The source temperature was maintained at 230°C throughout. 
31P NMR 
NCp7 ZnF2. 500 μL of a 0.3 mmol L-1 stock solution of NCp7 ZnF2 were mixed with 
compounds I-1 to I-5 dissolved in CD3CN (1.3 : 1 mol/mol of gold complex per zinc finger 
core). Reactions were monitored from t=0 up to 4 days. Spectra were recorded with standard 
phosphorus parameters and 256 scans.  
Full-length NCp7 ZnF. 375 µL of a 0.129 mmol L-1 stock solution of full-length NCp7 zinc 
finger were mixed with compounds I-1 to I-5 dissolved in acetonitrile (1.3 : 1 mol/mol  gold 
complex per zinc finger core). Reactions were monitored from t=0 up to 8 days. The final 
spectra, acquired after 8 days incubation, were recorded with standard phosphorus parameters 
and 256 scans.  
 
NCp7 (full) / SL2 (DNA) interaction and inhibition 
NCp7 and SL2 binding control experiment. A range of concentrations of NCp7 (aa 1-55) 
were mixed with 100 nM 3′-fluorescein-labeled hairpin SL2 DNA (sequence 
GGGGCGACTGGTGAGTACGCCCC). Samples were prepared in a 96-well black, low-
binding microplate (Greiner), with total a volume of 50 µL each, containing                                  
1.25 mmol L-1 NaCl, 0.125 mmol L-1 HEPES at pH 7.2. Fluorescence polarization (FP) 
readings were recorded immediately on Beckman Coulter DTX880 plate reader. 
Inhibition of NCp7-SL2 binding experiment. The compounds at various concentrations were 
incubated with 5 µmol L-1 full-length NCp7 ZnF for 1 h followed by addition of SL2 DNA 
(final concentration of 100 nmol L-1). Samples were prepared in a 96-well black, low-binding 
microplate (Greiner), with a total volume of 50 µL each, containing 1.25 mmol L-1 NaCl, 
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0.125 mmol L-1 HEPES at pH 7.2. Fluorescence polarization (FP) readings were recorded 
immediately on Beckman Coulter DTX880 plate reader. The full-length NCp7 ZnF 
concentration was chosen from the protein-SL2 binding experiment such that 90% of SL2 was 
bound. FP readings were recorded immediately after addition of the SL2 DNA on Beckman 
Coulter DTX880 plate reader.  
Results and Discussion 
Ligand scrambling assessed using variable temperature experiments 
Ligand scrambling has been extensively reported for Au(I)-phosphine complexes,23,31,32 
so we dedicated some attention to evaluate what is the influence of this phenomenon in our 
system. The following reaction can take place in solution, and justifies some of the major 
species observed in the mass spectra of the Au(I)-phosphine compounds: 
 
𝟐[(𝑹𝟑𝑷)𝑨𝒖𝑳]
+ → [(𝑹𝟑𝑷)𝟐𝑨𝒖]
+ + [𝑨𝒖𝑳𝟐]
+ 
 
The extent of ligand scrambling depends on intrinsic (steric hindrance and basicity of 
phosphine, as well as nature of the co-ligand) and extrinsic (polarity of the solvent, ionic 
strength of the medium) factors.31 Here we evaluated only the intrinsic factors, with the extrinsic 
factors kept constant (acetonitrile as solvent, without added electrolytes). In order to evaluate 
to which extent this reaction is important in our systems, some temperature-dependent 
experiments were done: 31P NMR and UV-Vis spectroscopy. In both experiments, increasing 
the temperature shifts the equilibrium towards the products while decreasing the temperature 
can make the reaction return to its initial state.  
Spectral changes were observed when running temperature-dependent UV-Vis 
experiments (Figure AI-1.5). The major changes observed for [AuCl(Cy3P)] happen with the 
bands centered at 236 and 241 nm. Coalescence and intensity increase were observed with 
temperature increase. For [Au(dmap)(Cy3P)]
+, the presence of a pyridine derivative ligand was 
also useful for assessing the system using UV-Vis spectroscopy. The band centered at 216 nm 
increased in intensity with temperature increase, while the ligand-related transition at 282 nm 
had an intensity decrease. For both compounds, returning the temperature to 20 °C led to 
identical spectra as the ones acquired initially at 20 °C. Furthermore, isosbestic points were 
identified with the temperature increase for [AuCl(Cy3P)] and [Au(dmap)(Cy3P)]
+ (at 242 and 
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260 nm respectively). That is indicative that an equilibrium is taking place in solution, 
consistent with the ligand scrambling reaction proposed. 
The 31P chemical shift of compound [AuCl(Et3P)] suffers a larger temperature effect 
(Figure AI-1.6, Δδ of 0.37 ppm) when compared to [AuCl(Cy3P)] (Figure AI-1.7, Δδ <0.01 
ppm). The co-ligand L also plays a role on the ligand scrambling reaction. The compound 
[Au(dmap)(Cy3P)]
+ underwent a slightly more prominent phosphorus signal shift (Figure AI-
1.8, Δδ of 0.457 ppm) with the temperature increase than its chloride precursor. Combining the 
data acquired by both techniques, it is possible to affirm that ligand scrambling happens to only 
a small extent in our compounds. 
 
Interaction with model biomolecules 
N-Ac-Cys was used as model for the interaction of Au(I)-phosphine series with sulphur-
containing proteins. The interaction was followed by MS and 31P NMR.  
For the chloride precursors (compounds I-1 and I-4) a sulphur-bridged [R3PAu-(N-Ac-
Cys)-AuPR3] species appears as the most abundant peak. These species appear at 792.13 and 
1116.42 m/z respectively for compounds I-1 and I-4 (Figure AI-1.9 and Figure AI-1.11). 
Simple chloride replacement by N-Ac-Cys is also observed for compound I-4 (Figure AI-1.11), 
at 640.23 m/z corresponding to [Cy3PAu-(N-Ac-Cys)]. A trinuclear gold species is observed 
for I-1 after 10 minutes incubation with N-Ac-Cys, at 1151.13 m/z corresponding to [Au3(N-
Ac-Cys)2(Et3P)2]
+, but this species is no longer present after 24 hours incubation (Figure AI-
1.9B). For the dmap-functionalized compounds (I-2 and I-5), as opposed to the Cl precursors, 
unreacted [R3PAu]
+ species are observed. When compound I-2 interacts with N-Ac-Cys (Figure 
AI-1.10), the ligand scrambling bisphosphine [Au(Et3P)2]
+ product is the most abundant peak, 
at 433.14 m/z. Simple ligand replacement [Et3PAu-(N-Ac-Cys)]
+ and the S-bridged species 
[Et3PAu-(N-Ac-Cys)-AuPEt3]
+ are also observed. For compound I-5 (Figure AI-1.12), the most 
abundant Au-containing peaks correspond the unreacted [Cy3PAu]
+ species and also to the 
bisphosphine compound [Au(Cy3P)2]
+ at 757.42 m/z. The presence of the unreacted [R3PAu]
+ 
peaks are indicative of a slower reaction rate for compounds I-2 and I-5 when compared to the 
chloride precursors I-1 and I-3.  
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When I-1 and I-4 were mixed with N-Ac-Cys under the experimental conditions 
described for the 31P NMR experiment, precipitation was observed immediately upon mixture 
(concentrations were higher than that used for the MS experiments previously described). This 
can be explained by the possible polymeric nature of the product, given the sulphur-bridged 
bimetallic species observed for those compounds by MS. Furthermore, the Au(I)(N-Ac-Cys) 
compound was synthesized before and it is insoluble in most common solvents, being slightly 
soluble only in dmso.33 On the other hand, when compounds I-2 and I-5 were mixed with N-
Ac-Cys, the product remained in solution allowing us to further characterize the system. For 
the interaction of [Au(dmap)(Et3P)]
+ with N-Ac-Cys, a shift in the phosphorous signal was 
observed from 30.05 to 47.24 ppm, while for [Au(dmap)(Cy3P)]
+ the shift was from 51.82 to 
57.87 ppm (Figure AI-1.13). The downfield shift is consistent with dmap replacement by a 
sulfur-donor.  
In order to first explore the π-stacking capabilities of the dmap-functionalized 
compounds (I-2 and I-5), a tryptophan fluorescence quenching assays was performed. Using 
the Stern-Volmer model (Figure AI-1.14), the association constants (KSV) obtained for 
[Au(dmap)(Et3P)]
+ and [Au(dmap)(Cy3P)]
+ were 4.0 x 105 and 6.2 x 105 respectively. The 
straight-line shape of the Stern-Volmer plots for both systems is indicative of pure static 
quenching, as expected for an interaction based on π-stacking. This data models the first step 
of association between compounds I-2 and I-5 and a tryptophan-containing protein, as NCp7. 
 
Targeting NCp7 (ZnF2) 
31P NMR  
The reaction of NCp7 (ZnF2) with the different gold(I) compounds was followed over 
time by 31P NMR spectroscopy. Phosphorus NMR is a technique sensitive to nature of the L 
ligand in a R3P-Au-L compound. When interaction with a biomolecule, His vs. Cys 
coordination can be easily distinguished by 31P NMR. When a Cl or N-heterocyclic ligand is 
replaced by sulfur, deshielding is often observed on the 31P signal. Table I-1.1 summarizes the 
data obtained when targeting NCp7 (ZnF2). 
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Table I-1.1. 31P NMR peaks summary for the reaction products identified after the interaction of Au(I)-
phosphine compounds with NCp7 ZnF2 and ‘full’ NCp7. 
Compound 
δ 31P / ppm 
Reagent NCp7 ZnF2 products (Δδ) “full” NCp7 product (Δδ) 
[AuCl(Et3P)] 33.63 43.04 (9.41); 49.62 (15.99) 47.28 (13.65) 
[Au(dmap)(Et3P)]
+ 30.05 46.96 (16.91) 47.28 (17.23) 
Auranofin 39.05 43.04 (3.99); 34.67 (-4,39) 39.17 (0.12); 32.40 (-6.65) 
[AuCl(Cy3P)] 55.42 56.54 (1.12); 59.80 (4.37) 64.12 (8.70) 
[Au(dmap)(Cy3P)]
+ 51.82 57.22 (5.40) 64.11 (12.29) 
N-Ac-Cys products: [Au(dmap)(Et3P)]+ 47.24 ppm; [Au(dmap)(Cy3P)]+ 57.67 ppm 
 
After reaction with NCp7, compounds I-1, I-2, I-4 and I-5 presented a downfield shift 
in the phosphorus signal (Figure I-1.2), indicative of Cys-binding. Two phosphorous-containing 
species were observed for the chloride precursors [AuCl(Et3P)] and [AuCl(Cy3P)], indicating a 
fast reaction rate and lack of selectivity. On the other hand, the dmap-functionalized compounds 
formed a single phosphorous-containing signal, which is indicative of a slower reaction rate 
with the target protein as consequence of replacement of the labile ligand chloride by the 
stronger sigma donor dmap.  
Auranofin, on the other hand, has a unique behavior among the compounds studied here. 
A more shielded phosphorous signal appears upon interaction with NCp7, indicative of a 
possible His-binding. 
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Figure I-1.2. 31P NMR spectra of the reaction product obtained after incubation of NCp7 ZnF2 with 
Au(I)-phosphine compounds for 6 hours. (1) [AuCl(Et3P)], (2). [Au(dmap)(Et3P)]+, (3) auranofin, (4) 
[AuCl(Cy3P)] and (5) [Au(dmap)(Cy3P)]+. 
 
ESI-MS 
The ESI-MS spectrum of the reaction between compound [AuCl(Et3P)]
+
 and NCp7 
(ZnF2) immediately upon incubation shows a number of Au-peptide adduct peaks (Figure I-
1.3A). The presence of the {(Et3P)Au} moiety bound to peptide, as indicated by 
31PNMR data, 
is confirmed by the presence of major peaks attributed to Au2(Et3P)-apoNCp7 and the oxidized 
Au(Et3P)-apoNCp7 species, caused by zinc displacement, along with free peptide (apoNCp7) 
and Au(Et3P)-NCp7 ZnF2. The most prominent peaks are those at 828.62 (3+) and 1242.43 
(2+) corresponding to the Au-ZnF species while the AuF (Au-apoF) species are also observed 
as minor species. At longer reaction times (2, 6 and 24 hours), the spectra are quite similar, 
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indicating the reaction between [AuCl(Et3P)]
+ and NCp7 (ZnF2) happens very fast. A different 
situation occurs for the dmap derivative, [Au(dmap)(Et3P)]
+ (compound I-2) where the auration 
of peptide is much slower. Immediately upon incubation with NCp7 (ZnF2), compound I-2 
remains unreacted and only ZnF signals are observed (Figure I-1.3B). Zinc displacement is only 
observed after 6 hours, with signals assigned to apo-peptide identified. Au incorporation into 
the structure of the protein is only observed after 24 hours. Signals assigned to [apoNCp7-
AuPEt3]
4+ at 630.51 and AuF3+ at 806.65 m/z were the very first Au-containing peptide species 
observed for this compound, clearly indicating the much slower reaction rate of 
[Au(dmap)(Et3P)] when targeting NCp7 (ZnF2). The presence of the thiosugar in the structure 
of auranofin (I-3) also slows down the reaction rate with NCp7 (ZnF2). For this compound, no 
Au adducts are observed immediately upon incubation but after 2 hours the species [NCp7-
Au(PEt3)]
3+ at 867.99 m/z was identified (Figure AI-1.15). Auranofin binding to HIV-2 
nucleocapsid protein from two different isolates was recently studied.34 Au(I) and Au(I)-Et3P 
adducts to the target peptides were observed after 1 hour of incubation. As time evolves, AuF 
signals became more abundant for both peptides evaluated. Futhermore, auranofin interaction 
with the model Cys2His2 zinc finger PYKCPECGKSFSQKSDLVKHQRTHTG was also 
recently reported.35 Auranofin was not able to displace Zn and no Au(I) adducts were observed. 
When the carrier ligand Et3P is replaced by Cy3P, a similar overall reactivity trend is 
observed. The Cl-containing precursor (compound I-4) is much more reactive than the dmap 
functionalized compound (I-5). On the other hand, the aurated species identified are slightly 
different. For [AuCl(Cy3P)]
+, immediately upon incubation the following Au-containing 
species and their respective m/z were identified: Au-ZnF3+ at 828.62, [oxidized apoNCp7-
{Au(Cy3P)}]
3+ at 900.39, [ZnF-AuCy3P]
3+ at 922.03, [apoF-Au2Cy3P]
3+ at 966.38 and Au-
ZnF2+ at 1242.43 (Figure I-1.3C). [Au(dmap)(Cy3P)] (I-5), as opposed to (I-2), reacts 
immediately with NCp7 (Figure I-1.3D), with a few Au-containing species appearing at t=0. 
Some examples are Au-ZnF3+ at 828.62, [oxiapoF-AuCy3P]
3+ at 900.39, [apoF-Au2Cy3P]
3+ at 
966.36 and Au-ZnF2+ at 1242.43. 
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Figure I-1.3. ESI-MS spectra (positive mode) for the reaction between NCp7 (ZnF2) and A. 
[AuCl(Et3P)], B. [Au(dmap)(Et3P)]+, C. [AuCl(Cy3P)] and D. [Au(dmap)(Cy3P)]+. A, C and D were 
obtained immediately after incubation. B was obtained after 6 hours of incubation. Reocurring species 
are color-coded across the spectra. 
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Based on the temporal evolution of Au-containing species, the following reactivity trend 
can be proposed for the Au(I)-phosphine series with NCp7 (ZnF2) based on ESI-MS data: 
 
 The most reactive compounds were the Cl-containing precursors, indicating that the 
lability of the co-ligand is the first aspect that needs control to fine tune the overall reactivity 
of the compounds. After that, the bulkiness of the phosphine ligands plays a role, with Cy3P-
containing compounds reacting faster than the Et3P-analogs. With respect to the electronic 
factor, Tolman36 has shown that Et3P and Cy3P have about the same electron donating 
capabilities, with Et3P being slightly more withdrawing. That can be better observed by 
comparing the Au-P and Au-Cl distances found in the structures of [AuCl(Cy3P)] and 
[AuCl(Et3P)] (CCDC entries BOPLIB10 and SATTEM respectively): Au–P 2.242 and 2.232 
Å, Au–Cl 2.279 and 2.306 Å. The electronic effect alone does not explain the reactivity 
observed, and for that reason a combination of good σ-donating capabilities and π acidity of the 
co-ligand dmap, in addition to the properties of Et3P might be the explanation for the low 
reactivity of [Au(dmap)Et3P]
+ compared to the other compounds synthesized here. The effect 
of the co-ligand is further observed in the case of auranofin, unique among the Au(I) compounds 
evaluated here since His-binding is observed and further confirmed based on MS/MS data 
(Figure AI-1.16).  
Circular Dichroism 
Circular dichroism is a useful spectroscopic technique that can be used to evaluate 
conformational changes caused by zinc displacement. NCp7 (ZnF2) characteristic CD profile 
has a negative signal centered around 205 nm, which is shifted to 200 nm upon zinc 
displacement. Furthermore, the most prominent change in the CD spectrum of the apo-peptide, 
when compared to NCp7(ZnF2), is the loss of the positive absorptions at ~190 nm and in the 
range 215-225 nm. As the CD profile of NCp7 (ZnF2) differs extensively from that of the apo-
peptide, CD can be used to follow the time-dependent zinc displacement caused by the reaction 
with gold(I)-phosphine compounds. 
 
[AuCl(Et3P)] = [AuCl(Cy3P)] (t=0) ≥ [Au(dmap)(Cy3P)]+ (t=0, few species) 
> auranofin (t=0, fewer species) > [Au(dmap)(Et3P)]
+ (24 hours) 
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All compounds evaluated in this study cause some degree of conformational change on 
NCp7 (ZnF2) secondary structure upon interaction. It is possible to observe a decrease in the 
intensity of the positive bands and a slight blue shift for the negative one when NCp7 is 
incubated with [AuCl(Et3P)], [Au(dmap)(Et3P)]
+, [AuCl(Cy3P)] and [Au(dmap)(Cy3P)]
+. 
These observations are indicative of major conformational changes that follow a time-
dependent mechanism. Analyzing the intensity of the positive band at 215-230 nm, 
[AuCl(Et3P)] seems to react significantly faster than the other evaluated compounds, followed 
by [AuCl(Cy3P)] (Figure I-1.4A and Figure I-1.4C respectively). This trend can be explained 
considering the lability of the Cl- ligand and also the cone angle of the phosphine ligand. Cy3P 
is bulkier compared to Et3P (Tolman cone angle of 170° vs 132°) so [AuCl(Cy3P)] is expected 
to react slower than [AuCl(Et3P)] considering the spatial approximation required for the 
electrophilic attack to take place. Both dmap analogs react slower than their chloride precursors, 
with [Au(dmap)(Et3P)]
+ reacting slower when compared to [Au(dmap)(Cy3P)]
+ (Figure I-1.4B 
and Figure I-1.4D, respectively), supporting the reactivity trend established based on MS data. 
Even after 1 hour, there is still some conformational retention as observed by the presence of 
the positive absorptions, which are not present anymore for [Au(dmap)(Cy3P)]
+ at this time 
point. Further analyzing the intensity of the positive band at 215-230 nm, it is possible to 
observe that the dmap-containing compounds seem to be less reactive compared to the chloride 
precursors. Among all the compounds evaluated in the phosphine series (I-1, I-2, I-4 and I-5), 
[Au(dmap)(Et3P)]
+ is the least reactive. Auranofin, on the other hand, follows a slightly 
different trend (Figure I-1.4C) with the negative CD signal slightly shifted to red at early time 
points after addition of the compound. 
As a complementary measurement, [Au(dmap)(Et3P)]
+ was titrated into a NCp7 sample 
(50 M; ri=0, 0.3, 0.5, 0.8, 1.0 and 1.3) and CD spectra were acquired immediately after mixing. 
Figure I-1.4F shows a concentration dependent conformational change induced by 
[Au(dmap)(Et3P)]
+, with an isodichroic point at 198 nm. The positive band at 215-230 is 
maintained throughout the experiment and the presence of the isodichroic point suggests a 2-
species equilibrium in solution. Combining these two pieces of information, it is possible to 
suggest that the ZnF structure is not completely disrupted but some conformational changes are 
caused by auration.  
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Figure I-1.4. A-E Time-dependent CD spectra following the reaction between the indicated Au(I)-
phosphine compound and NCp7 C-terminal finger. (A-E: [AuCl(Et3P)], [Au(dmap)(Et3P)]+, auranofin, 
[AuCl(Cy3P)] and [Au(dmap)(Cy3P)]+ respectively). The titration of [Au(dmap)(Et3P)]+ into NCp7 
(ZnF2) was also followed by CD as shown in F. 
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Targeting the full-length NCp7 zinc finger 
The reactivity of the Au(I)-phosphine series was further explored by targeting the viral 
full-length NCp7 zinc finger. The full-length NCp7 ZnF relies on the cooperation between the 
two zinc finger domains, which appear linked by a highly basic sequence RAPRKKG, for 
recognizing specific nucleic acid sequences.  
31P NMR 
The interaction of the Au(I)-phosphine series with full-length NCp7 ZnF was first 
investigated by 31P NMR, using the same approach followed for NCp7 ZnF2. Figure I-1.5 
shows the spectra obtained for the reaction products after 8 days incubation at 37 °C. Figure 
AI-1.17 to Figure AI-1.21 compare the spectra obtained for the reaction products with NCp7 
ZnF2 and full-length ZnF for each compound and Table I-1.1 summarizes the data discussed 
here. 
 
Figure I-1.5. 31P NMR spectra for the reaction products obtained after incubation of full-length NCp7 
zinc finger with Au(I)-phosphine compounds for 8 days. (1) [AuCl(Et3P)], (2) [Au(dmap)(Et3P)]+, (3) 
auranofin, (4) [AuCl(Cy3P)] and (5) [Au(dmap)(Cy3P)]+. 
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The full-length NCp7 zinc finger has a different behavior when compared to ZnF2. A 
single 31P signal was identified for the reaction product of this protein with the designed Au(I)-
phosphine compounds. On the other hand, auranofin produced two product peaks. Auranofin 
also differs from the other compounds by being the only compound that leads to the formation 
of a more shielded 31P species upon interaction with the protein, in agreement with the data 
obtained for NCp7 ZnF2, and suggesting a His-binding. Furthermore, the 31P signals observed 
here do not perfectly match the ones observed when interacting the Au(I)-phosphine 
compounds with ZnF2. This is indicative that the phosphine ligand appears in different 
chemical environments when interacting with both targets (ZnF2 and “full” zinc finger). The 
only case where the chemical shift of the reaction products with both targets is almost identical 
is for [Au(dmap)(Et3P)]
+ (Figure AI-1.18), another evidence that a slower reaction rate guides 
the reaction towards the formation of most stable Au(I)-protein bond. 
ESI-MS 
The Cy3P series, comprising compounds [AuCl(Cy3P)] and [Au(dmap)(Cy3P)]
+, was 
selected for further investigation, now targeting the dinuclear full-length NCp7 zinc finger. The 
MS spectra obtained for the interactions are shown in Figure I-1.6.  
[AuCl(Cy3P)] reacts with full-length NCp7 zinc finger immediately upon incubation. 
Unreacted Zn2F is observed at t=0 in multiple charge states (8+, 7+, 6+). The bisphosphine 
compound [Au(Cy3P)2]
+ is also observed, at 757.43 m/z. Zn1F species are observed as well, in 
multiple charge states (10+, 9+, 8+). Only one aurated protein species is observed, the Cy3PAu-
Zn1F (8+ at 871.77, 7+ 996.03 m/z). After 6 hours the spectrum is dominated by apopeptide 
species (11+, 10+, 9+, 8+, 7+, 6+), with no Zn-containing species or L-Au-protein species 
observed. AuF appears as the only Au-containing peptide species, (8+, 7+).  
At t=0, the spectrum obtained for the interaction between [Au(dmap)(Cy3P)]
+ with full-
length NCp7 ZnF is very similar to that obtained for [AuCl(Cy3P)]. [Au(Cy3P)2]
+ appears as 
the most abundant peak. Unreacted Zn2F species are observed, as well as Zn1F species. 
Cy3PAu-Zn1F represents the only aurated protein species observed. On the other hand, a much 
more complex metallation profile was observed after 6 hours of incubation. The bisphosphine 
compound still appears as the most abundant species. A mixture of Zn2F (8+,7+), Zn1F (9+, 8+, 
7+) and apopeptide (8+, 7+, 6+) was observed. In terms of aurated species, AuF (8+, 7+, 6+) 
and the heterobimetallic Au-Zn1F (8+, 7+) species were identified. 
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Figure I-1.6. ESI-MS spectra (positive mode) for the reaction between the full-length NCp7 ZnF and A. 
[AuCl(Cy3P)] immediately after incubation, B. [AuCl(Cy3P)] after 6 h incubation, C. 
[Au(dmap)(Cy3P)]+ immediately after incubation and D. [Au(dmap)(Cy3P)]+ after 6h incubation. 
Reocurring species are color-coded. 
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Circular Dichroism 
The full-length NCp7 ZnF has a CD profile very similar to that observed for NCp7 
ZnF2, with a valley at 200 nm and a positive absorption region with a maximum at 218 nm. 
The interaction of the Cy3P series with full-length NCp7 ZnF was further investigated (Figure 
I-1.7). Interestingly, a quick reaction (at t=0) is observed for compound I-4, with an increase in 
intensity of the negative absorption at 200 nm. On the other hand, the dmap-functionalized 
compound I-5 induced slight changes on the positive band and has almost no effect on the 
negative band of full-length NCp7 ZnF, even after 24 hours incubation.  
 
Figure I-1.7. Time-dependent CD spectra for the reaction between the indicated Au(I)-phosphine 
compound and the full-length NCp7 ZnF. A: [AuCl(Cy3P)] and B: [Au(dmap)(Cy3P)]+). 
 
Interaction with Sp1 ZnF3 
The interactionof the Au(I)-phosphine series with Sp1 (ZnF3) was followed by mass 
spectrometry. Sp1 (ZnF3) was shown to be intrinsically more reactive than another zinc finger, 
the viral HIV-1 NCp7 (ZnF2). The compound [AuCl(Et3P)]
+ reacts immediately with Sp1 
(ZnF3), giving a clean spectrum containing AuF only (Figure I-1.8), with the species AuF6+ 
(594.96), AuF5+ (713.75), AuF4+ (891.93) and AuF3+ (1188.91) being the most abundant peaks 
in the spectrum and very few other peaks observed. This is indicative of a mechanistically well-
definied reaction of Zn displacement and Au incorporation. [Au(dmap)(Et3P)], opposed to what 
is observed when targeting NCp7 (ZnF2), also reacts fast with Sp1 (ZnF3). Many AuF-related 
species are observed as well, such as AuF6+ (594.96), AuF5+ (713.75), AuF4+ (891.93) and 
AuF3+ (1188.91). As opposed to [AuCl(Et3P)]
+
, the heterobimetallic species Au-ZnF
  is also 
observed for the interaction of [Au(dmap)(Et3P)] with Sp1 (ZnF3). To some extent, peptide 
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oxidation is also observed, given the presence of the oxidized species oxiF5+ (674.15) and 
oxiF4+ (842.44).  
 
Figure I-1.8. ESI-MS spectrum (positive mode) for the reaction between Sp1 (ZnF3) and A. 
[AuCl(Et3P)]+, B. [Au(dmap)(Et3P)]+, C. [AuCl(Cy3P)]+ and D. [Au(dmap)(Cy3P)]+ immediately upon 
incubation. 
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Auranofin (3) interacts with Sp1 (F3) producing a much wider variety of Au-containing 
species immediately after incubation (Figure AI-1.15). AuF species were identified, such as 
AuF6+, AuF5+, AuF4+ and AuF3+. Non-metallated peptide was identified, in the form of apoF6+, 
apoF5+ and apoF4+. Interestingly auranofin presented some reaction producs where the 
phosphine ligand remained coordinated to Au(I), as exemplified by species such as Et3PAuF
6+ 
(614.64), Et3PAuF
5+ (737.37) and Et3PAuF
4+ (921.46).  [AuCl(Cy3P)]
+ is less reative than  
[AuCl(Et3P)]
+ when targeting Sp1 (ZnF3), as unreacted ZnF was still present (Figure I-1.8), 
with some gold incorporation observed due to the presence of AuF peaks (AuF4+ and AuF3+). 
The reactivity of[Au(dmap)(Cy3P)] (5) is different when compared to the chloride precursor 
(4). No unreacted ZnF is observed, apo-peptide is present (apoF4+ and apoF3+), and gold is also 
incorporated (AuF4+ at 891.94 and AuF3+ at 1188.91 m/z). 
Full-length NCp7 zinc finger/SL2 DNA interaction inhibition 
The macromolecular interaction (binding) between biomolecules can be studied using 
fluorescence polarization (FP). This technique is based on the tumbling movement of molecules 
in solution in presence of polarized light. Larger molecules (or interacting systems) will retain 
the polarization for longer time due to slower tumbling. The binding between full-length NCp7 
zinc finger and SL2 DNA was studied by FP. The binding curve is shown in Figure AI-1.23. 
The Kd value was found to be 899 ± 46 nM, using a Michaelis-Menten / Hill model (n=1). The 
inhibition experiments were set up knowing the maximum binding conditions. Once the binding 
event was well characterized, inhibition experiments were set up. Figure I-1.9 shows the 
binding behavior of the full-length NCp7 zinc finger with SL2 in the presence of the Cy3P 
series, [AuCl(Cy3P)] (I-4) and [Au(dmap)(Cy3P)]
+ (I-5), and also auranofin as a representative 
compound of the Et3P series. As shown in Figure I-1.9, inhibition was only observed for the 
Cy3P series, while auranofin was not able to induce the same binding inhibition, as well as 
[AuCl(Et3P)] and [Au(dmap)(Et3P)]
+ (data not shown). The inhibition constants obtained using 
an exponential trendline for fitting the data obtained for [AuCl(Cy3P)] and [Au(dmap)(Cy3P)]
+ 
were of 28.6 and 22.0 µM, respectively. FP demonstrates the final outcome of the auration 
process, since the natural function of the full-length NCp7 zinc finger relies on its interaction 
with the viral RNA. SL2 DNA is a representative oligonucleotide for this interaction. The large 
{(Cy3P)Au} moiety seems to be required for the inhibition, since Et3P-containing compounds 
caused no significant inhibition (auranofin data, as an example, is shown in Figure I-1.9).  
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Figure I-1.9. Inhibitory effect caused by compounds [AuCl(Cy3P)] (blue) and [Au(dmap)(Cy3P)]+ 
(orange) on the interaction between the full-length NCp7 zinc finger and the SL2 DNA model DNA. 
The Et3P-containing series (here represented by auranofin, grey) had no inhibitory effect. Exponential 
trendlines, used for obtaining the inhibition constants, are also given. 
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Conclusions 
In this chapter we explored structural variations in the phosphine ligand for fine-tuning 
the reactivity of a series of Au(I) compounds designed for targeting zinc finger proteins. 
Properties of the phosphine such as steric hindrance and basicity of the phosphorous atom were 
evaluated. The more basic and less hindered Et3P as well as the bulkier Cy3P were selected for 
this work. The nature of the co-ligand was also evaluated. 4-dimethylaminopyridine (dmap) 
was selected as an alternative co-ligand based on its π-stacking properties, which can mimic the 
naturally occurring interaction between NCp7 and nucleic acids, adding an extra specificity 
property to the designed compounds. Auranofin, the commercially available and widespread 
Au(I)-phosphine-based metallopharmaceutical was included in this study given the structural 
similarities with the compounds discussed here.  
The replacement of Cl by dmap decreases the reactivity rate of the Au(I) compound 
dramatically, in terms of the temporal evolution of the aurated species identified by MS. The 
reaction products of compounds I-1 and I-4 with NCp7 ZnF2 yielded phosphines in more than 
one chemical environment, as observed by 31P NMR. One single 31P NMR signal was observed 
for the dmap functionalized compounds I-2 and I-5. When comparing the ancillary phosphines, 
Et3P-containing compounds seem to be in general less reactive than Cy3P-containing 
compounds. Slower reaction rate is often translated into higher metalation selectivity. 
Combining the effects of the phosphine and ligand L, [Au(dmap)(Et3P)]
+ (I-2) was the least 
reactive compound in the series when targeting NCp7 ZnF2, as characterized by CD, MS and 
31P NMR. Auranofin is unique, as observe by 31P NMR and MS/MS data, as it is the only 
compound that leads to Au-His species. Scheme I-1.1 summarizes the Au(I) incorporation 
mechanisms observed here. 
The interaction between the full-length NCp7 zinc finger with the model SL2 DNA 
sequence was also targeted. Inhibition was closely associated with the steric hindrance of the 
phosphine ligands. Cy3P-containing compounds (I-4 and I-5) were the only ones capable of 
inhibiting the biomolecular interaction, as evaluated by fluorescence polarization. Although the 
phosphine can be lost throughout the reaction, as evidenced by MS data, it still plays an 
important role in the inhibition mechanism. An overall proposed inhibition mechanism caused 
by Cy3-containing compounds is presented in Scheme I-1.2.  
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Scheme I-1.1. Au(I) incorporation into NCp7 ZnF2 (the same can be extended to the full-length NCp7 
zinc finger). The first step is the electrophilic attack of the Au(I)-phosphine compounds on the Zn-
coordinated residues, forming a {R3PAu}-ZnF species.  Two alternative pathways open up from this 
species. The final Au-peptide species depends on both the phosphine and the co-ligand L. A. Along with 
Zn displacement, the {R3PAu} moiety remains coordinated to a Cys residue and, after loss of the 
phosphine, a Cys-Au-Cys AuF is obtained. This is the most typical pathway, observed for compounds 
I-1, I-2, I-4 and I-5. B. An alternative pathway was observed for auranofin, where the {R3PAu} moiety 
coordinates to a His residue. The final hypothetical AuF obtained from this pathway would have a Cys-
Au-His coordination sphere. 
 
 
Scheme I-1.2. Mechanism of inhibition of the recognition of SL2 model DNA by the full-length NCp7 
ZnF caused by the Au(I)-phosphines compounds. Zinc displacement followed by Au(I) replacement 
leads to loss of secondary structure of the protein. The Au(I)-containing protein adducts caused by the 
series containing Cy3P are unable to recognize the model SL2 DNA. 
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Appendix 
1H NMR 
 
Figure AI-1.1. 1H NMR spectra of (1) [AuCl(Et3P)], (2) [Au(dmap)(Et3P)]+, (3) [AuCl(Cy3P)] and (4) 
[Au(dmap)(Cy3P)]+ in deuterated acetonitrile. 
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Mass Spectra of zinc fingers 
 
Figure AI-1.2. Representative mass spectrum of the HIV-1 nucleocapsid protein NCp7 (ZnF2). 
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Figure AI-1.3. Representative mass spectrum of the HIV-1 nucleocapsid protein NCp7 “full” zinc finger. 
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Figure AI-1.4. Representative mass spectrum of the human transcription factor protein Sp1 (F3). 
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Ligand Scrambling 
 
Figure AI-1.5. Temperature dependent UV-Vis data for [AuCl(Cy3P)] (A) and [Au(dmap)(Cy3P)]+ (B). 
The arrows indicate intensity changes as consequence of temperature increase. 
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Temperature δ / ppm FWHM / ppm FWHM / Hz 
20 °C 31.34 0.012 3.66 
27 °C 31.44 0.011 3.40 
34 °C 31.53 0.019 5.58 
41 °C 31.61 0.026 7.68 
48 °C 31.70 0.035 10.6 
Figure AI-1.6. Temperature effect on the 31P NMR signal of [AuCl(Et3P)]. Spectral parameters are given 
for each temperature evaluated. The spectrum acquired at the starting temperature (27 °C) is presented 
in bold, with the 31P signal getting further deshielded with temperature increase. 
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Temperature δ / ppm FWHM / ppm FWHM / Hz 
20 °C 53.95 0.009 2.63 
27 °C 53.95 0.010 2.94 
34 °C 53.95 0.011 3.36 
41 °C 53.95 0.013 3.84 
48 °C 53.96 0.017 5.24 
Figure AI-1.7. Temperature dependence on the 31P NMR signal of [AuCl(Cy3P)]. Spectral parameters 
are given for each temperature evaluated. The spectrum acquired at the starting temperature (27 °C) is 
presented in bold, with the 31P signal getting further deshielded with temperature increase. 
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Temperature δ / ppm FWHM / ppm FWHM / Hz 
20 °C 50.57 0.031 9.37 
27 °C 50.92 0.035 10.5 
34 °C 50.96 0.037 11.0 
41 °C 50.99 0.041 12.4 
48 °C 51.03 0.042 12.7 
Figure AI-1.8. Temperature dependence on the 31P NMR signal of [Au(dmap)(Cy3P)]+. Spectral 
parameters are given for each temperature evaluated. The spectrum acquired at the starting temperature 
(27 °C) is presented in bold, with the 31P signal getting further deshielded with temperature increase. 
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Interaction with model biomolecules 
 
  
Figure AI-1.9. Interaction of compound [AuCl(Et3P)] with N-Ac-Cys monitored by MS. Spectrum 
acquired A. immediately after incubation and B. after 24 hours. 
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Figure AI-1.10. Interaction of compound [Au(dmap)(Et3P)]+ with N-Ac-Cys monitored by MS. 
Spectrum acquired immediately after incubation. 
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Figure AI-1.11. Interaction of compound [AuCl(Cy3P)] with N-Ac-Cys followed by MS. Spectrum 
acquired A. immediately after incubation and B. after 24 hours. 
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Figure AI-1.12. Interaction of compound [Au(dmap)(Cy3P)]+ with N-Ac-Cys monitored by MS. 
Spectrum acquired immediately after incubation. 
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Figure AI-1.13. 31P NMR spectra of the reaction products of A. [Au(dmap)(Et3P)]+ and B. 
[Au(dmap)(Cy3P)]+ with N-Ac-Cys (1) immediately after mixing and (2) 24 hours after incubation. 
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Tryptophan fluorescence quenching: Stern-Volmer model 
By graphing the ratio between the fluorescence intensity of the system in the absence of 
the quencher (F0) by the fluorescence in presence of the quencher (F) as a function of the 
concentration of the quencher [Q], the association constant KSV can be obtained.  
𝐹0
𝐹
= 1 + 𝐾𝑆𝑉[𝑄] 
 
Figure AI-1.14. Tryptophan fluorescence quenching assay. Data presented for the dmap-functionalized 
compounds [Au(dmap)(Et3P)]+ (I-2) and [Au(dmap)(Cy3P)]+ (I-5). Data was treated using the Stern-
Volmer model. 
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Interaction with NCp7 ZnF2 
 
Figure AI-1.15 ESI-MS spectrum (positive mode) of the reaction between auranofin and NCp7 ZnF2 
obtained after 2h of incubation. 
r161026r01 #1-50 RT: 0.01-0.37 AV: 50 NL: 1.09E7
T: FTMS + p NSI Full ms [200.00-2000.00]
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
433.1494
679.1423
993.1941
717.0988
499.0785315.0585 763.3087
559.1001
1144.4604
867.9935
1395.23701111.9978
645.1553
912.3427 1176.4165
1525.9494
404.1087
1819.88011689.9301 1990.8885
[Z
n
F-
A
u
P
Et
3]
3+
ZnF3+
ZnF2+
o
xi
ap
o
F2
+
[AuPEt3]
+
[Et3PAuPEt3]
+
Part I – Appendix 1 | 64 
 
 
 
Figure AI-1.16. MS/MS of the species [Et3PAu-NCp7 (ZnF2)]2+ (1301.48 m/z; theoretical 1301.48 m/z) 
obtained after incubation of auranofin with NCp7 ZnF2 for 6h. 
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Figure AI-1.17. 31P NMR spectra of the reaction product obtained after incubation of NCp7 (ZnF2) with 
[AuCl(Et3P)] (2) for 6 hours and (3) after incubation with the full-length NCp7 zinc finger for 8 days. 
(1) For comparison, the 31P NMR spectrum of the free [AuCl(Et3P)] is also shown. 
 
 
Figure AI-1.18. 31P NMR spectra of the reaction product obtained after incubation of NCp7 (ZnF2) with 
[Au(dmap)(Et3P)]+ (2) for 6 hours and (3) after incubation with the full-length NCp7 zinc finger for 8 
days. (1) For comparison, the 31P NMR spectrum of the free [Au(dmap)(Et3P)]+ is also shown. 
Part I – Appendix 1 | 66 
 
 
 
Figure AI-1.19. 31P NMR spectra of the reaction product obtained after incubation of NCp7 (ZnF2) with 
auranofin (2) for 6 hours and (3) after incubation with the full-length NCp7 zinc finger for 8 days. (1) 
For comparison, the 31P NMR spectrum of the free auranofin is also shown. 
 
 
Figure AI-1.20. 31P NMR spectra of the reaction product obtained after incubation of NCp7 (ZnF2) with 
([AuCl(Cy3P)]) (2) for 6 hours and (3) after incubation with the full-length NCp7 zinc finger for 8 days. 
(1) For comparison, the 31P NMR spectrum of the free [AuCl(Cy3P)] is also shown. 
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Figure AI-1.21. 31P NMR spectra of the reaction product obtained after incubation of NCp7 (ZnF2) with 
[Au(dmap)(Cy3P)] (2) for 6 hours and (3) after incubation with the full-length NCp7 zinc finger for 8 
days. (1) For comparison, the 31P NMR spectrum of the free [Au(dmap)(Cy3P)] is also shown. 
 
Interaction with Sp1 (ZnF3) 
 
 
Figure AI-1.22. ESI-MS spectrum (positive mode) for the reaction between Sp1 (ZnF3) and auranofin 
immediately upon incubation.  
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Full-length NCp7 ZnF / SL2 DNA interaction 
 
Figure AI-1.23. Fluorescence polarization-based binding assay of full-length NCp7 ZnF with the model 
SL2 DNA sequence. 
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Chapter 2 Probing the protein: Ion Mobility Spectrometry  
 
  
Probing the protein
Ion Mobility 
Spectrometry
Part I – Chapter 2 | 70 
 
 
Introduction 
The development of soft ionization techniques such as ESI and MALDI turned mass 
spectrometry into one of the most important tools for studying the interaction of metallodrugs 
with complex biological targets and also for identifying and characterising the interactions 
happening on the binding sites.37 The typical structural techniques, based on X-ray 
crystallography or NMR, assume one preferred binding site for the metal ion, although in many 
cases multiple binding possibilities can exist. An example of this diversity is the displacement 
of Zn(II) in zinc finger peptides by Au(I) and Au(III) compounds, leading to the formation of 
“gold fingers”. These metal replacements have interesting biological consequences, directly 
derived from the the differences in coordination geometry between the intrinsic tetrahedral 
Zn(II) and the exogenous linear Au(I) and square-planar Au(III), with potential therapeutic 
applications through inhibition of nucleic acid regnition of the parent zinc fingers.21  
Mass spectrometry has identified multiple {AunF} (n = 1,2,3) species following Zn(II) 
displacement in both the C-terminal finger of the HIV NCp7 nucleocapsid protein, and the 
finger 3 of Sp1 transcription factor for a series of (dien)Au(III)(N-heterocycle) compounds, a 
feature easily understood by the presence of multiple cysteines in the zinc finger template.38 
Similar results have been observed using poly(adenosine diphosphate(ADP)-ribose) 
polymerase 1 (PARP-1).35 Zn(II) ions from the full-length NCp7 zinc finger are also displaced 
by Au(dien)(9-ethylguanine)]3+, producing {AunF}.
 This gold complex shows micromolar 
efficacy in inhibiting viral infectivity, consistent with the ability to alter the native structure.39 
Auration of zinc finger peptides represents a topic of wide interest in bioinorganic chemistry as 
well as a fundamental problem for inorganic chemistry, since we are evaluating the replacement 
of a tetrahedrally-coordinated Zn(II) by a linear-coordinated Au(I). The compound 
[AuCl(Et3P)] (I-1) was selected as Au(I) donor, and the interaction with NCp7 (ZnF2) and Sp1 
(F3) were studied by traveling-wave ion mobility mass spectrometry (TWIM-MS) coupled with 
collision induced dissociation (CID). The structure of the model compound and that of the 
selected ZnFs are shown in Figure I-2.1. This approach allowed inequivocal elucidation of 
specific binding sites and modes of gold-modified NCp7 (ZnF2) and Sp1 (ZnF3). While linear 
Cys-Au-Cys is indicated for NCp7 (ZnF2), a Cys-Au-His mode is indicated for the Sp1 (ZnF3) 
case.  
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Figure I-2.1. The interaction of compound [AuCl(Et3P)] with the she selected zinc finger proteins NCp7 
(ZnF2) and Sp1 (ZnF3) was investigated by TWIM-MS coupled with collision induced dissociation 
(CID). 
Experimental Section  
Materials  
The complex [AuCl(Et3P)] was synthesized following the same procedure reported on Part I – 
Chapter 1.30 The peptides NCp7 (ZnF2) and Sp1 (ZnF3) were purchased from GenScript. 
Protein sequences: 
         10         20          
NCp7 ZnF2 KGCWKCGKEG HQMKNCTER 
Sp1 ZnF3 KKFACPECPK RFMSDHLSKH IKTHQNKK  
 
Preparation of Zinc Finger and Gold Finger 
The preparation of zinc finger followed published methods.2 The apopeptide was dissolved in 
deionized water at a concentration of 1 mmol L-1. Zinc acetate (1.2 : 1 mol/mol per zinc binding 
domain) was added to the solution and the pH was adjusted to 7.0 using NH4OH. The zinc 
finger solution was incubated for 2 h at 37 °C before any experiment. Secondary structure 
characterization of the zinc finger (ZnF) was monitored using ESI-MS and CD spectroscopy. 
Gold finger peptides were prepared by mixing [AuCl(Et3P)] in methanol with an equimolar 
amount of zinc finger peptide at 20 µM concentration at room temperature. The reaction time 
allowed before injection was 2 h for the NCp7 peptide whereas the Sp1 peptide reacted 
immediately. The mixture was then diluted with water/methanol 50% v/v to yield a 
concentration of 0.2 µM for electrospray ionization. 
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Travelling-Wave Ion Mobility Mass Spectrometry (TWIM-MS)  
Waters Synapt G2-Si travelling wave ion mobility instrument was used. Ions were generated in 
a nanoelectrospray ionization source (nESI) at positive mode and transferred to vacuum. The 
experimental settings for conformer-selected collision induced dissociation (CID) experiment 
were: source temperature, 80 °C; capillary voltage, 3 kV; sample cone, 50 V; source offset, 25 
V; cone gas flow, 50 L/H; trap collision energy, 4 V; trap gas flow, 2mL/min; helium cell gas 
flow, 180 mL/min; Ion Mobility Spectrometry (IMS) gas flow, 90 mL/min; trap DC bias, 45 V; 
IMS wave height, 40 V; IMS wave velocity, 1500 m/s. Transfer collision energy for NCp7 
AuF2 and Sp1 AuF3 is 35 and 45 eV, respectively. 
Conformer-Selected fragmentation peaks were analyzed using Protein-Prospector 
(http://prospector.ucsf.edu/prospector/mshome.htm). Masslynx 4.0 was used for the data 
processing and isotope modelling. Collision Cross-Section (CCS) Measurements: calibration 
of experimental arrival times into collision cross-section values was performed using 
polyalanine by the automated calibration routine and validated by leucine enkephalin. 
Results and Discussion 
The thiophilicity and soft Lewis acid electrophile nature of Au(I) makes sulfur-rich 
biomolecules logical as cellular targets. In this respect the interference with thioredoxin-
thioredoxin reductase is a general consensus as a potential mechanism for the biological 
activities of gold drugs.40–44 Early studies on Au(I) compounds such as aurothiomalate 
suggested possible zinc finger inactivation as contributing to their anti-arthritic activity.22,45 
Using [AuCl(PPh3)], both {(PPh3)AuF} and {AunF} species are formed with NCp7 ZnF2 and 
Sp1 ZnF3, where the transcription factor tends to show a higher propensity for the {AunF} over 
the gold phosphine adduct.18,20,46 The properties of [AuCl(PR3)] make it an ideal system for 
probing cysteine nucleophilicity in biomolecules, directly analogous to “organic” electrophiles 
such as maleimide and iodoacetamide. The distal Cys49 is indicated as the initial site of attack 
of N-ethylmaleimide (NEM), with a near complete reduction in reaction rate when the modified 
full-length NCp7 ZnF was complexed with nucleic acids.18  
We chose to study the products from [AuCl(Et3P)], structurally similar to auranofin,
47 
with two zinc finger sequences representing the C-terminal finger of the Cys2HisCys (Cys3His) 
NCp7 (ZnF2) and the Cys2His2 motif of Sp1 (F3). In both cases {(Et3P)AuF} and {AuF} 
species were formed with higher intensity for the “gold finger” {AuF} species .23 We chose the 
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{AuF} species at 4+ charge state for a detailed study. The peaks were then isolated for further 
IMS analysis. The arrival time distributions (ATDs) of these isolated species are shown in 
Figure I-2.2, along with the control NCp7 (ZnF2). As expected, the “native” NCp7 C-terminal 
zinc finger peptide existed as a single conformer (Figure I-2.2A). For the gold(I) finger formed 
from C-terminal NCp7 (ZnF2), three peaks were observed in the ATD indicating the {AuF} 
adduct exists as three isomeric species (labelled as x, y and z) in the gas phase, with one major 
conformer dominant (Figure I-2.2B). The ATD for the equivalent {AuF} adduct from the C-
terminal Sp1 (F3) is simpler exhibiting only one peak indicating the existence of a single 
conformer in the gas phase (Figure I-2.2C). The difference in ATD suggests differing reactivity 
preferences of the gold(I) drug towards cysteine within zinc finger peptides. 
 
 
Figure I-2.2. Arrival-time distributions (ATDs) as determined by TWIM-MS, and ESI-MS spectra of 
the A. NCp7 (ZnF2), used as control, along with the plot of m/z vs. drift time (bins) for the separated 
NCp7 (ZnF2) at 4+ charge state; B. NCp7 (AuF2), with three conformers (x, y and z) identified; and C. 
Sp1 (AuF3) at 4+ charge state; non-dominant peaks marked with * do not correspond to a AuF 
conformer.  
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To further investigate the nature of these conformational changes upon auration of the 
zinc finger peptides, we measured the average collision cross-section of the zinc finger and 
{AuF} peptides of the 4+ charge state, Figure I-2.2. Under the same conditions, the major 
{AuF} conformer derived from NCp7 ZnF2 appears slightly more compact (Ω = 174.53 Å2) 
compared to the zinc finger peptide itself (Ω = 179.83 Å2), as we can see from the smaller CCS 
and shorter drift time. On the other hand the Sp1-derived {AuF} has a slightly longer ATD and 
now a significantly higher CCS of Ω = 217.19 Å2, implying a significantly less compact 
structure. 
To understand these differences in CCS and to identify the auration sites of the various 
{AuF} conformers we selected a narrow arrival time range for each conformer and subjected 
the peaks to CID fragmentation. The selected regions are represented in Figure I-2.3. 
Crosslinking is destroyed upon CID fragmentation producing a discrete set of shorter but still 
gold-bound fragments from which the original binding sites can be deduced, as observed 
previously in MS/MS studies of a platinum cross-linked peptide.48  
 
Figure I-2.3. Narrow range of ATDs selected for the CID MS/MS experiments on the NCp7 (AuF2) and 
Sp1 (AuF3) in the 4 + charge state. The region selected for the major conformers are marked in red, 
while the region selected for the minor conformer is marked in blue. For NCp7 (AuF2), the overlap of 
the third conformer (marked with an arrow) with the major conformer precluded its isolation. 
 
The MS/MS spectra of the major and minor conformers of the {AuF} derived from 
NCp7 ZnF2 at 4+ charge state are shown in Figure I-2.4. The identified gold-binding fragments 
from the MS/MS spectrum of the major conformer are shown in Table AI-2.1.  
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Figure I-2.4. Collision induced dissociation fragment spectra of the A. major and B minor conformers 
in NCp7 AuF2 4+ and C. the only conformer in Sp1 AuF3 4+ peaks (isolated regions are highlighted in 
Figure I-2.3). Proposed structures of each conformer based on the CID data are shown. a ion = b ion – 
carbonyl (C=O).49  
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Analysis of the CID spectrum of the major conformer revealed that Au+ mainly bound 
at the Cys36 and Cys49 as we can observe the aurated a3-NH3, y4, y6, y7 and y8 fragments. The 
observation of aurated y11 to y15 cannot give a definite assignment of the auration site but it is 
consistent with the auration of Cys49. Considering the tendency of gold(I) to form two-
coordinate, linear complexes with thiolates, it is reasonable to propose that Au(I) coordinates 
in the CCHC zinc finger through Cys36 - Cys49 crosslinking (Figure I-2.4A). The observation 
of aurated y4-NH3 in both the major and minor conformers of NCp7 AuF2 shows that Cys49 
was metallated in both cases. The aurated a3-NH3 is mainly located in the dominant major 
conformer although some overlap with the minor conformer is observed. 
The identified gold-binding fragments from the MS/MS spectrum of the minor 
conformer are shown in Table AI-2.2. The minor conformer is more compact (Ω = 163.57 Å2) 
and has good separation from the major conformer. Besides Cys49 auration, we can observe 
the aurated a8-NH3, y7 and y8 in the MS/M in total indicative of auration in either Cys36 or 
Cys39. Considering the above assignment of the major conformer, the minor conformer should 
have auration at Cys39 and Cys49 (Figure I-2.4B). 
Cys3His zinc fingers are especially susceptible to electrophilic attack and the C-terminal 
NCp7 ZnF2 is identified as being one of the most reactive, with Cys49 being the most labile 
site.16,17 The auration of Cys49 in both conformers confirms its greater reactivity. As stated, 
Cys49 is also the site of attack of NEM and treatment of infectious virus with NEM eliminated 
retroviral infectivity in a manner proportional to NEM concentration.19 Replacement of Zn2+ in 
the full zinc finger NC eliminates the nucleic acid binding abilities of the peptide – crucial to 
its biological function in the HIV replication cycle.50 These results strengthen our analogy 
between “organic” and Lewis acid electrophiles and suggest that, as well as useful probes of 
NC topography, the Au-based agents could provide a rich source of targeted anti-HIV agents 
based on a thiolate modification strategy.11,12,39  
For {AuF} derived from Sp1 (ZnF3), only one conformation was observed whose 
MS/MS spectrum is shown in Figure I-2.4C. The observation of aurated a5 showed that Cys5 
is a gold-binding site while the aurated y9 is indicative of auration in either His 20 or His 24. 
The observation of aurated y21, y23-25, y27 is also consistent with the binding at His 20/His 24 
and Cys5. The identified gold-binding fragments from the MS/MS spectrum are shown in Table 
AI-2.3. The linear Cys-Au-Cys was discarded based on MS/MS assignment. 
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 Mass spectrometry and tandem MS have been used successfully to characterize gold-
peptide/protein interactions but cannot assign specific binding sites in multi-receptor systems 
nor suggest the existence of conformers.51 To our knowledge, this is the first demonstration that 
{AuF} can exist in structurally distinct conformations and represents a novel use of IM in 
protein structure analysis complementary to other spectroscopic and X-ray techniques.35,38,51–54 
Ion Mobility was used to study changes in the tertiary structure of ubiquitin upon metallation 
with cisplatin and revealed the presence of up to three different conformations of the Ub–
{Pt(NH3)2} mono-adduct.
55,56 Ruthenium(II)-peptide interactions studied by IM highlighted the 
important role played by the ligand in determining the shape of the adduct formed.57 
Furthermore, the conformational diversity of cancer-associated mutations in the zinc-bound p53 
tumor suppressor protein has been probed by ion-mobility mass spectrometry.58 A further 
relevant example is the assignment of Cu coordination sites on a methanobactin model peptide 
with potential Cys2His2 binding sites analogous to the Sp1 ZnF3 case.
59  
 
Conclusions 
Here we demonstrate the utility of ion mobility combined with MS/MS for the study of 
zinc finger protein/metal drug interactions. The ion mobility experiments are rapid (ms time-
scale) and, when combined with MS/MS, will provide information not only on shape and 
conformer profile, but also on metalation selectivity and reactivity. TWIM allows separation of 
peptide species of the same mass-to-charge (m/z) ratio that exhibit multiple conformations. 
Therefore, when coupled to mass spectrometry TWIM-MS leads to very specific and 
complementary information about macromolecules, such as the crosslinking residues 
coordinated to Au different conformers of a protein (Scheme I-2.1). In this specific case, the 
ability to identify precisely the nature of the auration and zinc displacement on the protein 
elucidates the details whereby DNA/RNA recognition is abrogated, considered essential in the 
inhibition of antiviral activity by these drugs. The screening of new metal-based anticancer or 
antiviral agents would benefit from quantitative information on the shape changes induced upon 
zinc finger protein metalation and the selectivity and reactivity of metalation. 
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Scheme I-2.1. Experimental route for separation of the different conformers of AuFs by TWIM-MS 
followed by CID. 
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Appendix 
MS/MS fragment lists 
Table AI-2.1. Identified gold-binding fragments arising from the MS/MS of the major conformer of 
NCp7 AuF2. “an” and “bn” ions are N-terminal fragments while “yn” ions are C-terminal fragments. 
Peptide fragment with Au(I) Theoretical m/z* Observed m/z* 
a3-NH3+Au(I) 440.07
+ 440.10+ 
y14-NH3+Au(I) 600.88
3+ 600.913+ 
y4-NH3+Au(I) 687.15
+ 687.19+ 
y11+Au(I) 765.26
2+ 765.302+ 
y12+Au(I) 829.31
2+ 829.372+ 
y13+Au(I) 857.82
2+ 857.872+ 
y14-NH3+Au(I) 900.81
2+ 900.862+ 
y6+Au(I) 947.30
+ 947.35+ 
y15+Au(I) 973.37
2+ 973.422+ 
y7+Au(I) 1078.34
+ 1078.39+ 
y8+Au(I) 1206.40
+ 1206.46+ 
* most abundant isotopomer 
Table AI-2.2. Identified unique gold-binding fragments arising from the MS/MS of the minor conformer 
(blue color) of NCp7 AuF2 
Peptide fragment with Au(I) Theoretical m/z * Observed m/z * 
a3-NH3+Au(I) 440.07
+ 440.11+ 
a8-NH3+Au 1042.37
+ 1042.46+ 
y7+Au(I) 1078.34+ 1078.42+ 
y8+Au(I) 1206.40+ 1206.49+ 
 * most abundant isotopomer  
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Table AI-2.3. Identified gold-binding fragments arising from the MS/MS of the only conformer of Sp1 
C-terminal gold finger. 
Peptide fragment with Au(I) Theoretical m/z * Observed m/z * 
FAC-28+Au(I)  490.09+ 490.07+ 
y9+Au(I)  665.31
2+ 665.292+ 
 a5+Au(I) 746.27
+ 746.27+ 
y27+Au(I) 859.91
4+ 859.884+ 
y21-NH3+Au(I) 915.10
3+ 915.063+ 
y21+Au(I) 920.77
3+ 920.753+ 
y23+Au(I) 996.14
3+ 996.103+ 
y24-NH3+Au(I) 1024.81
3+ 1024.753+ 
y24+Au(I) 1030.48
3+ 1030.443+ 
y25+Au(I)  1054.49
3+ 1054.443+ 
y21-NH3+Au(I) 1372.15
2+ 1372.102+ 
y23+Au(I)  1493.70
2+ 1493.632+ 
 * most abundant isotopomer
Chapter 3 Probing gold: X-ray absorption spectroscopy  
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Introduction 
In an effort to obtain further information on the systems addressed in Part I (interaction 
of Au(I) compounds with ZnF proteins), we discussed in Part I – Chapter 2 the approach of 
using TWIM-MS to observe and distinguish among different conformers of Au(I)-protein 
adducts based mainly on properties of the proteins. Here, our focus shifts towards probing 
directly the metal. X-ray Absorption Spectroscopy (XAS) is appropriate for structural studies 
due to its capability to specifically probe the geometry around the metal absorber. Additionally, 
XAS spectra are sensitive to the electronic density on the mental center. As consequence, it 
represents an extremely powerful technique that is able to distinguish between oxidation states 
and coordination spheres of a metal complex, providing insights on the electronic and geometric 
structural details of the protein bound metal centers.  
In this chapter, the interaction of [AuCl(Et3P)] (I-1) and auranofin (I-3) with zinc finger 
peptides was investigated using Au L3-edge XAS measurements. To further support our 
conclusions, the data obtained for the reaction products were compared to the XAS spectra of 
selected model compounds and also to TD-DFT-calculated spectra. The viral NCp7 ZnF2 was 
compared to the human transcription factor Sp1 ZnF3. These represent two different families 
of ZnF proteins, NCp7 being the -Cys-X2-Cys-X4-His-X4-Cys- (C2HC) motif of the HIV-1, and 
the Cys-X2-Cys-X12-His-X3-His (C2H2) Zn coordination sphere of Sp1, as schematically 
represented in Figure I-3.1. We examine the effects of the zinc coordination sphere in dictating 
reactivity and delineating the intimate mechanisms of metal ions substitution in a ZnF template. 
In the case of Au(I) compounds, we confirm the Lewis acid electrophilic attack of [AuCl(Et3P)] 
and auranofin after interaction with NCp7, resulting in a common final product with Cys-Au-
PEt3 coordination sphere. In Part I – Chapter 1, we demonstrated that the reaction product of 
[AuCl(Et3P)] with Sp1 had a remarkably clean mass spectrum (Figure I-1.8). For that reason, 
we decided to purify and isolate the AuF obtained from that reaction and also study it using 
XAS.  A Cys-Au-Cys coordination sphere is suggested for the the purified AuF studied here, 
as indicated by the electron rich gold center observed by XAS. As first discussed in Part I – 
Chapter 1, we also demonstrate here that the reactivity of [AuCl(Et3P)] is also dependent on the 
ZnF core targeted.  
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Figure I-3.1. Structural formulas of Au(I) compounds used in this study. The zinc finger model peptides 
NCp7 and Sp1 are also shown. 
 
Experimental 
Synthesis and zinc finger preparation 
Compounds I-1, I-3 and M-6 were acquired from Sigma-Aldrich and used without further 
purification. The model compounds M-1 to M-5 (Figure AI-3.1) were synthesized and purified 
according to literature procedures.33,60–62 The crystal structures of all compounds, except M-2 
and M-5, have been already reported elsewhere.60,61,63–68 Characterization of compounds M-1 
to M-5 was performed by conventional spectroscopic techniques including 1H, 13C, 31P NMR 
spectroscopy, mass spectrometry, elemental analysis, and infrared and UV spectroscopies, 
attesting the success of the synthesis and their integrity.23,33 
The zinc finger models used in this study were the HIV-1 nucleocapsid protein ZnF2 and the 
human transcription factor Sp1 ZnF3. NCp7 ZnF2 and Sp1 ZnF3 were purchased from 
Aminotech Co. (São Paulo, Brazil), the full-length NCp7 ZnF was acquired from Invitrogen 
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(USA). The apopeptides were checked by mass spectrometry and used as received. Both zinc 
fingers were prepared by dissolving sufficient mass of apopeptides in a 100 mmol L-1 solution 
of zinc acetate prepared in degassed water. The pH was adjusted to 7.2~7.4 using NH4OH or 
HOAc if needed, leading to a solution with final concentration of 30 mmol L-1 of zinc finger. 
Sequences: 
         10         20          
NCp7 ZnF2 KGCWKCGKEG HQMKNCTER 
Sp1 ZnF3 KKFACPECPK RFMSDHLSKH IKTHQNKK  
 
Sample Preparation 
The solid samples of compounds I-1 and I-3 and model compound M-1 to M-6 were finely 
grounded and diluted in boron nitride to a maximum X-ray absorbance of about 1. They were 
then pressed into circular pellets of 13 mm diameter using a hydraulic press, placed in a plastic 
sample holder and covered with polyimide adhesive tape (Kapton) with about 40 μm thickness. 
Gold L3-edge XAS measurements of the complexes I-1 and I-3 and model compound M-1 to 
M-6 were performed in solid state at XAFS1 beamline. 
Stock solutions of [AuCl(Et3P)] (I-1) and auranofin (I-3) were prepared by dissolving the solid 
compounds in dmf to a final concentration of 100 mmol L-1. For evaluating the interaction of 
the model compounds with the zinc fingers, a total sample volume of 10 µL of the Au(I) 
complexes I-1 and I-3 were prepared by mixing sufficient volumes of the solutions of model 
compounds to each zinc finger solution (NCp7(F2) and Sp1(F3)) in a molar ratio of 1:1.  
The gold finger sample (AuF) from Sp1 (F3) was obtained incubating [AuCl(Et3P)] with Sp1-
ZnF3 in a 1:1 molar ratio for 1h. The reaction mixture was purified using a Waters 515 HPLC 
instrument with a reverse phase Phenomenex Jupiter C18 column (5µm, 250 mm×4.6 mm, 300 
Å) and a 100 µL sample injection loop. Flow rate of 1 mL/min was used for all the experiments. 
The following gradient was used: 0-30min, 10-80% B:A where A is H2O with 0.1% TFA and 
B is acetonitrile with 0.1% TFA. UV detection wavelengths were 280 nm and 220 nm. The 
HPLC run is given in Figure AI-3.2. The composition of the isolated fraction was further 
characterized by ESI-MS. The eluent from the collected sample was lyophilized and the solid 
was redissolved in ammonium phosphate buffer prior to XAS measurements. A sample with 
final concentration of 48 µM was used. 
In each XAS measurement of the samples in solution, about 3 µL of the prepared solutions of 
the zinc fingers and the Au(I) interaction products (I-1 and I-3) were placed in a plastic sample 
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holder, covered with the same 40 μm thick Kapton adhesive and frozen in a closed-cycle liquid 
helium cryostat. The solution samples were kept below 50 K during these measurements. 
Inspection of fast XANES scans revealed no signs of radiation damage, and the first and last 
scans of each data set used in the averages were identical. Gold L3-edge X-ray absorption 
spectra of the samples in solution were acquired at the XAFS2 beamline.69 
Data averaging, background subtraction and normalization were done using standard 
procedures using the ATHENA package.70 
 
XAFS1 and XAFS2 beamlines 
XAFS1 an XAFS2 beamlines are located at the Brazilian Synchrotron Light Laboratory 
(CNPEM/LNLS).69,71 At the XAFS1 beamline the incident energy was selected by a channel-
cut monochromator equipped with a Si(111) crystal, and at the XAFS2 beamline a double-
crystal, fixed-exit monochromator was used. The beam size at the sample was approximately 
2.5 x 0.5 mm2 (hor. x vert.) at XAFS1 and 0.4 x 0.4 mm2 at XAFS2, with an estimated X-ray 
flux of 108 ph/sec (XAFS1) and 109 ph/sec (XAFS2). The incoming X-ray energy was 
calibrated by setting the maximum of the first derivative of L3-edge of a gold metal foil to 11919 
eV. The XAS spectra of the solid samples (complexes I-1 and I-3 and model compound M-1 
to M-6) were collected in conventional transmission mode using ion chambers filled with a 
mixture of He and N2. In the case of the samples in solution, fluorescence mode detection was 
used. The fluorescence signal was recorded using a 15-element Ge solid-state detector (model 
GL0055S – Canberra Inc.) by setting an integrating window of about 170 eV around the Au 
Lα1 and Lα2 emission lines (9713.3 eV and 9628.0 eV, respectively). 
 
TD-DFT 
Calculations were performed on all Au(I) compounds (I-1 and I-3 and model compound M-1 
to M-6) to see if our protocol could reproduce the trends in energy shifts and intensities. TD-
DFT-obtained L3-edges are shown in Part I – Appendix 3, in an overall good agreement with 
the experimental data. Furthermore, theoretical models were created to model the Et3P-Au(I)-
Cys (T-1), Cys-Au(I)-Cys (T-2), His-Au(I)-His (T-3) and Cys-Au(I)-His (T-4) motifs. All 
calculations were performed using the ORCA quantum chemistry code, version 3.0.3.72 All 
molecules were optimized at the PBE0/def2-TZVP level of theory using the def2-ECP effective 
core potential.73 TD-DFT calculations (using the Tamm-Dancoff approximation) 74 as 
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implemented in ORCA were performed with the PBE075–77 functional using an all-electron 
scalar relativistic Douglas-Kroll-Hess Hamiltonian78–80 with the DKH-def2-TZVP-SARC basis 
set.81 The Au 2p to valence excitations were performed by only allowing excitations from the 
Au 2p donor orbitals to all possible virtual orbitals of the molecule (only limited by the number 
of calculated roots). Intensities include electric dipole, magnetic dipole and quadrupole 
contributions. The RIJCOSX approximation82,83 was used to speed up the Coulomb and 
exchange integrals in both geometry optimizations and TD-DFT calculations.  
Results and Discussion 
Eight Au(I) complexes representing different X-Au-Y coordination spheres (with the 
donor atoms X, Y = S, P, Cl, N and/or C) were selected (Figure AI-3.1) to serve as models for 
different relevant coordination spheres of Au(I), functioning as analogues to the interaction 
products between the [AuCl(Et3P)] and auranofin with the target zinc finger proteins.  
In general, the XAS spectra of the Au(I) model compounds present the expected white 
line peak in the 11923-11925 eV range. L3-edge whitelines have been seen for Au(I) [d106s0 
valence configuration], suggesting some unoccupied d-orbital character to be present or perhaps 
being due to other transitions (see TD-DFT discussion). In a first approximation, the intensity 
of the L3-edge XAS white line is proportional to the d-electron count allowing the inference of 
the metal oxidation state.84 A summary of the spectroscopic features observed for each model 
compound is given in Part I – Appendix 3 (Figure AI-3.1, Table AI-3.1). Figure AI-3.3 shows 
the TD-DFT spectra obtained for the model Au(I) compounds, in comparison to the 
experimental data.  
Interaction with NCp7 ZnF2. 
Figure I-3.2 shows the Au L3-edge XANES spectra of the Au(I) compounds I-1, I-3 and 
M-5 and the interactions of I-1 with the NCp7 and Sp1 zinc fingers. Compound I-1 presents a 
Au XANES spectrum similar to the other Au(I) compounds with P-Au-Y coordination (where 
Y can be Cl, N or S), with a white line peak located at 11924.2 eV and about 0.83 normalized 
units. After interaction with NCp7, the XANES of the resulting product I-1+NCp7 changes 
slightly: the broad and weak white line sharpens and gains intensity, peaking at 11925.7 eV and 
0.97 normalized units. This final spectrum is almost identical to that of auranofin (I-3), which 
has a peak at the same energy and only slightly more intense (0.98 units), indicating similar 
geometry and electronic configuration between these species.  In Figure I-3.2 the XANES 
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spectrum of free auranofin (compound I-3) is remarkably similar to that of the reaction I-
1+NCp7 and I-3+NCp7. As the near-edge XAS region is sensitive to both the atomic 
arrangement and the electronic structure around the metal,85–88 this indicates that the products 
formed present the same coordination sphere as found in auranofin, i.e., a P-Au-S coordination. 
The same also holds true regarding the electronic configuration of these compounds, being all 
formally Au(I). The similarity in coordination sphere between auranofin and its product 
preclude conclusions on substitution at this early time point, but the MS spectrum obtained for 
I-3+NCp7 shows the presence of the {Et3PAu} moiety bound to the peptide, suggesting a 
possible replacement of the thiosugar by apo-NCp7 (Figure AI-1.15). The proposed 
coordination environment for the reaction products of the Au(I) models with NCp7 is further 
supported by the inspection of the EXAFS (Extended X-ray Absorption Fine Structure) region 
of the spectra. The EXAFS of I-1+NCp7 and I-3+NCp7 are virtually superimposable with that 
of free auranofin up to k=10 Å-1 (Figure AI-3.4). As the crystal structure of the latter is known,68 
it is possible to conclude that the gold atoms in these reaction products have identical 
neighborhoods, i.e., P-Au-S. This confirms our previous findings that the reaction of I-1 with a 
NCp7 zinc finger results in a long-lived Et3PAu finger species (see Part I – Chapter 1), while 
also revealing that the reaction of auranofin with NCp7 also produces the same species.22 
Travelling Wave Ion Mobility spectra of the {AuF} species formed from I-1+NCp7 indicated 
the presence of Cys-Au-Cys conformers (Part I – Chapter 2), a consequence of the multiple 
possible cysteine binding sites.89 The formation of these conformers can now be readily 
understood by first the formation of {Au(Et3P)-F} species as confirmed here followed by loss 
of the Et3P ligand and formation of a second Au-Cys bond. 
The purified AuF and interactions with Sp1 
The XANES of the purified AuF obtained by the reaction of [AuCl(Et3P)] with Sp1 
ZnF3, which was isolated and purified by HPLC (from here on referred to as I-1+Sp1(AuF)) 
differs considerably from that of compound I-1, as shown in Figure I-3.2 and Figure I-3.4. The 
white line region of I-1 contains a broad and weak peak, which splits in two in the interaction 
product I-1+Sp1(AuF), with an energy separation of about 5.5 eV. Moreover, the spectrum of                    
I-1+Sp1(AuF) is clearly distinct from that of pure auranofin (6) and the interaction products    
I-1+NCp7 and I-3+NCp7, indicating that different species are formed for I-1+Sp1 and pointing 
to possible selectivity. The weak double feature in the white line of I-1+Sp1(AuF) (around 
11924-11929 eV) is also evident in the XANES of compound M-5 ([Au(N-Ac-Cys)]), which 
contains an S-Au-S environment. In the post-edge region of I-1+Sp1(AuF) a single broad 
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feature is present, contrasting with the two marked structures observed in the spectra of I-3,     
I-3+NCp7 and I-1+NCp7. Since a similar single feature is also observed in the spectrum of         
M-5, we can infer that the purified gold-finger has a similar structure as compound M-5, i.e., a 
S-Au-S coordination and formally Au(I) oxidation state. The EXAFS of I-1+Sp1(AuF) 
essentially overlaps with that of compound M-5 up to k=8 Å-1 (Figure AI-3.5). The apparently 
slightly shorter bond distance in the first coordination shell of AuF suggested by EXAFS and 
the differences in the white line of I-1+Sp1(AuF) and compound M-5, could be explained by 
the formation of a shorter and more covalent Au-S bond in the pure gold finger or perhaps a 
slightly different S-Au-S local geometry in I-1+Sp1(AuF) than in compound M-5. Geometry 
optimizations using density functional theory of a single molecule of compound M-5 (N-Ac-
Cys)-Au-(N-Ac-Cys) gave an approximately linear S-Au-S geometry (S-Au-S angle of 177°). 
The peptide in AuF, however, may impose a different S-Au-S angle that may deviate more from 
linearity. The low quality of the EXAFS data of I-1+Sp1(AuF) and the absence of a crystal 
structure for compound M-5, unfortunately, hindered a complete structural analysis.  
 
Figure I-3.2. XANES spectra of the compounds I-1 and I-3 and of the products of the their interaction 
with NCp7 and Sp1. Compound M-5 (S-Au-S coordination) is also shown for comparison. The inset 
shows a zoom-in of the white line region, highlighting the spectral changes after interaction with the 
ZnFs. 
I-1
I-3
M-5
I-1+NCp7
I-1+Sp1 (AuF)
I-3+NCp7
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This suggestion contrasts with the conclusions from Travelling Wave Ion Mobility Mass 
Spectral study (see Part I – Chapter 2), which suggested a Cys-Au-His coordination 
environment for [AuF] formed from I-1+Sp1.89 In the latter case, the gas-phase product ion was 
isolated and immediately subjected to further analysis whereas in the present case we are 
dealing with an isolated product. Therefore, discrepancies may reflect kinetic versus 
thermodynamic preferences given the two methodologies. The Cys-Au-His electronic structure 
is in fact very similar to that of Cys-Au-Cys and may also explain the spectra and the differences 
from model compound M-5. What is clear is the lack of any contribution from the {Au(Et3P)} 
moiety. 
TD-DFT  
To provide a quantitative description of the interaction products of the Au(I) compounds 
with the ZnFs, we have employed DFT structural modeling and TD-DFT calculations of the Au 
L3-edge XAS. TD-DFT calculations of metal K-edge XAS spectra have become popular and 
have been found to reproduce important pre-edge spectral features of metal complexes and 
cofactors well.90–96 While L-edge spectra of first-row transition metals require more 
sophisticated wavefunction theory calculations that account for the difficult multiplet effects 
and spin-orbit coupling involving p- and d-shells, it has been found that a TD-DFT approach, 
neglecting both spin-orbit coupling and multiplet effects works well for L-edges of second-row 
transition metals such as molybdenum and ruthenium, where the multiplet effects should be 
small.88,97 For Au, a third-row transition metal, this approach would also be expected to work 
well.  
The Au(I) compounds evaluated in this work had their structures optimized using DFT. 
More specifically, compound M-5 was modeled as an almost linear Cys-Au-Cys model, while 
I-1, I-3 and M-3 had their structures optimized based on the available crystalline 
structures.60,61,68 Optimized structures are shown in Figure AI-3.3. Theoretical models of the 
interaction products were also created based on Et3P-Au(I)-Cys (T-1), Cys-Au(I)-Cys (T-2), 
His-Au(I)-His (T-3) and Cys-Au(I)-His (T-4) motifs with Cys being modeled as N-acetyl-N-
methylamide-cysteine and His residues modeled as 5-methylimidazole (Figure I-3.3). 
Optimizations and TD-DFT calculations were performed using a protocol described 
previously.97 Additional details are given in the Experimental Section. 
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Figure I-3.3. A. DFT optimized structures of the theoretical models used for the Au(I)-protein adducts. 
Cys was modeled as N-acetyl-N-methylamide-cysteine and His residues were modeled as 5-
methylimidazole. B. TD-DFT-calculated spectra of the theoretical Au(I) model compounds. 
 
Figure I-3.4 shows a zoom-in of the white line region of the Au L3-edge XANES of the 
Au(I) model compounds (I-1, I-3, M-3 and M-5) and the selected interaction products                  
I-1+NCp7 and I-1+Sp1(AuF), and their corresponding TD-DFT-calculated spectra, 
respectively. An energy shift of -465 eV was applied to the calculated spectra based on the 
correlation between experimental and calculated energies. The constant shift is necessary due 
to the sensitivity of the 2p core-orbital energies to relativistic effects as well as the approximate 
exchange-correlation potential, which are not perfectly described in our calculations. A 
broadening of 4.4 eV FWHM, based on the Au 2p3/2 core-hole lifetime, was used in all 
calculated spectra. We note that the TD-DFT-calculated spectra can only be expected to model 
the edge-region well, not the post-edge region of the XAS spectra. Overall, the calculated 
spectra nicely reproduce the observed experimental trends, both in terms of the energies and 
the intensity distribution (Figure I-3.4). Furthermore, TD-DFT can reveal the nature of the 
transitions involved. As these are all Au(I) model compounds with formally a full d-electron 
shell, from an electronic structure point of view, Au 2p → Au 6s orbital excitations should be 
the first main contribution to the edge. Analysis of the transitions reveals that the Au 6s orbital 
mixes strongly with the bound-ligand orbitals in these compounds and the excitations are better 
described as Au 2p → Au-L σ*. These excitations make up the main peak in the near edge 
region of the spectrum of all Au(I) compounds, but higher energy charge-transfer excitations 
into various empty ligand orbitals, in particular the phosphorus and sulfur d-shells, contribute 
as well and broaden the peak or result in a second peak, as in the case of compounds I-1, M-5, 
and Cys-Au-Cys (T-2). In the sulfur-containing Au-compounds (M-3, M-5, Et3P-Au(I)-Cys 
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(T-1) and Cys-Au(I)-Cys (T-2)), the Au 2p → Au-L σ* excitations are shifted slightly to higher 
energies, while the higher intensity of the peak compared to compound I-1 can be attributed to 
additional Au 2p → S d excitations (with some mixing with Au 5d orbitals due to covalency), 
that arise due to the more covalent Au-S bond compared to the Au-Cl bond.  
 
Figure I-3.4. A. Experimental Au L3-edge XANES spectra of Au(I) compounds I-1, I-3, M-3 and   M-
5, and interaction products I-1+NCp7 and I-1+Sp1 (AuF). B. TD-DFT-calculated L-edge XANES 
spectra of the same compounds and the proposed models Et3P-Au-Cys (T-1) for I-1+NCp7 and Cys-
Au-Cys (T-2) for I-1+Sp1. The TD-DFT-calculated spectra have been shifted in energy by -465 eV and 
broadened by 4.4 eV(FWHM). 
 
Furthermore, the calculated spectrum of the simple theoretical models Et3P-Au(I)-Cys 
(I-A, Figure I-3.3) is similar to that of compound I-3, in agreement with the experimental 
spectrum, again supporting our hypothesis that the I-1+NCp7 and I-3+NCp7 products consist 
of a P-Au-S local geometry, i.e., the Et3P-Au motif binding to a single Cys residue within the 
peptide. In the case of interaction with Sp1, the comparison of the simulated spectra with the 
experimental ones indicates that Cys-Au(I)-Cys (T-2) is clearly a much better model for I-
1+Sp1 than Et3P-Au(I)-Cys (T-1) although the spectrum of the Cys-Au-His (T-4) is quite 
similar to that of T-2, with slightly different relative intensities. Theoretical model T-2 and 
compound M-5 are structurally very similar and this can be verified by comparing their 
calculated spectra. We also note that the lower energy of the phosphorus d-shell compared to 
the sulfur d-shell, results in a single broad high-intensity peak for the P-Au(I)-S compounds   
(I-3 and Et3P-Au(I)-Cys (theoretical model T-1)), while the S-Au-S compounds and S-Au-N 
compounds (M-5, T-2 and T-4) give two peaks (See Figure II-2.3C, Part 2 – Chapter 2).  
The overall picture in the case of Au(I) model compounds interacting with NCp7 and 
Sp1 ZnFs is that the gold atom maintains its oxidation state upon interaction. However, it 
A B
I-1
I-3
M-3
M-5
I-1+NCp7
I-1+Sp1 (AuF)
I-1
I-3
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presents a slightly higher electronic density on the metal center in the case of the interaction 
product with Sp1 when compared to NCp7. The stronger donor character of thiols might be 
responsible for the reduction of the metal center. The formation of different final products after 
interaction with Au(I) compounds, depending on the ZnF is evidenced and suggests different 
zinc displacement mechanisms for compound I-1 when targeting NCp7 or Sp1. This is an 
important information for the design of more specific inhibitors. The observation of different 
products after interaction of I-1 with the two zinc fingers is intriguing – why do we observe 
{AuF} as a dominant species? The result may reflect the greater reactivity of the Sp1 core with 
respect to Zn2+ affinity. The PR3 adduct must be formed but further reaction on Sp1 may be too 
fast to be observed. In this respect it is of interest to note that binding constants for Zn2+ to the 
two peptides differ significantly with the NCp7 being held much more tightly.9,98 This 
interpretation is bolstered by observation of {PPh3)Au-F}adducts when the electrophile is the 
relatively more substitution-inert [Au(PPh3)(dmap)]
+.23 Likewise the ESI-MS spectrum of I-3 
where the S-bound leaving group is more inert than Cl- does show the presence of {(Et3PAuF} 
species (see Figure AI-1.15, Part I – Chapter 1). 
To our knowledge, this is the first Au(I)+ZnF system evaluated by a combination of 
XAS and TD-DFT. Here, the element-specific technique of XAS combined with the TD-DFT 
calculations corroborate the hypothesis of electrophilic attack of the metal center (Au(I)) on the 
cysteine, with replacement of the chloride (compound I-1) or thiosugar (compound I-3) ligands, 
and the maintenance of the Et3P group upon initial reaction with NCp7. Interestingly, this 
coordination environment has also been observed for the systems auranofin + bovine serum 
albumin and auranofin + apo-transferrin.99 In contrast, the human transcription factor Sp1 
presented a different reaction product when interacting with [AuCl(Et3P)], showing no evidence 
for the phosphine-bound intermediate, and generating species with S-Au-S or a S-Au-N- 
coordination.  
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Conclusions 
A systematic study using a combination of XAS and TD-DFT calculations based on a 
selection of experimental and theoretical models allowed the assessment of the coordination 
environments of the gold complexes formed by the interaction of Au(I) compounds with 
different zinc fingers. Gold L3-edge XAS allowed the identification of the interaction products 
of [AuCl(Et3P)] (I-1) and auranofin (I-3) with NCp7 ZnF2, which have S-Au-P coordination 
spheres, as detected for reaction products immediately frozen and analyzed. This observation 
confirms the mechanism based on the electrophilic attack of the Au(I) centers on the zinc-bound 
Cys residues, with maintenance of the coordinated phosphines in the resulting products. TD-
DFT calculations provided more information based the comparison of theoretical models for 
Au(I) linear coordination (namely Et3P-Au-Cys, Cys-Au-Cys, His-Au-His and Cys-Au-His,) 
with the experimental XAS data, supporting the proposed Et3P-Au-S(Cys) coordination sphere 
for I-1+NCp and I-3+NCp7.  
Furthermore, our results show that the I-1+Sp1(AuF) is different from the product 
formed when interacting I-1 with NCp7. TD-DFT supports the conclusion of an (Cys)S-Au-
S(Cys) coordination sphere for I-1+Sp1 (AuF), in agreement with a slightly more electron-rich 
gold center. 
 
Scheme I-3.1. Proposed mechanism for Zn(II) displacement caused by [AuCl(Et3P)] (compound I-1) 
upon interaction with NCp7 and Sp1. The final coordination sphere of Au is highlighted in each case. 
 
In summary, we demonstrated that a combination of XAS and TD-DFT calculations can 
be a powerful tool allowing the elucidation of the coordination sphere and oxidation state of Au 
compounds upon interaction with two different ZnFs. We also demonstrated that the reactivity 
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depends on properties of both the Au complex and the ZnF studied. The XAS results obtained 
and discussed here bring additional structural information providing means to distinguish 
between limiting mechanisms involving structurally distinct zinc fingers. Understanding the 
factors governing the metal replacement reaction will allow the rational design of new 
compounds with better inhibition properties towards ZnFs. The robust approach presented here, 
combining experimental XAS data with TD-DFT calculation can be extended to evaluate the 
interaction of a wide range of metallodrugs with target biomolecules.  
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Appendix 
XAS of Au(I) model compound and TD-DFT calculations 
 
Figure AI-3.1. A. List of Au(I) model compounds used in this study. B. Gold L3 XANES spectra of the 
model complexes. The spectrum of Au foil (represented as Au) is also shown for comparison, and its 
edge position (19919 eV) is marked as a dashed vertical line. Note the strong white line peak present in 
the Au(I) compounds M-4 and M-6 with CN- ligands. 
M-1 M-2 M-3
M-4 M-5
M-6
A
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I-3
M-1
M-2
M-3
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 Table AI-3.1. Edge position, oxidation state and approximated site symmetry from studied compounds 
and Au(0) as reference.  
 
 
 
Figure AI-3.2. HPLC run for the separation of the products obtained by the reaction of I-1 with Sp1 
(ZnF3). The species eluted at 13.8 min was isolated. 
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Compound 
Edge 
position / eV 
Oxid. St. 
Site Symmetry 
(around Au Atom) 
# Name 
Au(0) Au foil 11919.0 0 - 
I-1 [AuCl(Et3P)] 11920.0 1+ C∞v 
I-3 auranofin 11920.4 1+ C∞v 
M-1 [AuCl(Ph3P)] 11920.2 1+ C∞v 
M-2 [Au(dmap)(Ph3P)]+ 11920.7 1+ C∞v 
M-3 [Au(mtz)(Ph3P)] 11920.4 1+ C∞v 
M-4 [Au(CN)(Ph3P)] 11922.3 1+ C∞v 
M-5 [Au(N-Ac-Cys)] 11919.7 1+ D∞h 
M-6 [Au(CN)2]- 11921.5 1+ D∞h 
Reaction Name 
Edge position 
/ eV 
Oxid. St. Coordination sphere 
I-1+NCp7 [AuCl(Et3P)] +NCp7 ZnF2 11920.8 1+ P-Au-S(Cys) 
I-3+NCp7 auranofin + NCp7 ZnF2 11920.9 1+ P-Au-S(Cys) 
I-1+Sp1 AuF prepared from Sp1 ZnF3 11920.3 1+ (Cys)S-Au-S(Cys) 
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Figure AI-3.3. A. Experimental Au L3-edge spectra Au(I) compounds I-1, I-3 and models M-1 to   M-
6 compared to B. TD-DFT-calculated L-edge spectra. The TD-DFT-calculated spectra have been shifted 
by 465 eV to lower energies. C. DFT-optimized structures of the experimental Au(I) model compounds. 
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EXAFS 
 
Figure AI-3.4. Comparison of the k2-weighted EXAFS of auranofin (I-3), the product I-1+NCp7 and 
the product I-3+NCp7. 
I-3
I-1+NCp7
I-3+NCp7
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Figure AI-3.5. Comparison of the k2-weighted EXAFS of model compound M-5, with coordination 
sphere S-Au-S, and the isolated pure gold finger (Sp1).
I-1+Sp1 (AuF)
M-5
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Chapter 4 Probing cells: Cytotoxicity Evaluation 
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Introduction 
Auranofin is an FDA approved drug for the treatment of rheumatoid arthritis. In a 
repurposing effort, it has been extensively tested as an anticancer drug throughout the past 
decade. Regardless of the potent cytotoxicity observed for auranofin, there are many reports on 
lack of selectivity. Early mechanistic studies evidenced that auranofin and the precursor 
[AuCl(Et3P)] affect mitochondrial function,
100 and these results have been recently interpreted 
as induction of programmed cell death rather than inducing growth arrest of cycling cells.101 
Auranofin was shown to induce mitochondrial swelling and loss of membrane potential, related 
to mitochondrial membrane permeability transition (MPT).102,103 The chemical state of the 
thiols present in mitochondria are important for controlling MPT and the Trx/TrxR system was 
expected to play a role. Auranofin was shown to be a more potent inhibitor of mitochondrial 
TrxR than [AuCl(Et3P)]
104 but [AuCl(Et3P)] is still highly cytotoxic. Differences on the 
inhibition of TrxR points to different mechanisms of cytotoxicity between the two compounds. 
 Inspired by the structure of auranofin, and aiming to improve the cytotoxic selectivity, 
we decided to evaluate the cytotoxicity of the Au(I)-phosphine series of compounds (Figure I-
4.1). The correlation between chemical structure and reactivity of the compounds with model 
biomolecules such as N-Ac-Cys and ZnFs was deeply discussed in Part I – Chapters 1 and 3. 
Furthermore, the very same aspects that govern reactivity in the molecular level, such as the 
basicity and bulkiness of the phosphine ligand, σ-donating properties and lability of the co-
ligands L (L=Cl or 4-dimethylaminopyridine, dmap) and overall charge of the compounds 
(neutral vs. cationic) are also expected to play a role in cytotoxic response, establishing an 
interesting set of parameters that can be correlated. 
Regarding the selection of cell lines, auranofin went through phase II clinical trials for 
treating Chronic Lymphocytic Leukemia.105 For that reason, the present chapter focuses on 
evaluating the cytotoxic effects of the Au(I)-phosphine series of compounds on T lymphocity 
tumorigenic cell line (CEM). The non-tumorigenic cell line HUVEC (human umbilical vein 
endothelial cells) was studied for comparison, to determine selectivity. To further understand 
the factors governing cytotoxicity, additional assays were used, such as cell uptake of Au, 
evaluation of cell cycle arrest and determination of apoptosis-related protein expression profile. 
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Figure I-4.1. Designed gold(I) compounds (I-1, I-2, I-4 and I-5). Auranofin (I-3) was studied within the 
Et3P series due to structural similarities. 
Experimental 
Materials  
Compounds I-1, I-2, I-3 and I-4 were synthesized as described in Part I – Chapter 1. Auranofin 
was acquired from Sigma-Aldrich.  
Cytotoxicity assay  
Human umbilical vein epithelial cells (HUVECs) were seeded in 96-well plates (5000 
cells/well) containing 100 μL of Vasculife Endothelial Media (Lifeline), and allowed to attach 
overnight at 37 °C in 5% CO2. The cells were treated with various concentrations of compounds 
I-1 to I-5 in sets containing 4 replicates per concentration. After 72 h, the media was removed 
and 0.5 mg mL-1 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
I-1
I-2
I-4
I-3
+
+
I-5
Part I – Chapter 4 | 103 
 
 
(Sigma) was added to each well and incubated for 3 h at 37°C. The MTT reagent was removed 
and 100 μL of dmso were added to each well. Spectrophotometric readings were determined at 
570 nm using a Synergy H1 microplate reader (BioTek). Percent cell survival was determined 
as treated/untreated controls × 100. The T lymphoblast cell line, CCRF-CEM, was seeded in 
96-well plates (5000 cells/well) containing 100 µL of RPMI media. The cells were treated the 
same as above and assayed using the Cell Counting Kit 8 (Dojindo) according to the 
manufacturer's instructions. 
Cellular morphology 
Following the same experimental conditions described for the cytotoxicity assay, but in a larger 
scale, 1 x 105 CEM cells were seeded in 100 mm dishes containing RPMI media and treated 
with IC25 and IC75 concentrations of the Au(I)-phosphine compounds Cells were then incubated 
at 37 °C (TC incubator) for 24 hours. Images were acquired and processed using an Olympus 
IX70 inverted light microscope coupled with CellSens digital imaging software. 
ICP-MS analysis of Au cellular accumulation 
Following the same experimental conditions described for the cytotoxicity assay, but in a larger 
scale, 1 x 106 CEM cells were seeded in 100 mm dishes containing RPMI media and treated 
with 0.18 µM of each compound for 10 min, 1.5 h or 3 h. Cells were harvested and washed 
twice with PBS. Cell pellets were digested overnight using 1 mL of conc. HNO3 and diluted to 
2 mL with water. Quantitation of Au content for each sample was analyzed using the Varian 
820-MS ICP Mass Spectrometer. An 8-point standard curve (ranging from 100 to 0.7813 ppb) 
was generated for each experiment. 
Cell cycle analysis using flow cytometry 
1 x 106 CEM cells were seeded in 100 mm dishes containing RPMI media. Cells were treated 
with IC75 concentrations of each compound and incubated for 6 or 24 h at 37 °C. Both floating 
and attached cells were harvested, washed, and resuspended in 1 mL of propidium iodide 
solution (3.8 mmol L-1 sodium citrate; 0.05 mg/mL propidium iodide; 0.1% Triton X-100) with 
added RNase B (7 Kunitz units/mL). After staining, the solutions were passed through 35 µm 
filters. The samples (20,000 events each) were immediately analyzed at 670 nm by flow 
cytometry using a BD FACSCanto II flow cytometer and FACSDiva software. 
 
Part I – Chapter 4 | 104 
 
 
Antibody array analysis of phospho-protein expression 
The PathScan Stress and Apoptosis Signaling Antibody Array Kit (Cell Signaling) was used 
according to the manufacturer's instructions. Briefly, 2 x 106 CEM cells were seeded in two 100 
mm dishes per sample and allowed to attach overnight. The cells were treated with IC75 
concentrations of each compound for 3, 6 and 12 h time points. The cells were washed, 
harvested on ice, and lysed in the presence of protease and phosphatase inhibitors. The amount 
of protein for each sample was quantified using the Bradford assay. Blocking buffer was added 
to each array for 15 min. at room temperature, removed and replaced with 75 μg of protein 
overnight at 4°C. After removal of the protein, arrays were washed, and detection antibody 
cocktail supplied with the kit was added for 1 h at room temperature. The arrays were washed 
and incubated for 30 min with HRP-linked Streptavidin solution at room temperature. Finally, 
the slide was covered with lumiGLO/Peroxide reagent and the chemiluminescent array images 
were captured on film following 3–5 s exposure times. The density of the spots was quantified 
using the Protein Array Analyzer by ImageJ and normalized to the α-tubulin values for each 
sample. The difference in protein expression between the untreated control and treated samples 
is expressed as fold-change (normalized treated sample / normalized untreated control sample). 
Results and Discussion 
Cytotoxicity 
Figure I-4.2 shows the growth inhibition profile of CEMs and HUVECs treated with the 
five Au(I)-phosphine compounds. An interesting selectivity was observed towards the 
tumorigenic cell line, as observed by the comparison of IC50 (Table I-4.1). The IC50 values 
obtained were always lower for CEMs than for HUVECs for every newly designed compound 
in the series (I-1, I-2, I-4 and I-5), indicating the selectivity of the Au(I)-phosphine compounds 
towards the tumorigenic cell line over the normal one. Auranofin, on the other hand, had no 
selectivity between the two cell lines and was marginally more cytotoxic against the non-
tumorigenic HUVEC cell line.  
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Figure I-4.2. Growth inhibition profile of compounds of A. CEM and B. HUVEC cell lines exposed to 
compounds I-1. [AuCl(Et3P)], I-2. [Au(dmap)(Et3P)]+, I-3. Auranofin, I-4. [AuCl(Cy3P)] and I-5. 
[Au(dmap)(Cy3P)]+. 
 
Table I-4.1. Summary of the cytotoxicity profile of the Au(I)-phosphine compounds. 
Compound 
IC50 / μmol L-1  
HUVEC CEM 
[AuCl(Et3P)] 6.77 ± 0.15 1.54 ± 0.06 
[Au(dmap)(Et3P)]
+ 18.44 ± 0.92 0.32 ± 0.01 
Auranofin 2.13 ± 0.08 2.91 ± 0.48 
[AuCl(Cy3P)] 8.39 ± 0.34 1.29 ± 0.08 
[Au(dmap)(Cy3P)]
+ 3.59 ± 0.39 1.35 ± 0.05 
 
Compound [Au(dmap)(Et3P)]
+ presented a >57 selectivity index towards the 
tumorigenic CEM cell line. The replacement of Cl by dmap decreases the reactivity rate of the 
Au(I) compound dramatically when targeting model biomolecules (N-acetyl-L-Cys) and also 
zinc fingers (HIV-1 nucleocapsid protein NCp7), in terms of the temporal evolution of the 
aurated species identified by MS. When comparing the ancillary phosphines, Et3P-containing 
compounds (I-1 and I-2) seem to be in general less reactive than Cy3P-containing compounds 
(I-4 and I-5). Slower reaction rate is often translated into higher metalation selectivity. 
Combining the effects of the phosphine and ligand L, [Au(dmap)(Et3P)]
+ was the least reactive 
compound in the series when targeting NCp7 ZnF2, as characterized by CD, MS and 31P NMR 
(See Part I – Chapter 1). The unique profile of cytotoxicity observed for I-2 is translated from 
a unique chemical reactivity within the Au(I)-phosphine series studied here. 
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Figure AI-4.1 (see Appendix 4) shows the morphology of CEM cells untreated and 
treated with compounds 1-3. Untreated CEMs have a distinguished feature of forming clusters 
of cells, that are disrupted upon treatment with the Au(I)-phosphine compounds. A larger 
amount of cellular debris and non-intact cells can be observed for treatment with compound 
[AuCl(Et3P)]. Treatment with compound 2 led to the larger number of intact cells, while 
treatment with auranofin induced aggregation in the cytoplasm but most cells remained with 
intact cellular membranes.  
Regarding molecular targets, [AuCl(Et3P)] was shown to bind to DNA,
106 as opposed 
to auranofin. A series of Au(I)-triethylphosphine, including auranofin, was shown to inhibit 
cytosolic and mitochondrial thioredoxin reductase,28 the most recurring target in the literature 
for this class of compounds. Some other explored targets include glutathione-S-transferase, 
which was inhibited by auranofin;26 lymphoid tyrosine phosphatase (over other tyrosine 
phosphatases), reported to be inhibited by chlorido(bis(cyanoethyl)phenylphosphine)gold(I);29 
the proteasome, with all three enzyme activities (chymothryptic-like, caspase-like and tryptic-
like) inhibited in the micromolar range by [(pbiH)Au(PPh3)]PF6 (pbiH = 2‐(pyridin‐2‐yl)‐1H‐
1,3‐benzimidazole),107 and not by auranofin. As demonstrated here, a wide range of possible 
molecular targets are available for Au(I)-phosphine compounds, with important consequences 
for cytotoxic selectivity. Due to the potent cytotoxic effect observed by us for the Au(I)-
phosphine series (µM to sub-µM range) against the CEMs, we decided to run additional 
experiments to further understand the mechanism of cytotoxicity of the Au(I)-phosphine series: 
flow cytometry, Au intracellular accumulation and protein expression profile. 
 
Flow Cytometry 
Flow cytometry was used to evaluate cellular integrity and to assess changes in CEM’s 
cell cycle induced by treatment with Au(I)-phosphine compounds. It was interesting to observe 
that typical incubation times (24 hours) for CEMs exposed to the Au(I)-phosphine compounds 
led to high apoptotic activity (Figure I-4.3A). The apoptosis-inducing behavior is clearly 
observed at the sub-G1 region. Cells treated with compound I-5 ([Au(dmap)(Cy3P)]
+) were the 
least affected, but still with a high population in the sub-G1 region when compared to control. 
The experimental conditions were further tuned in order to get the details lost at the highly 
cytotoxic treatment regimen. CEM exposed to IC75 concentrations but at reduced incubation 
times gave much more information regarding the mechanism of action of the tested compounds 
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(Figure I-4.3B). Auranofin and compound I-1 ([AuCl(Et3P]) had a similar apoptotic effect, with 
a high population of dead cells / debris. Both Cy3P containing compounds (I-4 and I-5) induced 
an accumulation in the G1/S transition when compared to control. Cells treated with compound 
[Au(dmap)(Et3P)]
+ (I-2) presented a particularly distinguished behavior, with reduced G1 
population and a slight accumulation in G2. This behavior is indicative of a different 
mechanism of cell death, since the G2 arrest is often a result of DNA damage or mitotic 
catastrophe. Flow cytometry data obtained for treatments with IC25 for 6 hours can be found in 
Figure AI-4.2.  
 
Figure I-4.3. Flow cytometry profile of CEM cells treated with IC75 concentrations for A. 24 hours, 
highlighting the highly apoptotic response caused by the Au(I)-phosphine series and B. for 6 hours, 
showing differences within the series. Cell counts corresponding to the Sub-G1 region are marked in 
red, the G0/G1 region in blue and the G2/M region in yellow 
 
As a comparison, previous studies indicated that B16 melanoma cells treated with 
auranofin in the range 0.0125-0.2 µM for 24 hours led to 90% or greater cell survival, with no 
changes from the control experiment observed in the DNA distribution histograms. Treatments 
with 0.2 µM and higher concentrations led to extensive cellular lysis. Auranofin showed no 
selectivity against cycling versus noncycling cells.108  
 
Cellular uptake of Au 
Knowing the cellular accumulation is important for drug design and further 
development, since ineffectiveness is often related to low cellular uptake. A metallodrug 
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facilitates the quantification of drug incorporated into cells, as the metal can be directly 
quantified by means of instrumental techniques such as inductively coupled plasma mass 
spectrometry (ICP-MS). Some structural trends can also be observed analyzing the Au 
intracellular accumulation profile (Figure I-4.4). The size of the phosphine ligands has the first 
and most noticeable effect. Et3P-containing compounds (I-1, I-2 and I-3) have a higher final 
accumulation than Cy3P-containing compounds (I-4 and I-5). Figure I-4.4 shows that the same 
final Au content, considering the standard deviation, was observed for CEMs treated with 
compounds I-1 and I-3. In our case, a clear temporal evolution of the Au uptake by CEM cells 
can be observed for the cationic compounds (I-2 and I-5). On the other hand the neutral 
compounds [AuCl(Et3P)], auranofin and [AuCl(Cy3P)] had an inconclusive temporal evolution 
behavior, with a constant Au incorporation (within the standard deviations) throughout the 
experiment. 
The interaction of [AuCl(Et3P)] and auranofin with RAW 264.7 macrophages has been 
described in the literature.109 The interaction of the compounds with the target cell line was 
based on 195Au-labled compounds. A higher Au uptake was observed in RAW 264.7 cells 
treated with [AuCl(Et3P)] than with auranofin. The time course of the cellular association of 
the 195Au-labled compounds with RAW 246.7 cells was also studied. The195Au content was 
evaluated up to 60 min incubation. The total 195Au content increased for up to 20 min and then 
started to drop, as did the total number of cells (cytotoxic effect). The incorporation of Au from 
[AuCl(Et3P)] was higher than from auranofin.
109 
 
Figure I-4.4. Au accumulation in CEM cells treated with compounds I-1. [AuCl(Et3P)], I-2. 
[Au(dmap)(Et3P)]+, I-3. Auranofin, I-4. [AuCl(Cy3P)] and I-5. [Au(dmap)(Cy3P)]+. 
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Protein Expression Profile 
The activation of 19 cell stress and apoptosis-related proteins in response to treatment 
of CEMs with IC75 concentrations of auranofin, [AuCl(Et3P)] and [Au(dmap)(Et3P)]
+ were 
compared using phospho-antibody array kits (Figure I-4.5A). The Pathscan Stress and 
Apoptosis Signaling antibody array kit with chemiluminescent readouts makes it easy to 
simultaneously detect the cleavage of poly (ADP-ribose) polymerase (PARP) (Asp214), 
caspase-3 (Asp175) and caspase-7 (Asp198); phosphorylation of extracellular signal-regulated 
kinase (ERK)-1/2 (Thr202/Tyr204), protein kinase B (Akt; Ser473), BCL-2-associated death 
promoter (Bad; Ser136), heat shock protein 27 (HSP27; Ser82), Smad2 (Ser465/467), p53 
(Ser15), p38 mitogen activated protein kinase (p38 MAPK; Thr180/Tyr182), stress-activated 
protein kinases and Jun amino-terminal kinases (SAPK/JNK; Thr183/Tyr185), checkpoint 
kinase 1 (Chk1; Ser345), checkpoint kinase 2 (Chk2; Thr68), NF-κB inhibitor α (IκBα 
Ser32/36), eukaryotic translation initiation factor 2 subunit α (elF2; Ser51) and transforming 
growth factor-β-activated kinase 1 (TAK1) (Ser412) and determination of protein content of 
IκBα, survivin and α-tubulin. These signaling molecules represent a good starting point for 
probing the mechanism of cell death when studying a new cytotoxic agent. Quantification using 
densitometric analysis is also shown (Figure I-4.5B).  
The series containing triethylphosphine was selected because it demonstrated better 
selectivity towards the tumorigenic cell line and compound I-2 exhibited the highest 
cytotoxicity among the compounds discussed here. For all three compounds, significant 
proteolytic degradation of caspase-3 was observed, an important substrate of intrinsic (caspase-
9) and extrinsic (caspase-8) mediators of apoptosis. This was accompanied by proteolytic 
degradation of poly(ADP-ribose)-polymerase (PARP), a downstream indicator of cells in the 
final stage of apoptotic DNA fragmentation. DNA strand-break induced phosphorylation of 
Chk2 Thr68 was apparent for all three compounds, however only [Au(dmap)(Et3P)]
+ showed a 
concomitant increase in p53 ser15 phosphorylation and G2-arrest at this time point. Survivin, 
an anti-apoptotic protein only expressed during the G2-phase of the cell cycle, is also elevated 
in this sample. It is possible that auranofin and [AuCl(Et3P)] also induce p53 phosphorylation 
and cell cycle arrest, but at earlier time points. Indeed, for these two compounds, the percentage 
of cells in the sub-G1 fraction is higher than for [Au(dmap)(Et3P)]
+ suggesting a faster rate of 
cell death (see Figure I-4.3B). It is important to mention that CEM cells are compound 
heterozygous for p53 mutations R175H and R248Q, that render p53 unable to activate typical 
response genes and to mediate apoptosis.110 As observed in Figure I-4.4, although the final 
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concentration of gold per cell is similar for the 3 compounds evaluated, [AuCl(Et3P)] and 
auranofin had a higher accumulation at earlier time points, while [Au(dmap)(Et3P)]
+ took a 
longer time to reach the final concentration observed. These observations are suggestive of an 
alternative mechanism of cell death for [Au(dmap)(Et3P)]
+, a direct consequence of the slower 
chemical reactivity achieved by replacing the labile chloride by dmap.  
 
 
Figure I-4.5. A. CEM cells either untreated (control) or treated with Au(I)-phosphine compounds I-1 to 
I-3. Cell lysates were analyzed with the PathScan stress and apoptosis signaling antibody array kit. B. 
Densitometric protein profile of CEM cells treated with compounds I-1 to I-3. 
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CEM cells treated with auranofin showed increased phosphorylation of p38 MAPK 
(Thr180/Tyr182) and SAPK/JNK (Thr183/Tyr185), as previously reported for HL-60 leukemia 
cells.111 This result is consistent with the well-documented cellular response to the increase of 
reactive oxygen species due to inhibition of cytosolic and mitochondrial thioredoxin reductase 
(TrxR).112,113 Furthermore, [Au(dmap)(Et3P)]
+ showed elevated levels of Smad2/3 
(Ser465/467) phosphorylation when compared to the untreated control. Auranofin, in fact, 
showed the opposite result. Although we cannot be certain Smad2/3 is not activated at earlier 
or later time points in this system, to our knowledge increases in Smad2/3 phosphorylation have 
never been reported for auranofin. Smad2 and Smad3 become phosphorylated at their carboxyl 
termini by the receptor kinase TGF-β Receptor I following stimulation by TGF-β. Recent 
reports correlate activation of TGF-β with induction of apoptosis.114,115 Latent TGF-β acts as 
an extracellular sensor of oxidative stress. Release of active TGF-β from the latent complex 
binding protein (LTBP) and latency associated peptide (LAP) occurs in response to a variety of 
agents such as heat, acidic pH, chaotropic agents, and reactive oxygen species.  
ERK1 and ERK2 are protein-serine/threonine kinases that participate in the Ras-Raf-
MEK-ERK cascade. This cascade is responsible for regulating a large variety of cellular 
processes, mainly proliferation and survival but also including adhesion, cell cycle progression, 
migration and differentiation.116 The ERK1/2 catalyzed phosphorylation of nuclear 
transcription factors requires the translocation of ERK1/2 into the nucleus by active and passive 
processes involving the nuclear pore. These transcription factors participate in the immediate 
early gene response. Auranofin and [AuCl(Et3P)] led to ERK1/2 phosphorylation levels similar 
to that of the untreated control. On the other hand, increased ERK1/2 phosphorylation was 
observed for CEM cells treated with [Au(dmap)(Et3P)]
+. Although ERK1/2 phosphorylation 
generally promotes cell survival, it has been shown that under certain circumstances of DNA 
damage stimuli, ERK1/2 can have pro-apoptotic functions. For example, ERK promotes p53 
stability by phosphorylation on Ser15,117,118 leading to its accumulation by inhibition of the 
association with Mdm2.119 CEM cells treated with [Au(dmap)(Et3P)]
+ had both ERK 1/2 and 
p53 phosphorylation upregulated. Furthermore, it has been hypothesized that the main cause of 
ERK sustained activation is the presence of ROS.120  
Finally, HSP27 is a mediator of cell stress, conferring resistance to adverse conditions, 
being activated by phosphorylation at Ser82. CEM cells treated with [Au(dmap)(Et3P)]+ had a 
significant increase in HSP27 phosphorylation, which is not observed for treatment with 
[AuCl(Et3P)]. A significant HSP27 phosphorylation induction was also recently observed when 
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HT-29 cells were treated with organometallic Au(I)(triphenylphosphine) compounds 
containing alkynyl and N-heterocyclic carbene ligands.121,122 HSP27 activation, along with 
eIF2, is consistent with a mechanism based on extracellular oxidative stress. 
 
Conclusions 
A series of Au(I)-phosphine compounds based on the Et3P and on the bulkier Cy3P 
ligands was evaluated in terms of cytotoxicity. Two cell lines were selected, a T lymphocyte 
tumorigenic cell line (CEM) and the non-tumorigenic the Human Umbilical Vein Endothelial 
cells (HUVEC). IC50 values obtained using the MTT protocol were found in lower µM range, 
or even sub-µM for the compound [Au(dmap)(Et3P)]
+. All compounds evaluated here, besides 
auranofin, demonstrated selectivity towards the CEM cell line. The highest selectivity (>57 x) 
was found for [Au(dmap)(Et3P)]
+. High apoptotic activity was observed on CEM cells treated 
with each compound tested here based on flow cytometry data. Under typical exposure time 
(24 hours), a high population of CEMs in the sub-G1 region was observed, relative to the 
untreated control, caused by treatment with the Au(I)-phosphine compound. Reducing the 
exposure time to just 6 hours, CEMs treated with [Au(dmap)(Et3P)]
+ showed a very particular 
behavior within the series, with arrest in G2.  The CEM cells treated with Et3P-containing 
compounds were further evaluated by protein expression profile. The compound 
[Au(dmap)(Et3P)]
+ was shown to cause a wide range cellular responses that trigger apoptosis 
(based for example on activation of Chk2, HSP27, sustained activation of ERK 1/2), as opposed 
to auranofin that mainly activates p38 MAPK. The sub-µM cytotoxicity observed over CEM 
cells is a direct consequence of this multi-modal response. The mechanism of apoptosis induced 
in CEM cells by treatment with [Au(dmap)(Et3P)]
+ is summarized in Scheme I-4.1. For 
comparison, the overall mechanism of cytotoxicity caused by auranofin is given in Figure AI-
4.3, which is in agreement with the apoptotic mechanism previously reported for HL-60 
leukemia cells treated with auranofin.111  
Part I – Chapter 4 | 113 
 
 
 
Scheme I-4.1. Apoptotic mechanism proposed for [Au(dmap)(Et3P)]+. The proteins directly observed 
written in blue, while the expected/required intermediates are written in white. 
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Appendix 
Cellular morphology 
 
Figure AI-4.1. Morphology of CEM cell line untreated and treated with IC75 concentrations of 
compounds [AuCl(Et3P)] (I-1), [Au(dmap)(Et3P)]+ (I-2) and auranofin (I-3). 
 
Flow cytometry 
 
Figure AI-4.2. Flow cytometry profile of CEM cell treated with IC25 concentrations for 6 hours. 
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Mechanism auranofin-induced apoptosis 
 
 
Figure AI-4.3. Apoptotic mechanism caused by auranofin on CEM cells. The mechanism is consistent 
with previous results on HL-60 leukemia cells treated with auranofin.111  
 Au(III) complexes 
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Introduction 
Gold(III) complexes are often seen as unstable in biological media, mainly due to the 
high content of sulfur-containing species that lead to redox processes. On the other hand, 
stabilizing Au(III) represents an interesting synthetic challenge, given the wide variety of 
possible strategies available. For that reason, we decided to explore the stabilization of Au(III) 
using the N^C donor 2-benzylpyridine (bnpy) ligand and compare it to the classic bipy-like 
N^N coordination motif (Figure II-1.1). 
 
Figure II-1.1. Au(III) complexes designed for this study. The organometallic Au(N^C) compound II-1 
[Au(bnpy)Cl2] was studied in comparison to the classic coordination compounds II-2 ([AuCl2(bipy)]+), 
II-3 ([AuCl2(dmbipy]+) and II-4 ([AuCl2(phen)]+), based on the motif Au(N^N). The zinc finger targets 
evaluated are also represented: the HIV-1 nucleocapsid protein NCp7 (ZnF2 boxed), along with the 
human transcription factor Sp1. 
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Although presenting many stability-related advantages over the Au(N^N) motif, the 
Au(C^N) motif has been much less explored in the literature, with few examples reported.102,123–
125 Au(C^N) organometallic complexes have been studied mainly for anticancer applications. 
Parish introduced, in 1996, the complexes [AuX2(damp)] (damp=o-C6H4CH2NMe2; X = Cl
-, 
OAc- or X2 = dithiocarbamate, malonate).
126 The gold(III) complexes [Au(acetato)2(damp)] and 
[Au(malonato)(damp)] exhibited selective cytotoxicity in vitro and showed in vivo antitumor 
activity against subcutaneously implanted xenografts derived from the HT1376 bladder and 
CH1 ovarian cell lines.127 Au(III) complexes based on the C^N or C^N^N motifs (deprotonated 
C-donors) such as 2-(2-phenylpropan-2-yl)pyridine (pydmb-H) and 6-(2-phenylpropan-2-yl)-
2,2’-bipyridine (bipydmb) ligands were studied by Messori and co-workers and exhibited 
remarkable redox and ligand replacement stability in biological media, even in the presence of 
relatively high concentrations of intracellular thiols.125,128  
Regarding studies targeting biomolecules, the Au(C^N^N) compound containing the 
deprotonated 6-(1,1-dimethylbenzyl)-2,2′-bipyridine) as ligand demonstrated amino acid-level 
selectivity when reacted with hen egg white lysozyme. The reaction product (which had its 
crystal structure determined) had a Au(I) coordinated to a Gln residue. Although the starting 
compound suffered reduction, the N-coordinated Au(I) is unusual.129   Au(III)(N^N) and 
Au(III)(N^N^N) compounds were shown to cause zinc displacement in ZnF proteins but often 
followed by Au(III) to Au(I) reduction, leading to the formation of gold(I) fingers, as previously 
demonstrated for compounds such as [Au(dien)(N-donor)]39 and [Au(terpy)Cl].54  
Given the unique stability of the Au(C^N) class of compounds, and the unusual 
interaction products with proteins obtained in the few cases reported in the literature, we 
explored the application of compound II-1 as a Zn ejector targeting the HIV-1 nucleocapsid 
protein (“full” protein and F2, with Cys3His domains) as well as the human transcription factor 
Sp1 (Cys2His2). The Au(III) compounds were also evaluated regarding the inhibition of the 
interaction between the full-length NCp7 ZnF and a model DNA sequence (SL2).  
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Experimental 
Materials 
H[AuCl4], was purchased from Acros. 2,2’-Bipyridine (bipy), 4,4’-dimethyl-2,2’-bipyridine 
(dmbipy) and 1,10-phenanthroline (phen) monohydrate were obtained from Sigma-Aldrich. 
Deuterated solvents are from Cambridge isotopes or Sigma-Aldrich. 
Synthesis 
[Au(bnpy)Cl2] (II-1). An adaptation of a published method was used.130 In summary, 
H[AuCl4]·3H2O (0.25 mmol, 98.5 mg) was dissolved in 5 mL of distilled water. To this 
solution, the ligand 2-benzylpyridine (0.25 mmol, 40.1 μL) was added. A yellow solid 
precipitated immediately. The suspension was left under reflux for 18 hours and the solid turned 
white. The solid was isolated by filtration, washed with cold water and dried in vacuo. Anal. 
Calcd. for C12H10AuCl2N (436.09 g mol
-1): C 33.05%, H 2.31%, N 3.21%. Found: C 33.16%, 
H 1.87%, N 3.47%. ESI(+)-QTOF-MS ([M-Cl+CH3CN]
+, m/z): 441.0446, calculated 
441.0438. 1H NMR (dmso-d6, 400 MHz): δ 4.50 (dd, 2H), 7.08 (td, 1H), 7.20 (td, 1H), 7.26 
(dd, 1H), 7.42 (dd, 1H), 7.72 (ddd, 1H), 8.00 (dd, 1H), 8.27 (td, 1H), 9.19 (dd, 1H)Crystals 
suitable for single crystal X-ray analysis were obtained by recrystallization from acetonitrile. 
[AuCl2(bipy)][PF6] (II-2). An adaptation of a published method was used.131 In summary, 
K[AuCl4] (0.25 mmol, 95.0 mg) was dissolved in 3 mL of H2O/CH3CN (1:5). The ligand bipy, 
(0.25 mmol, 39.5 mg) was dissolved in 0.5 mL of CH3CN and added to the gold(III)-containing 
solution. NH4PF6 (0.75 mmol, 124.6 mg) was added as a solid to the solution. The mixture was 
refluxed for 16 hours. The solids were isolated by filtration and washed with cold water and 
dried in vacuo. Anal. Calcd. for C10H8AuCl2F6N2P (569.02 g mol
-1): C 21.11%, H 1.42%, N 
4.92%. Found: C 21.08%, H 0.99%, N 5.00%. ESI(+)-QTOF-MS (M+, m/z): 422.9755, 
calculated 422.9730. Crystals suitable for single crystal X-ray analysis were obtained by 
recrystallization from acetonitrile. 1H NMR (dmso-d6, 400 MHz): δ 8.15 (ddd, 2H), 8.74 (dd, 
2H), 8.94 (dd, 2H), 9.42 (dd, 2H). 
[AuCl2(dmbipy)][PF6] (II-3) was synthesized following the same procedure used for 
compound II-2, using dmbipy instead of bipy. Anal. Calcd. for C12H12AuCl2F6N2P (597.07 g     
mol-1): C 24.14%, H 2.03%, N 4.69%. Found: C 24.47%, H 1.49%, N 4.89%. ESI(+)-QTOF-
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MS (M+, m/z): 453.0089, calculated 453.0015. 1H NMR (dmso-d6, 400 MHz): δ 2.68 (s, 6H), 
7.96 (dd, 2H), 8.78 (d, 2H), 9.21 (d, 2H). 
[AuCl2(phen)][PF6] (II-4) was synthesized following the same procedure used for compound 
II-2, using 1,10-phenanthroline instead of 2,2’-bipy. Anal. Calcd. for C12H8AuCl2F6N2P 
(593.04 g mol-1): C 24.30%, H 1.36%, N 4.72%. Found: C 24.08%, H 0.70%, N 4.73%. ESI(+)-
QTOF-MS (M+, m/z): 446.9707, calculated 446.9730. 1H NMR (dmso-d6, 500 MHz): δ 8.26 
(dd, 2H), 8.40 (s, 2H) 9.11 (dd, 2H), 9.33 (dd, 2H). Crystals suitable for single crystal X-ray 
analysis were obtained by recrystallization from acetonitrile.  
Elemental Analysis data were acquired on an Elemental Analyzer CHNS-O 2400 Perkin Elmer. 
Mass spectra were acquired in a XEVO QTOF–MS instrument (Waters). The sample was 
dissolved in the smallest possible volume of DMSO and diluted in a 1:1 (v/v) mixture of water 
and acetonitrile containing 0.1% formic acid. NMR spectra (1H, HSQC and HMBC) were 
acquired on a Bruker Avance III 400/500 MHz instrument.  
NCp7 (F2 and “full”) and Sp1 preparation. An adequate amount of apo-NCp7 was dissolved 
in water and zinc acetate was added (1.2 :1 mol/mol per zinc binding domain). The pH was 
adjusted to 7.2-7.4 using a solution of NH4OH. The final solution was incubated for 2 h at 37 
°C prior to any experiments. The ZnF formation was confirmed by circular dichroism and mass 
spectrometry. The overall CD profile and species distribution in MS were in agreement with 
data previously reported for all ZnFs studied here. 
X-Ray Crystal Structures 
Single crystals of compounds II-1, II-2 and II-4 were analyzed on a Bruker ApexII CCD 
diffractometer using graphite monochromated Mo Kα (λ = 0.71703 Å) radiation. Least squares 
refinement was used to determine unit cell parameters (dimension and orientation matrices) 
obtained by θ-χ scans. The ApexII Suite ([APEX2 v2014.1-1 (Bruker AXS), SAINT V8.34A 
(Bruker AXS Inc., 2013)] was used for data integration and scaling.  
The structures were solved using direct methods available on ShelXT and refined using a full-
matrix least-squares technique on F2 using ShelXL132, as part of Olex2.133 Non-hydrogen atoms 
were refined anisotropically while hydrogen atoms were added in idealized positions and 
further refined based on the riding model. Figures were generated using Mercury 3.6. 
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Cyclic Voltammetry 
Cyclic voltammograms were obtained in an Autolab EcoChemie PGSTAT20 potentiostat using 
tetrabutylammonium hexafluorophosphate (0.10 mol L-1 in dry dmf) as supporting electrolyte 
for all measurements. An Ag/AgCl electrode was used as pseudo-reference, a Pt wire was used 
as auxiliary electrode and a glassy carbon electrode was used as the working electrode. Stock 
solutions containing 5 mmol L-1 of compounds II-1, II-2, H[AuCl4]∙3H2O and the ligands bnpy 
and 2,2’-bipy were used for measurements. Every solution evaluated was prepared in dry, 
degassed dmf containing 0.10 mol L-1 tetrabutylammonium hexafluorophosphate. The scan 
rates evaluated were 10, 25, 50, 100, and 200 mV s–1. 
Interaction with model biomolecules 
N-Acetyl-L-Cysteine 
NMR. To a 10 mmol L-1 solution of compound II-1 in dmso-d6, N-Ac-Cys was added (1:1 
mol/mol). 1H NMR spectra were acquired on a Bruker Avance III 400/500 MHz immediately 
after mixing and over time (one spectrum was acquired every 15 minutes for 4 hours). Spectra 
were also acquired after 24 and 96 hours. MS. To a 10 mmol L-1 of compound II-1 in acetonitrile 
was added 1 eq of N-Ac-Cys dissolved in acetonitrile. MS was acquired immediately after 
mixing. 
GSH 
NMR. To a 25 mmol L-1 solution of compound II-1 in dmso-d6, GSH was added (1:1 mol/mol). 
1H NMR spectra were acquired on a Varian 300 MHz immediately after mixing and over time 
(one spectrum was acquired every 15 minutes for 4 hours; a final spectrum was acquired after 
24 hours). 
Gly-L-His 
NMR. To a 10 mmol L-1 solution of compound II-1 in dmso-d6, Gly-L-His was added (1:1 
mol/mol). 1H NMR spectra were acquired on a Bruker Avance III 400/500 MHz immediately 
after mixing and over time (one spectrum was acquired every 15 minutes for up to 4 hours; a 
final spectrum was acquired after 24 hours). 
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Targeting NCp7 F2 and the full-length NCp7 ZnF by MS 
For MS experiments, 1 mmol L-1 reaction mixtures (1:1 mol/mol of Au(III) complex per ZnF 
core) were prepared in water/acetonitrile mixtures at pH 7.0 (adjusted using NH4OH). The 
reaction solutions were incubated at room temperature for 0 h, 2 h, 6 h and 24 h. The samples 
were sprayed using a final concentration of ~100 μmol L-1. Experiments were carried out on an 
Orbitrap Velos from Thermo Electron Corporation operated in positive mode. Samples (25 μL) 
were diluted with methanol (225 μL) and directly infused at a flow rate of 0.7 μL/min using a 
source voltage of 2.30 kV. The source temperature was maintained at 230°C throughout.  
NCp7 (full) / SL2 (DNA) interaction and inhibition 
NCp7 and SL2 binding control experiment. A range of concentrations of NCp7 (aa 1-55) 
were mixed with 100 nM 3′-fluorescein-labeled hairpin SL2 DNA (sequence 
GGGGCGACTGGTGAGTACGCCCC) in a final volume of 50 µL buffer containing 
1.25 mmol L-1 NaCl, 0.125 mmol L-1 HEPES pH 7.2 in a 96-well black, low-binding 
microplate (Greiner). Fluorescence Polarization (FP) readings were recorded immediately on a 
CLARIOstar microplate reader.  
Inhibition of NCp7-SL2 binding experiment. Serially diluted samples of compounds II-1, 
II-2 and II-4 (stocks prepared in dmf) were incubated with 5 µmol L-1 NCp7 for 30 min before 
addition of SL2 DNA. The final concentration of DNA was 100 nmol L-1 in a total volume of 
50 µL. The solution was buffered with 0.125 mmol L-1 HEPES at pH 7.2 containing 1.25 mmol 
L-1 NaCl. Experiments were carried out in a 96-well black, low-binding microplate 
(Greiner). The NCp7 concentration was chosen from the NCp7-SL2 binding experiment such 
that 90 % of SL2 was bound. FP readings were recorded immediately after the addition of SL2. 
Results and Discussion 
Single-Crystal X-ray Diffraction 
Crystals suitable for single-crystal X-ray diffraction were obtained for compounds II-1, 
II-2 and II-4. The structures of compounds II-2 (Figure II-1.2 and Figure AII-1.1) and II-4 
(Figure II-1.3 and Figure AII-1.2) are new and will be further discussed. The structures of 
compounds II-1 (Figure AII-1.3, also previously deposited under CCDC entry HOSHEE) and 
II-3 (published elsewhere,131 CCDC entry KUMYEX) will be brought in for comparison. Bond 
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distances of the first coordination spheres of compounds II-1 to II-4 are summarized in Table 
II-1.1. A full description of the crystallographic data and refinement parameters obtained for 
compounds II-1, II-2 and II-4 is given in Table AII-1.1.  
Table II-1.1. Selected structural parameters for the organometallic compound II-1 in comparison to the 
Au(N^N) compounds II-2 to II-4. 
Compound Distance / Å Angles / deg 
Au(C^N) Au-N Au-C Au-Cl Au-Cl’ N-Au-C Cl-Au-Cl 
II-1 2.046(7) 2.060(7) 2.324(2) 2.348(3) 86.9(3) 91.73(9) 
Au(N^N) Au-N Au-N' Au-Cl Au-Cl' N-Au-N Cl-Au-Cl 
II-2 2.040(2) 2.036(2) 2.271(1) 2.269(1) 80.79(8) 88.65(3) 
II-3 2.027(9) 2.020(10) 2.257(3) 2.250(4) 80.7(4) 88.9(1) 
II-4 2.036(2) 2.032(2) 2.251(1) 2.255(1) 81.75(9) 89.28(3) 
 
 
Figure II-1.2. A. Ellipsoid view (50% probability) of the asymmetric unit of compound 
[AuCl2(bipy)]PF6. B. Packing view along the a axis. C. Packing view along the c axis. 
A
B C
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The longest Au-N bond in the series (2.046(7) Å) was observed for [Au(bnpy)Cl2], 
while the shortest (2.020(10) Å) was part of [AuCl2(dmbipy)]
+. The high pKa of dmbipy (caused 
by the inductive effect of the methyl groups) can explain the shorter bond distances. In terms 
of Au-Cl bonds, the longest observed in the series appears for the chloride trans to the Au-C 
bond (2.348(3) Å), as expected by the strong trans effect caused by the carbanion. Even the 
Au-Cl trans to the pyridine ring in compound II-1 (2.324(2) Å) is still longer than the average 
Au-Cl found on the Au(N^N) series. In the Au(N^N) series, [AuCl2(bipy)]
+ has slightly longer 
Au-Cl bonds than the other compounds (2.27 vs. 2.25 Å). As comparison, the compound 
[AuCl4]
-, which has the chlorides perfectly positioned in the vertices of a square centered in the 
Au atom, has an average Au-Cl bond distance of 2.26-2.29 Å.134  
In terms of short contacts, [AuCl2(bipy)]
+ has the most complex network, relying on 
interactions with the [PF6]
- counterion and also with other [AuCl2(bipy)]
+ subunits to keep the 
crystal structure together (Figure AII-1.1). Two [PF6]
- units appear positioned right above and 
below the coordination plane of [AuCl2(bipy)]
+, which leads to the shortest anion-π interactions 
observed in the structure  [Cg1 · · ·F3 (2.983 Å), Cg1 · · ·F1i (3.019 Å), (i) = ½ – x, – ½ + y, 
½ – z]. In addition, one of the pyridine rings appears surrounded by [PF6]- units, with many C-
H∙∙∙F contacts adding up to the stability of the crystal [C3-H3· · ·F2ii, C4-H4· · ·F5ii, C4-H4· · 
·F4iii, C5-H5· · ·F3iv, C6-H6· · ·F5iv, with the corresponding C3 · · ·F interactions ranging from 
3.133 to 3.433 Å. Symmetry codes (ii) = –x, 1 – y, – z; (iii) = 1 – x, 1 – y, –z ; (iv) = 1 + x, y, 
z]. Additionally, interactions between [AuCl2(bipy)]
+ subunits take place through three             
Cl· · ·H-C interactions, with corresponding Cl· · ·C interactions in the range of 3.487 to 3.530 
Å [Cl1· · ·H4’-C4’v, Cl1· · ·H3’-C3’v, Cl2· · ·H5’-C5’vi. Symmetry codes (v) = ½ – x, ½ + y, 
½ – z; (vi) = –x, 1 – y, 1 – z]. 
The structure of compound II-3, reported elsewhere,131 differs dramatically from 
compounds II-2 and II-4 in terms of interaction between the [AuCl2(N^N)]
+ group with the PF6 
counter-ion. One of the faces of [PF6]
- is positioned right above the [AuCl2(dmbipy)]
+ unit. As 
consequence, F ∙ ∙ ∙Au (shortest: 3.11Å) and F ∙ ∙ ∙N (shortest: 2.97 Å) interactions are also 
present, in addition to the F ∙ ∙ ∙C (shortest: 2.99 Å) and F ∙ ∙ ∙HC (shortest: 2.52 Å). Regarding 
the chlorides, interactions with both aliphatic (Cl ∙ ∙ ∙H3C, shortest: 2.9 Å) and aromatic               
(Cl ∙ ∙ ∙HC, shortest: 2.75 Å) hydrogens can be observed. 
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Figure II-1.3. A. Ellipsoid view (50% probability) of the asymmetric unit of compound 
[AuCl2(phen)]PF6. B. Intermolecular interactions, highlighting the hydrophobic CH∙∙∙F and the anion-π 
interactions with the hexafluorophosphate counterion. C. Packing view along the c axis. 
 
In the structure of [AuCl2(phen)]
+ (Figure II-1.3), Au(III) deviates from planarity (as 
determined based on the four coordinating atoms) by 0.018 Å (r.m.s). Despite the highly 
symmetrical nature of the hexafluoridophosphate counter-ion, this unit does not show any 
disorder. The molecular packing of the [AuCl2(phen)]PF6 crystal is shown in Figure AII-1.2. 
Despite the square-planar coordination environment around Au(III) and the presence of the 
highly conjugated and planar 1,10-phenanthroline ligand, π interactions have little relevance to 
the stabilization of the crystal. The shortest π-like interaction between the centroids                 
[Cg2 ∙ ∙ ∙Cg3vii; symmetry code: (vii) ½ + x, y, ½ – z] of two neighboring 1,10-phenanthroline 
rings are associated with a distance of 4.2521(15) Å, which is very close to the upper limit of 
the threshold established by Janiak135 for a relevant offset interaction. The interactions between 
the hexafluorophosphate counter-ion and the 1,10-phenanthroline ligands constitute the major 
A
B C
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intermolecular interactions in the crystal and can be divided into two types. The first type 
corresponds to an anion donor π-acceptor interaction,136 with the shortest contact being             
C2-H2· · ·F5viii with a corresponding C2 · · ·F5viii distance of 3.096(4) Å [symmetry code        
viii = x, ½ – y, ½ + z]. The second and unique type of interaction between the PF6 anion and 
the system of the phenanthroline ligand is observed where fluorine atoms point directly to the 
mid-point of an aromatic C-C bond. The distance between F6ix and the mid-point of C5 and C6 
is 2.822 Å. The individual distances are C5-F6ix 2.925 (3) and C6-F6ix 2.894 (3) A˚ [symmetry 
code: (ix) = – ½ + x, y, ½ – z] 
The organometallic compound [AuCl2(bnpy)] has the ligand coordinated by the nitrogen 
of the pyridyl moiety and a carbon of the benzyl ring. The ligand itself acquires a non-planar 
conformation when coordinated, as consequence of the CH2 bridge between both aromatic 
rings. In terms of short contacts present in the structure (Figure AII-1.3), non-classical                 
C-H · · ·Cl hydrogen bonds are observed with a C-H of the CH2 group [Cl1· · ·H7B-C7
x        (Cl1 
· · ·C7x, 3.841 Å). Symmetry code (x) = 1 + x, y, z] and also with an aromatic C-H          [(Cl2 
· · ·H6-C6xi (Cl2 · · ·C6xi, 3.471 Å). Symmetry code (xi) = 3/2 – x, ½ + y, ½ – z]. Finally, a 
variant of a π interaction is observed between a hydrogen of the CH2 group and the pyridine 
ring of the bnpy ligand [H7A · · ·Cg5xii (C7 · · ·Cg5xii 3.398 Å). Symmetry code                          
(xii) = ½ – x, ½ + y, ½ – z]. 
 
NMR 
The full NMR characterization of compound [Au(bnpy)Cl2] was not reported in the 
literature so far. For that reason, compound II-1 was fully characterized by solution NMR 
techniques (Figure AII-1.4). The most distinct spectroscopic feature of [Au(bnpy)Cl2] is the 
non-equivalency of the hydrogens of the CH2 group when bnpy acts as a bidentate ligand. This 
feature allows us to probe coordination and, indirectly, the oxidation state of Au (as bnpy can 
be a bidentate ligand for Au(III) only). 
The labile chlorides found in compounds II-1 to II-4 are susceptible to solvent 
replacement as previously described in the literature, for example, for [AuCl2(phen)]
+ in 
water.137 How quickly this reaction happens depends on the strength of the Au-Cl bond and also 
on the trans effect induced by the bidentate ligand. Figure AII-1.5 to Figure AII-1.8 show the 
1H NMR spectra of compounds II-1 to II-4 in dmso-d6 immediately after dissolution and after 
24-72 hours. Considering the lower lability of the bidentate C^N / N^N ligands over the 
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chloride, three species are expected to coexist in dmso: [AuCl2L]
+, [AuClL(dmso)]2+ and 
[AuL(dmso)2]
3+. All three species were identified for compound II-2, while [AuLCl2]
+ and a 
ligand replacement product were identified for compound II-3. Of all the Au(N^N) complexes, 
[AuCl2(phen)]
+  (II-4) has the largest amount of the chloride replacement product shortly after 
dissolution (most likely [AuL(dmso)2]
3+), which becomes the only species in solution after 72 
hours. The cyclometallated compound II-1, on the other hand, shows no evidence of extensive 
chloride replacement by dmso-d6, even 48 hours after dissolution.  
Compounds II-1 to II-4 were also compared in terms of 15N chemical shifts.  This data 
was obtained indirectly, using the {1H,15N} HMBC technique and samples with natural 
abundance of 15N (Figure AII-1.9). The 15N signal observed for [Au(bnpy)Cl2] (227.54 ppm) 
does not differ significantly from that of [AuCl2(bipy)]
+ (230.30 ppm)  and [AuCl2(dmbipy)]
+ 
(224.26 ppm). The signal obtained for [AuCl2(phen)]
+ (244.32 ppm) is the one that differs the 
most from the rest of the series, as consequence of the different electronic system (delocalized 
over three fused aromatic rings) of phen. 
 
Redox stability by Cyclic Voltammetry (CV) 
The redox stability of organometallic compound II-1 was further studied in comparison 
to compounds II-2 and the precursor H[AuCl4] (Figure II-1.4). Reduction of compound II-2 is 
observed at -0.42 V and for H[AuCl4] at -0.45. On the other hand, for compound II-1, the 
reduction process happens at -1.21 V, in agreement to previously published data.138 The -0.8 V 
difference indicates an increased stability of compound II-1 towards reduction, a very desirable 
property for a compound that will be exposed to the Cys-rich biological media. Comparisons 
with the free ligand and the solvent (dmf) are shown in Figure AII-1.10.  
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Figure II-1.4. Cyclic voltammogram (vs. Fc/Fc+) of the organometallic compound II-1 in comparison 
to the Au(N^N) compound II-2 and the gold precursor [AuCl4]-. Tetrabutylammonium 
hexafluorophosphate (0.10 mol L-1 in dry dmf) was used as supporting electrolyte in all measurements. 
An Ag/AgCl electrode was used as pseudo-reference, a Pt wire was used as auxiliary electrode and a 
glassy carbon electrode was used as the working electrode. 
  
Targeting model biomolecules 
N-Acetyl-L-cysteine (N-Ac-Cys) 
N-Ac-Cys was selected because it is a biologically relevant model S-donor. The 
interaction of [Au(bnpy)Cl2] (II-1) with N-Ac-Cys was followed using NMR (Figure AII-1.11) 
and mass spectrometry (Figure AII-1.12). By 1H NMR, it was possible the determine whether 
bnpy is still coordinated as bidentate ligand to Au(III). The 6-membered metallacycle can still 
be observed even after 24h of incubation with N-Ac-Cys, which can be followed based on the 
coupling of the hydrogens on the CH2 group. The two hydrogens are non-equivalent only when 
bnpy acts as a bidentate ligand. The MS spectrum acquired for the interaction between 
compound II-1 and N-Ac-Cys shows very interesting features that are representative of the 
overall reactivity of this compound with Cys-containing biomolecules. The most abundant peak 
(527.06 m/z) corresponds to the simple ligand-replacement product, [Au(bnpy)(N-Ac-Cys)]+. 
More interestingly, it is also possible to observe the C-transferred product bnpy-N-Ac-Cys with 
high abundance at 331.11 m/z. This unique product is evidence of an Au-mediated C-transfer 
to the S-donor (Cys arylation). 
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Glutathione (GSH) 
As the most abundant intracellular S-containing peptide, GSH represents a relevant 
biological target. Using NMR, we probed the redox stability of compound II-1 in presence of 
a high concentration of GSH (25 mmol L-1), much higher than the intracellular total 
concentration of 7 mmol L-1.139 Figure AII-1.13 shows the spectra acquired for the interaction 
of [Au(bnpy)Cl2] in presence of GSH (t=0 and up to 24 hours after mixing). The metallacycle 
is still stable even after 24 hours as observed by the presence of the non-equivalent hydrogens 
of the CH2 group (in the 4.5 ppm region). The stability of the [Au(bnpy)] moiety in presence of 
GSH observed by 1H NMR agrees with the CV electrochemical data of the free compound. 
Figure AII-1.14 shows the MS spectrum obtained for the interaction between compound II-1 
[Au(bnpy)Cl2] and GSH. The signal at 671.11 m/z corresponds to the major Au-containing 
product observed, [Au(bnpy)(GSH)]+, which indicates chloride replacement by GSH. 
Furthermore, oxidized GSH (GSSH+) was also observed at 613.15 m/z, which may correlate to 
Au(III) reduction to some extent. As a minor product, the species [Au(bnpy)]2-GSH
+ was also 
identified at 1034.48 m/z. 
Gly-L-His 
Besides Cys residues, ZnF proteins also have His residues coordinated to Zn. Gly-L-His 
was selected as a model to His binding. The compound II-1 was mixed with Gly-L-His and the 
reaction was followed by 1H NMR (Figure AII-1.15). Compound II-1 is less reactive with Gly-
L-His than with the Cys-containing GSH and N-Ac-Cys. No changes are observed in the 
hydrogen signals of [Au(bnpy)Cl2] even 24 hours after mixing. Some changes were observed 
over time for the hydrogens H2 and H5 of the imidazole ring140 of histidine, indicating an 
interaction. 
 
Targeting Zinc Fingers 
NCp7 (ZnF2) 
The interaction of compounds II-1 to II-4 with NCp7 (ZnF2) was followed over time 
using MS (Figure AII-1.16 to Figure AII-1.19). The typical reactivity behavior of Au(III) 
complexes was observed for compounds II-2 to II-4 when interacting with NCp7 (ZnF2) at t=0 
(immediately after interaction). Reduction to different extensions was always observed, and the 
bidentate N-donor was not observed coordinated to Au. Compound II-2 ([AuCl2(bipy)]
+) 
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interacts immediately with NCp7 F2 and the species oxiF (4+ at 555.99 and 5+ at 444.99 m/z) 
and Au(I)2oxiF (3+ at 872.29, 4+ at 654.47 and 5+ at 523.77 m/z) represent the main observable 
products. Compound II-3 [AuCl2(dmbipy)]
+ also reacts fast, but AuF is the main gold-
containing product observed here (2+ at 1209.97, 3+ at 806.98, 4+ at 605.48 and 5+ at 484.89 
m/z). Oxidized finger is also observed immediately (oxiF2+ at 1110.98 and oxiF5+ at 445.00 
m/z). Compound II-4 ([AuCl2(phen)]
+) was the least reactive compound among the Au(N^N) 
series since an aurated ZnF species, Au-ZnF (4+ at 621.21 m/z), was still observed at t=0. AuF 
(4+ at 605.23 m/z) and oxiF (4+ at 556.24 m/z) were also identified. After 48 hours, further 
auration was observed, with Au(I)2F (3+ at 872.97, 4+ at 654.97 m/z) being identified, 
accompanied by AuF (4+ at 605.48, 3+ at 807.31 m/z). 
On the other hand, compound II-1 demonstrated an unique reactivity. At t=0 (Figure 
AII-1.16A), the chlorides were lost but bnpy remained coordinated to Au(III). Zinc 
displacement was also observed. Three related species were identified immediately after 
incubation: Au(III)(bnpy)-F (4+ at 647.50 m/z, 3+ at 876.15 m/z), Au(III)(bnpy)-ZnF (4+ at 
663.49 m/z, 3+ at 884.31 m/z) and Au(III)(bnpy)-Zn2F (4+ at 678.97 m/z, 3+ at 909.64 m/z). 
After 48 h further auration is observed, as observed by the presence of species such as 
([Au(III)(bnpy)]3-F)
4+ at 829.27 and ([Au(III)(bnpy)]3-F)
3+ at 1105.36 m/z. Even more 
interestingly, the S-arylated product (first observed based on the interaction of compound II-1 
with N-Ac-Cys) was also identified here, after 24 hours (Figure AII-1.16C). The product 
(bnpy)-oxiapoF (5+ at 478.81 and 2+ at 1195.52 m/z) gives strong evidence for the Au(III)-
mediated C-bond transfering to cysteine residues. Therefore, the following reactivity trend was 
established based on the reactivity of the Au(III) compounds with NCp7 (ZnF2): 
 
Targeting the full-length NCp7 zinc finger 
Two compounds were selected for further studies using the full-length NCp7 ZnF as 
target. The organometallic [Au(bnpy)Cl2] (Figure II-1.5A) was compared to [AuCl2(bipy)]
+ 
(Figure II-1.5B).  
[Au(bnpy)Cl2] << [AuCl2(phen)]
+ < [AuCl2(dmbipy)]
+ < [AuCl2(bipy)]
+ 
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Figure II-1.5. Mass spectra obtained for the interaction of selected Au(III) compounds with the full-
length NCp7 ZnF. A. [Au(bnpy)Cl2] in comparison to B. [AuCl2(bipy)]+, immediately after mixing. 
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Both compounds interact with the full-length NCp7 ZnF immediately after mixing. 
[AuCl2(bnpy)] leads to the formation of oxiF (11+ at 584.64, 10+ at 642.90, 9+ at 714.33 and 
8+ at 803.38). The chlorides are labilized and the cyclometallated adduct Au(bnpy)oxiF is 
observed (11+ at 617.73, 10+ at 679.50, 9+ at 754.78 and 8+ at 849.01 m/z). After 48 hours 
(Figure AII-1.20) another species appears, the Au-catalyzed C-S coupling product bnpy-oxiF 
(10+ at 659.92 and 9+ at 733.89 m/z). The mass spectrum of the species bnpy-oxiF10+, in 
comparison to the theoretical isotopic distribution, is shown in Figure II-1.6. 
 
Figure II-1.6. Representative signal corresponding to the Au-catalyzed C-S bond product bnpy-oxiF 
species (10+), obtained after reaction of [Au(bnpy)Cl2] with the full-length NCp7 ZnF after 24 hours. 
Inset: theoretical mass spectrum expected for the aforementioned species. 
 
[AuCl2(bipy)]
+ also leads to the formation of oxiF (12+ at 536.00, with 11+, 10+ and 9+ 
charge states also being observed). On the other hand, AuF (11+ at 602.64, 10+ at 662.70 and 
9+ 736.11 m/z) and Au2F (11+ at 620.45, 10+ at 682.39 and 9+ at 757.99 m/z) are the main Au-
containing species, with no N^N ligand coordination observable.  
Combining the information acquired on the behavior of compound II-1 ([Au(bnpy)Cl2]) 
in the presence of the model S-donor N-Ac-Cys and also the ZnFs NCp7 (F2) and the full-
length NCp7, the mechanism of C-S coupling shown in Scheme II-1.1 can be proposed. 
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Scheme II-1.1. Generalized Au-mediated C-S coupling mechanism, observed based on the interaction 
of [Au(bnpy)Cl2] with N-Ac-Cys, NCp7 (ZnF2) and the full-length NCp7 ZnF. 
 
This is the first direct observation of a C-S coupling on a ZnF obtained by the interaction 
of a metal complex with this class of protein, representing a completely new mechanism of zinc 
displacement.  
 
Targeting the human transcription factor Sp1 (ZnF3) 
Cleaner mass spectra were obtained for the interaction of compounds II-1 to II-4 with  
Sp1 ZnF3 (Figure II-1.7), as consequence of the higher intrinsic reactivity of the Cys2His2 motif 
(Sp1) when compared to the Cys3His motif (NCp7). The Au(N^N) motif lead mainly to the 
formation of apoF (8+ at 421.72, 7+ at 481.82, 6+ at 561.96, 5+ at 674.15, 4+ at 842.44 m/z). 
[AuCl2(phen)]
+, on the other hand, let to the appearance of AuF (7+ at 509.96, 6+ at 594.28 and 
5+ at 712.94 m/z). Again, the most different behavior in the series was observed for 
[Au(bnpy)Cl2], agreeing with the reactivity trend observed for NCp7 (ZnF2). The species 
Au(bnpy)-F (7+ at 533.97, 6+ at 622.80, 5+ at 747.16 and 4+ at 933.70 m/z) was the main 
product identified, as opposed to the Au(bnpy)-oxiF species identified when targeting NCp7 
(ZnF2).  
2 Cl-
Reductive 
elimination
Au-L
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Figure II-1.7. Interaction of A. [Au(bnpy)Cl2], B. [AuCl2(bipy)]+, C. [AuCl2(dmbipy)]+ and D. 
[AuCl2(phen)]+ with the human transcription factor Sp1 (F3) immediately after mixing. 
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Full-length NCp7 zinc finger/SL2 DNA interaction inhibition 
Given the unique mechanism of Zn displacement observed for compound II-1, an 
experiment based on fluorescence polarization was set up to determine whether this compound 
is able to disrupt the interaction of NCp7 full-length zinc finger with the model DNA. The 
Au(N^N) compounds II-2 to II-4 were also studied in comparison (Figure II-1.8).  
 
Figure II-1.8. Inhibitory effect of the Au(III) compounds II-1 to II-4 on the interaction of the full-length 
NCp7 ZnF with SL2 model DNA. 
 
The Au(N^N) motif had no inhibitory activity, while some inhibition was observed for 
the organometallic compound [Au(bnpy)Cl2] at concentrations above 0.1 mmol L
-1. The 
inhibitory effect observed for compound II-1 is lower than that observed for 
[Au(dien)(dmap)]3+ and [Au(dien)(9-ethylguanine)]3+.39 Still, given the significant inhibitory 
effect observed for compound II-1, further chemical modifications can be achieved by 
replacement of the labile chloride ligands, opening up the possibility of fine tuning the 
inhibitory activity of this class of compounds based on the co-ligand.  
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Conclusions 
The present work described the unique behavior of compound [Au(bnpy)Cl2], an 
Au(C^N) compound, that was studied in comparison to the Au(N^N) motif. 
The bidentate coordination of bnpy in [Au(bnpy)Cl2] was shown to be stable in presence 
of Cys-containing biomolecules such as N-Ac-Cys and even GSH (as monitored by MS and 
NMR). The high stability towards reduction of the organometallic compound was further 
observed by cyclic voltammetry. NMR measurements indicated the replacement of the labile 
chlorides and confirmed the bidentate coordination of bnpy for up to 24 hours in presence N-
Ac-Cys  and GSH. A unique reactivity behavior was identified when [Au(bnpy)Cl2] was reacted 
with N-Ac-Cys and the reaction was followed by MS. The Au(III)-catalyzed C-S coupling 
product bnpy-N-Ac-Cys was formed. This unique reactivity was further explored targeting zinc 
finger proteins. For the HIV-1 protein NCp7 and the truncated model, zinc displacement was 
observed and the C-S coupling products were also identified.  
On the other hand, the Au(N^N) compounds II-2, II-3 and II-4 were shown to react 
much faster with the target ZnFs evaluated here, undergoing reduction even at t=0. Within the 
Au(N^N) series, [AuCl2(phen)]
+ had lowest reactivity with ZnFs as demonstrated by MS 
experiments.  
The unique mode of zinc displacement observed for the organometallic II-1 also 
translated into a relevant inhibition of the full-length NCp7 zinc finger interaction with the SL2 
model DNA, with no inhibitory effects observed for the Au(N^N) compounds.
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Appendix 
Crystal Structures 
 
Figure AII-1.1. Intermolecular contacts found in the structure of [AuCl2(bipy)][PF6], emphasizing A. 
contacts with the [PF6]- counterion and B. between [AuCl(bipy)]+ subunits. [Symmetry codes (i) = ½ – 
x, – ½ + y, ½ – z; (ii) = –x, 1 – y, – z; (iii) = 1 – x, 1 – y, –z ; (iv) = 1 + x, y, z; (v) = ½ – x, ½ + y, ½ – 
z; (vi) = –x, 1 – y, 1 – z] 
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Figure AII-1.2. Intermolecular anion-π interactions between [AuCl2(phen)]+ and [PF6]- subunits . The 
distance between the two centroids Cg2 ∙ ∙ ∙Cg3vii is too long to be considered a relevant π-interaction. 
[Symmetry codes (vii) ½ + x, y, ½ – z; viii = x, ½ – y, ½ + z; (ix) = – ½ + x, y, ½ – z] 
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F5viii
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Figure AII-1.3. A. Ellipsoid view (50% probability) of the asymmetric unit of compound [Au(bnpy)Cl2] 
B. Packing view along the a axis. C. Detailed view of the CH∙∙∙π interaction. D. Intermolecular 
interactions, highlighting the hydrophobic CH2∙∙∙Cl interaction between the CH2 bridge and Cl ligands 
and also the CH∙∙∙π interaction between the CH2 bridge and the π-density on the pyridine ring of the 
bnpy ligand. [Symmetry codes (x) = 1 + x, y, z; (xi) = 3/2 – x, ½ + y, ½ – z; (xii) = ½ – x, ½ + y, ½ – z] 
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Table AII-1.1. Crystallographic data and refinement parameters for compounds II-1, II-2 and II-4 
Parameters [Au(bnpy)Cl2] [AuCl2(bipy)]+ [AuCl2(phen)]+ 
Formula C12H10AuCl2N C10H8AuCl2N2PF6 C10H8AuCl2N2PF6 
Mr 436.08 569.02 593.04 
T/ K 150(2) 150(2) 150(2) 
    
Crystal system Monoclinic Monoclinic Orthorhombic 
Space group P21/n P21/n Pbca 
a/ Å 8.0827(12) 6.738(3) 12.9983(7) 
b/ Å 8.4639(12) 14.809(6) 15.2709(10) 
c/ Å 17.392(3) 14.728(6) 15.5153(10) 
β (o) 91.420(3) 100.605(10) 90 
V/ Å3 1189.4(3) 1444.5(11) 3079.7(3) 
Z 4 4 8 
ρcalc/ g·cm-3 2.435 2.616 2.558 
μ/ mm-1 12.786 10.726 10.068 
F000 808 1056 2208 
    
Radiation Mo Kα (λ = 0.71703 Å) 
2θ range/ o 4.69-54.79 3.93-56.56 4.88-56.56 
Reflections collected 9594 28635 15573 
Independent reflections 2675 3566 3822 
Rint, Rσ 0.0377, 0.0375 0.0329, 0.0186 0.0268, 0.0231 
Parameters, Restraints 145, 0 199, 0 217, 0 
S (on F2) 1.161 1.020 1.007 
R1,wR2 [I ≥ 2σ (I)] 0.0382, 0.0749 0.0154, 0.0327 0.0190, 0.0381 
R1, wR2 (all data) 0.0488, 0.0777 0.0186, 0.0336 0.0273, 0.0399 
Δρmax/Δρmin/e·Å-3 2.30/ -2.33 1.31/ -0.70 1.08/ -0.56  
  
Part II – Appendix 1 | 142 
 
 
Nuclear Magnetic Resonance 
 
Figure AII-1.4. A. 1H NMR, B. 13C NMR, C. {1H, 1H}COSY and D. {1H,13C} HMBC of [Au(bnpy)Cl2]. 
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Table AII-1.2. 13C assignments based on {1H,13C} correlations identified by HSQC and HMBC NMR.   
δ 13C   1H correlation Assignment 
 HSQC HMBC  
46.56 - 7.25 (dd), 7.99 (dd)  CH2 
124.98 7.71 (ddd) 9.17 (dd), 7.25 (dd) 4’ 
126.89 7.99 (dd) 4.48 (CH2), 7.71 (dt) 8.26 (dt) 3’ 
127.42 7.07 (dt) 7.25 (dd) 4 
128.45 7.19 (dt) 7.42 (dd) 5 
129.11 7.25 (dd) 4.48 (CH2), 7.07 (dt) 3 
132.44 - 4.48 (CH2), 7.42 (dd) 2’ 
133.20 7.42 (dd) - 6 
141.56 - 7.42 (dd), 7.25 (dd), 7.18 (dt), 7.07 (dt), 4.48 (CH2) 2 
143.76 8.27 (dt) 9.17 (dd) 5’ 
152.56 9.17 (dd) 8.27 (dt) 7.71 (dt) 6’ 
156.16 - 9.17 (dd), 8.27 (dt), 7.99 (dd), 4.48 (CH2) 1’ 
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Figure AII-1.5. (1) 1H NMR of complex [Au(bnpy)Cl2] freshly dissolved in dmso-d6 and spectra 
obtained (2) 24 hours and (3) 48 hours after dissolution. The spectrum of the free ligand bnpy is shown 
in (4) for comparison. 
 
Figure AII-1.6. 1H NMR following the Cl replacement by dmso-d6 in the complex [AuCl2(bipy)]PF6. 
(1) Spectrum obtained for a freshly dissolved sample and (2) 24 hours after dissolution. Three 
populations were identified, [AuCl2(bipy)]+ (∎), [AuCl(bipy)(dmso)]2+ (○) and [Au(bipy)(dmso-d6)2]3+ 
(●). 
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Figure AII-1.7. 1H NMR following the Cl replacement by dmso-d6 in the complex [AuCl2(dmbipy)]PF6. 
(1) Spectrum obtained for a freshly dissolved sample and (2) 24 hours after dissolution. Two populations 
were identified, [AuCl2(dmbipy)]+ (∎) and a chloride replacement product (●). 
 
 
Figure AII-1.8. 1H NMR following the Cl replacement by dmso-d6 in the complex [AuCl2(phen)]PF6. 
(1) Spectrum obtained for a freshly dissolved sample and (2) 72 hours after dissolution. Two populations 
were identified, [AuCl2(phen)]+ (∎) and a chloride replacement product (most likely       
[Au(phen)(dmso-d6)2]3+, marked as ●). 
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Figure AII-1.9. {1H, 15 N}HMBC spectrum of of compounds. A. [Au(bnpy)Cl2], B. [AuCl2(2,2’-bipy)]+, 
C. [AuCl2(dmbipy)]+ and D. [AuCl2(phen)]+ obtained using samples with natural abundance of 15N. 
 
 
Cyclic Voltammetry 
 
Figure AII-1.10. A. CV profile of the organometallic compound II-1 in comparison to the free bnpy and 
B.  CV of[AuCl2(bipy)]+ in comparison to free bipy. 
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Interaction with model biomolecules 
 
Figure AII-1.11. 1H NMR spectra followed over time for the interaction of (1) [Au(bnpy)Cl2] with N-
Ac-Cys (2) immediately after incubation, (3) after 4 hours, (4) after 1 day and (5) after 4 days. The 1H 
NMR spectrum of free N-Ac-Cys is given (6) for comparison. 
 
 
Figure AII-1.12. MS spectrum obtained for the interaction between compound II-1 [Au(bnpy)Cl2] and 
N-Ac-Cys immediately after mixture. 
Part II – Appendix 1 | 148 
 
 
 
Figure AII-1.13. 1H NMR spectra followed over time for the interaction of (1) [Au(bnpy)Cl2] with GSH 
(2) immediately after incubation, (3) after 1 hour, (4) after 3 hours and (5) after 24 hours. The 1H NMR 
spectrum of GSH is given (5) for comparison. 
 
 
 
Figure AII-1.14. MS spectrum obtained for the interaction between compound II-1 [Au(bnpy)Cl2] and 
GSH. A. major and B. minor species identified. 
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Figure AII-1.15. 1H NMR spectra followed over time for the interaction of (1) [Au(bnpy)Cl2] with the 
dipeptide Gly-L-His (2) immediately after incubation, (3) after 3 hours and (4) after 24 hours. The 1H 
NMR spectrum of Gly-L-His is given (5) for comparison. Top: Full spectrum; bottom: detailed view of 
the aromatic region. Hydrogens H2 and H5 of the imidazole ring found on Gly-L-His are marked in 
mustard and cyan respectively. 
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Mass Spectrometry 
Interaction with NCp7 (ZnF2) 
 
 
(continues) 
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Figure AII-1.16. Mass spectra obtained for the interaction [Au(bnpy)Cl2] with NCp7 (ZnF2) A. 
immediately after mixing and (B-D) 24 hours after mixing, in different m/z regions. 
 
C
D
r160623r05 #1-50 RT: 0.00-0.36 AV: 50 NL: 2.82E5
T: FTMS + p NSI Full ms [151.00-2000.00]
1000 1020 1040 1060 1080 1100 1120 1140 1160 1180 1200
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
1040.0417
1105.3609
1004.6983
1033.3371
1058.0489
1049.0446
1023.3309
1013.9960
1079.0219
1095.7295 1161.0501
1061.6809
1144.34081110.69001067.6785
1195.52661131.1462 1172.79311151.3600
{Au(III)(bnpy)}3-F
3+
(bnpy)-oxiapoF2+
r160623r05 #1-50 RT: 0.00-0.36 AV: 50 NL: 3.46E4
T: FTMS + p NSI Full ms [151.00-2000.00]
1200 1220 1240 1260 1280 1300 1320 1340 1360 1380 1400
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
1378.0443
1308.9524
1340.4106
1294.0047
1391.5517
1226.3735
1363.60461259.4181 1326.4620
1205.1612 1269.50431241.4286
1220.5192
1313.4849
1250.4767 1345.35091276.1580
1374.1987
1287.5555
1382.4540
1335.9474
Au(III)(bnpy)-F2+
Au(I)2F
2+
Au(I)2ZnF
2+
A
u
(I
II
)(
b
n
p
y)
-Z
n
F2
+
Part II – Appendix 1 | 152 
 
 
 
Figure AII-1.17. Mass spectrum obtained for the interaction of [AuCl2(bipy)]+ with NCp7 (ZnF2) 
immediately after mixing. 
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Figure AII-1.18.  Mass spectrum obtained for the interaction of [AuCl2(dmbipy)]+ with NCp7 (ZnF2) 
immediately after mixing. 
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Figure AII-1.19. Mass spectra obtained for the interaction of [AuCl2(phen)]+ with NCp7 (ZnF2) A. 
immediately and B. 48 hours after mixing. 
  
r160621r03 #1-50 RT: 0.00-0.36 AV: 50 NL: 5.31E5
T: FTMS + p NSI Full ms [255.00-2000.00]
520 540 560 580 600 620 640 660 680 700
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
653.3839
556.2424
612.2368 663.4484
526.2568
635.5617
627.9667605.2330
511.2824 621.2141536.0470 672.0339
562.7432
601.4764576.4064551.9855 698.6232
568.4903
685.4303
519.3612
647.7557547.3556
oxiF4+
A
u
F4
+
A
u
-Z
n
F4
+
r160623r07 #1-50 RT: 0.00-0.36 AV: 50 NL: 3.35E5
T: FTMS + p NSI Full ms [151.00-2000.00]
600 620 640 660 680 700 720 740 760 780
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
654.9766
672.0333
637.2997
663.4478
612.2365
647.7552
605.4839
620.4315
708.4828689.5235
675.0318
752.5088
741.6558
696.7447
624.1738
729.9936 780.8942757.6498
712.0086
705.3115
722.2832
784.4809
AuF4+
Au2F
4+
A
B
Part II – Appendix 1 | 155 
 
 
Interaction with the full-length NCp7 ZnF 
 
 
Figure AII-1.20. Mass spectrum obtained for the interaction of the organometallic compound 
[Au(bnpy)Cl2] with the full-length NCp7 ZnF 48 hours after interaction. 
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Introduction 
The success of antitumor Pt(II) compounds directs the scientific interest toward the 
isoelectronic Au(III) for the synthesis of therapeutic agents.40 Although Au(III) is not very 
stable under biological conditions due to its proneness to reduction and fast ligand exchange 
rates, many recent Au(III)-containing compounds have been rationally designed by tailoring 
the ligands to stabilize Au(III), overcoming those limitations and still demonstrating relevant 
antitumor activities in vitro.141–143  
The Au(III) compounds evaluated so far as ZnF inhibitors often undergo reduction to 
Au(I) with loss of all ligands and concomitant electrophilic attack on the Zn-bound residues, 
resulting in zinc displacement.54,144 In the case of Au(III), it is commonly accepted that 
oxidation state of incorporated gold from a variety of complexes in {AuF} is +1, thus 
implicating concomitant oxidation of the peptide core. The use of N-donors, such as chelating 
ligands, nucleobases or simple planar amines in gold compounds have been suggested as 
potential stabilizers for the Au(III) oxidation state, even in the presence of peptides with high 
cysteine content such as ZnF. Farrell and co-workers developed a series of Au(III) compounds 
with tridentate diethylenetriamine, dien (NH2CH2CH2NHCH2CH2NH2, N^N^N coordination) 
where the fourth coordination site is occupied by a Cl-, pyridine derivatives or nucleobases.38,145 
Significative changes in the reactivity with ZnFs was observed for the [Au(III)(dien)L]n+ motif 
depending on the nature of the ligand L.  
However, the structural details of the products formed by the interaction of those Au(III) 
complexes with ZnFs after zinc displacement are currently lacking, hindering a mechanistic 
description of the Zn displacement process. This information is fundamental for designing new 
compounds with better stability and specificity towards inhibition of the HIV-1 ZnF protein 
and also to obtain insights on the mechanism of inhibition. For that purpose, XAS represents a 
powerful technique for probing the oxidation state and coordination sphere of Au-containing 
species in solution. In addition, in the context of the interaction of metallodrugs with a 
metalloprotein, XAS can be used in a “dual-probe” approach, by monitoring both the absorption 
edge of the metal complex and also the edge of the metal present in the metalloprotein. As a 
proof-of-concept, we evaluated the interaction of Au(III) complexes with ZnFs by monitoring 
the Au L3-edge and also the Zn K-edge. Furthermore, given the unique stability and reactivity 
of the Au(C^N) coordination motif discussed in Part II-Chapter1, the interaction of the 
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compound [Au(bnpy)Cl2] with ZnFs was also studied by XAS. Figure II-2.1 shows the Au(III) 
complexes evaluated here, along with the structures of the ZnF targets.  
 
Figure II-2.1. Structural formulas of Au(III) compounds selected for this study. The zinc finger model 
peptides full-length NCp7 (F2 boxed) and Sp1 are also shown. 
 
Experimental 
Synthesis and zinc finger preparation 
H[AuCl4] was acquired from Sigma-Aldrich and used without further purification. Complexes 
II-1, II-3, II-5 and II-6 were synthesized and purified according to published 
procedures.38,130,131,145 Characterization of the synthesized compounds was performed by 
conventional spectroscopic techniques including 1H, 13C, 31P NMR spectroscopy, mass 
spectrometry, elemental analysis, and infrared and UV spectroscopies, attesting the success of 
the synthetical procedures. 
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The zinc finger models used in this study were: HIV-1 nucleocapsid protein ZnF2 and “full” 
zinc finger (ZnF1 + ZnF2) and the human transcription factor Sp1 ZnF3. NCp7 ZnF2 and Sp1 
ZnF3 were purchased from Aminotech Co. (São Paulo, Brazil), the full-length NCp7 ZnF was 
acquired from Invitrogen (USA). The apopeptides were checked by mass spectrometry and used 
as received. Both zinc fingers were prepared by dissolving sufficient mass of apopeptides in a 
100 mmol L-1 solution of zinc acetate prepared in degassed water. The pH was adjusted to 
7.2~7.4 using NH4OH or HOAc if needed, leading to a solution with final concentration of 30 
mmol L-1 of zinc finger. Sequences: 
        10         20         30         40         50 
NCp7 ZnF2 KGCWKCGKEG HQMKNCTER 
full-length NCp7 MQRGNFRNQR KNVKCFNCGK EGHTARNCRA PRKKGCWKCG KEGHQMKDCT ERQAN 
Sp1 ZnF3 KKFACPECPK RFMSDHLSKH IKTHQNKK  
 
Sample Preparation 
Gold L3-edge XAS measurements of the compound H[AuCl4] were performed in solid state at 
XAFS1 beamline. The compounds [Au(bnpy)Cl2] (II-1) and [AuCl2(dmbipy)]
+ (II-3) were 
measured as solids at the XAFS 2 beamline. The solid samples used in the XAS measurements 
were finely grounded and diluted in boron nitride to a maximum X-ray absorbance of about 1. 
The homogeneous powder was then pressed into circular pellets of 13 mm diameter using a 
hydraulic press, placed in a plastic sample holder and covered with polyimide adhesive tape 
(Kapton) with about 40 μm thickness.  
The complexes II-5 and II-6, the isolated zinc fingers and the respective interaction products 
were measured in solution at the XAFS2 beamline.69 For the interaction with ZnFs, stock 
solutions of II-1, II-5 and II-6 were prepared by dissolving the solid compounds in 
dimethylformamide (dmf) to a final concentration of 100 mmol L-1. For evaluating the 
interaction of the model compounds with the zinc fingers, a total sample volume of 10 µL (30 
mmol L-1) was prepared by mixing sufficient volumes of the stock solutions of the Au(III) 
compounds II-1, II-5 and II-6 with stocks of the corresponding zinc finger in a molar ratio of 
1:1. The interaction of compound II-1 with N-acetyl-L-cysteine was also followed by XAS. 
For that purpose, a stock of II-1 (83.3 mmol L-1 in dmso) was mixed with the proper amount of 
a stock of N-Ac-Cys (500 mmol L-1 in dmso) for a final sample concentration of 70 mmol L-1. 
In each XAS measurement of the samples in solution, about 3 µL of the prepared solutions of 
the zinc fingers, Au(III) complexes in dmf or interaction products were placed in a plastic 
sample holder, covered with the same 40 μm thick Kapton adhesive and frozen in a closed-
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cycle liquid helium cryostat. The solution samples were kept below 50 K throughout the 
measurements.  
Zinc K-edge XAS were also collected for the isolated zinc fingers and the interaction products 
of compound II-5 and II-6 with NCp7(ZnF2) and Sp1 (ZnF3). As comparison, the Zn K-edge 
XAS spectrum of the interaction of [AuCl(Et3P)] with NCp7 (ZnF2) was also acquired. Zinc 
K-edge XAS was recorded in fluorescence mode at XAFS2 beamline using the same 15-
element Ge solid-state detector and setting an integrating window of about 170 eV around the 
Zn Kα1 and Kα2 emission lines (8637.2 eV and 8614.1 eV, respectively). In the Zn K-edge XAS 
experiments the incoming energy was calibrated by setting the absorption edge of a Zn foil to 
9659 eV. 
Inspection of fast XANES scans revealed no signs of radiation damage for both Au L3-edge 
and Zn K-edge measurements, and the first and last scans of each data set used in the averages 
were identical. Data averaging, background subtraction and normalization were done using 
standard procedures using the ATHENA package.70  
 
XAFS1 and XAFS2 beamlines 
Both beamlines are located at the Brazilian Synchrotron Light Laboratory (CNPEM/LNLS).69,71 
At the XAFS1 beamline the incident energy was selected by a channel-cut monochromator 
equipped with a Si(111) crystal, and at the XAFS2 beamline a double-crystal, fixed-exit 
monochromator was used. The beam size at the sample was approximately 2.5 x 0.5 mm2 
(horizontal x vertical) at XAFS1 and 0.4 x 0.4 mm2 at XAFS2, with an estimated X-ray flux of 
108 ph/sec (XAFS1) and 109 ph/sec (XAFS2). The incoming X-ray energy was calibrated by 
setting the maximum of the first derivative of L3-edge of a gold metal foil to 11919 eV. At 
XAFS1, XAS spectra were collected in conventional transmission mode using ion chambers 
filled with a mixture of He and N2 while at XAFS2 fluorescence mode detection was used. The 
fluorescence signal was recorded using a 15-element Ge solid-state detector (model GL0055S 
– Canberra Inc.) by setting an integrating window of about 170 eV around the Au Lα1 and Lα2 
emission lines (9713.3 eV and 9628.0 eV, respectively).  
 
TD-DFT 
TD-DFT calculations of the Au L3-edges of compounds [AuCl(dien)]
2+ and [Au(dien)(dmap)]3+ 
were used to make sure our protocol could reproduce the trends in energy shifts and intensities 
observed experimentally. TD-DFT-calculated L3-edges have an overall good agreement with 
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our experimental data, as shown in Figure AII-2.2. All calculations were performed using the 
ORCA quantum chemistry code, version 3.0.3.72 All molecules were optimized at the 
PBE0/def2-TZVP level of theory using the def2-ECP effective core potential.73 TD-DFT 
calculations (using the Tamm-Dancoff approximation)74 as implemented in ORCA were 
performed with the PBE075–77 functional using an all-electron scalar relativistic Douglas-Kroll-
Hess Hamiltonian78–80 with the DKH-def2-TZVP-SARC basis set.81 The Au 2p to valence 
excitations were performed by only allowing excitations from the Au 2p donor orbitals to all 
possible virtual orbitals of the molecule (only limited by the number of calculated roots). 
Intensities include electric dipole, magnetic dipole and quadrupole contributions. The 
RIJCOSX approximation82,83 was used to speed up the Coulomb and Exchange integrals in both 
geometry optimizations and TD-DFT calculations.  
Mass Spectrometry 
A stock solution of the [Au(dien)(dmap)]3+ in acetonitrile was mixed with a stock solution of 
the full-length NCp7 ZnF in water (1:1 mol/mol of Au complex per ZnF core). The pH final 
solution was adjusted to 7.2 with NH4OH. leading to a solution containing the interaction 
product in a 1 mmol L-1 concentration, which was incubated for up to 24 h at room temperature. 
MS experiments were carried out on an Orbitrap Velos from Thermo Electron Corporation 
operated in positive mode. Samples (25 μL) were diluted with methanol (225 μL) and directly 
infused at a flow rate of 0.7 μL/min using a source voltage of 2.30 kV. The source temperature 
was maintained at 230 °C throughout the experiment.  
 
Results and Discussion 
The Au(III) compounds [AuCl4]
-, [Au(bnpy)Cl2] (II-1), [AuCl2(dmbipy)]
+ (II-3),  
[AuCl(dien)]2+ (II-5) and [Au(dien)(dmap)]3+ (II-6) were selected as experimental models. 
XAS was used to evaluate the interaction of II-1, II-5 and II-6 with NCp7 (ZnF2). Compounds 
II-5 and II-6 evaluated when interacting with Sp1 (ZnF3). 
A detailed analysis of the XAS spectra of compounds is given in Part II – Appendix 2, 
including a summary of the spectroscopic features observed for each compound (Figure AII-
2.1, Table AII-2.1). Figure AII-2.2 shows the TD-DFT spectra obtained for compounds II-5 
and II-6. It is important to note that the reaction products discussed here were obtained and 
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immediately frozen for the spectroscopic measurements (unless otherwise stated). Therefore 
the spectra obtained and discussed in this chapter represent a snapshot of the species that appear 
at the very beginning of the reactions evaluated. 
Au L3-edge: the Au(C^N) vs the Au(N^N) motif 
XAS has the major advantage of being sensitive to both the vicinity (nature of the 
ligands) and the oxidation state of the metal center. The interaction of the organometallic 
compound [Au(bnpy)Cl2] with NCp7 ZnF2 was studied in comparison to [AuCl2(dmbipy)]
+  by 
XAS. When comparing the spectra obtained for the two model compounds, it becomes clear 
that the N^N bidentate ligand leads to a Au L3-edge spectrum that better resembles that of the 
spectra discussed in the previous sub-session for [Au(dien)L]n complexes, with a strong white 
line peak (normalized intensity of ~1.2 a.u.). On the other hand, the organometallic compound 
[Au(bnpy)Cl2] had a much weaker white line signal, indicating fewer d holes as consequence 
of deprotonated bnpy acting as a better electron donor than dmbipy.  
The interactions of compound [Au(bnpy)Cl2] with the model S-donor N-Ac-Cys and 
with NCp7 (ZnF2) were also studied by XAS. Interestingly, two different behaviors were 
observed.  
An increase in intensity of the white line is observed for the interaction 
[Au(bnpy)Cl2]+N-Ac-Cys. That observation alone is a strong evidence that a ligand 
replacement reaction took place, with one of the chlorides found in the organometallic 
compound being replaced by N-Ac-Cys. The thiolate has stronger donating properties when 
compared to chloride, which explains the increase in intensity observed here. 
On the other hand, a prominent decrease of the white line intensity was observed for the 
interaction [Au(bnpy)Cl2]+NCp7 (ZnF2). The L3-edge spectrum obtained here resembles, but 
is not identical to, the theoretical model Cys-Au(I)-His (see Part I – Chapter 3, Figure I-3.3).  
The similarity between the Au-L3 XANES spectrum obtained for II-1+NCp7 and the TD-DFT 
calculated spectrum of theoretical model T-4 support the hypothesis that, after the reductive 
elimination step that leads to the C-S coupling (see Scheme II-1.1, Part II – Chapter I), Au(I) 
stays coordinated to the pyridine ring found in the bnpy moiety. Despite the difference in the 
ring size, a pyridine (from bnpy) or a His residue coordinated to Au(I) are expected to have 
similar XANES spectra. 
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Figure II-2.2. A. XANES spectrum of compound II-1 and interactions with NCp7 and model S-donor 
N-Ac-Cys. A selected typical Au(N^N) compound (II-3) is also shown for comparison. B. expansion 
around the white line.  
 
Au L3-edge:  reactions of Au(N^N^N) complex with ZnF proteins 
The XANES spectra of the Au(III) model compounds II-5 and II-6 are presented in 
Figure II-2.3, together with the reaction products formed after their interaction with NCp7 and 
Sp1 zinc fingers. As expected for Au(III) compounds, these spectra contain a strong absorption 
in the white line region as a consequence of empty Au d orbitals promoting the allowed 2p3/2 
→ 5d transitions in the L3-edge XAS. Compounds II-2 and II-3 have a white line peak located 
at about 11921 eV with a normalized peak intensity of about 1.2 units.  
NCp7. The interaction product II-5+NCp7 presents a white line of low intensity, similar 
to that expected for the previously examined Au(I) compounds or an even more reduced gold 
species, thus suggesting that a reduction of Au(III) took place upon the interaction of II-5 with 
NCp7. Structurally, II-5+NCp7 differs from the pure compound [AuCl(dien)]2+, as evidenced 
by both the XANES (Figure II-2.3A) and EXAFS (Figure AII-2.3).The XANES of product II-
5+NCp7 closely resembles that of model compound M-5 from Part I – Chapter 3 (coordination 
sphere model shown in Figure AII-2.4), presenting a rather weak white line peak, a pronounced 
post-edge feature at around 11930 eV and another broad one at 11940-11985 eV (Figure II-
2.3A). Moreover, the k2-weighted EXAFS spectra of II-5+NCp7 and that of model compound 
M-5 are virtually superimposable up to k=10 Å-1, indicating that both contain a similar 
environment around the gold atom, i.e., linear S-Au-S coordination with a similar Au-S distance 
of about 2.30 Å (Figure AII-2.3). This corroborates the hypothesis that upon reaction with 
NCp7, [AuCl(dien)]2+ looses all its ligands and undergoes Au(III) → Au(I) reduction, leading 
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to the formation of gold finger in a Cys-Au(I)-Cys linear geometry, the same coordination 
sphere observed for other Au-protein adducts reported elsewhere.99,146 Additionally, it also 
agrees with previous mass spectrometry studies showing the formation of only gold finger 
(without ligands) when [AuCl(dien)]2+ interacts with NCp7.144,145  
 
Figure II-2.3. Gold L3-edge XANES spectra of A. compound II-5 ([AuCl(dien)2+]) and its respective 
reaction products with NCp7 and Sp1 (red and blue, respectively), B. compound II-6 
([Au(dien)(dmap)]3+) and its respective reaction products with NCp7 and Sp1 (red and blue, 
respectively). The spectrum of model compound [Au(N-Ac-Cys)] (M-5) is also shown (gray dashed 
line) for comparison. C and D. TD-DFT-calculated XANES spectra of the Au(III) compounds II-5 and 
II-6 together with the theoretical models for the coordination sphere of the products obtained upon 
interaction of Au(III) complexes with NCp7 (theoretical models Cys-Au(I)-Cys (T-2) and His-Au(I)-
Cys (T-4)) and Sp1 (theoretical models His-Au(I)-His (T-3), dien-Au(III)-Cys (T-5), dien-Au(III)-His 
(T-6) and Au(III)-Cys2-His2 (T-7)). The optimized structures of the Au(III) theoretical models are 
shown in Figure II-2.4. The energy shift of 465 eV was applied to the calculated spectra. 
 
In contrast, the spectra of reaction product II-6+NCp7 (Figure II-2.3B) resembles that 
of its precursor, [Au(dien)(dmap)]3+, with only a slight increase in the white line intensity. 
Additionally, despite the relatively low quality, the EXAFS data overlaps up to k=8 Å-1, which 
is sufficient to conclude that they have identical first coordination shell around the gold (Figure 
AII-2.5). These results indicate that the Au(III) in [Au(dien)(dmap)]3+ remains mostly 
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unreacted upon interaction with NCp7, on contrary to what is observed in the case of II-5. This 
is in agreement with MS data reported previously, which shows zinc displacement (apopeptide 
signal) and signals of [Au(dien)dmap]3+. Thus, to some extent, Au(III) redox stability was 
achieved, even in the presence of the rich Cys content of NCp7, by modulating the first 
coordination sphere of Au(III)-dien complex. However, the observed changes in the white line 
intensity indicate different degrees of reduction after interaction of II-5 and II-6 with NCp7 
(Figure AII-2.6). In the case of II-5+NCp7, the pronounced diminishing of the white line points 
to a more reduced gold metal center when compared to II-6+NCp7.  
Sp1. II-5+Sp1 and II-6+Sp1 still present a well-defined white line peak and the 
obtained XANES spectra are identical, with the white line peak shifting slightly to higher 
energies (about 1.4 eV) and reducing its intensity to about 1.0 normalized units, suggesting a 
change in oxidation state. 
TD-DFT. TD-DFT-calculated L-edge spectra of different models were again 
fundamental in revealing the nature of the interaction products. Figure II-2.3C and D shows the 
TD-DFT spectra of compounds [Au(N-Ac-Cys)] (M-5 from Part I – Chapter 3), II-5, II-6 and 
theoretical models for II-5+NCp7, II-6+NCp7, II-5+Sp1 and II-6+Sp1. The DFT-optimized 
structures of the theoretical Au(III) models, supplementing the already considered Au(I) models 
(Part I - Chapter 3, Figure I-3.3) are presented in Figure II-2.4 (T-5: (dien)Au(III)-Cys, T-6: 
(dien)Au(III)-His and T-7: Cys2-Au(III)-His2).  
 
Figure II-2.4. A. DFT optimized structures of the theoretical Au(III) models proposed for the reaction 
products of II-5 and II-6 with the ZnF proteins. Cys was modeled as N-Ac-L-Cys and His residues were 
modeled as 5-methylimidazole or imidazole. B. TD-DFT-calculated spectra of the theoretical Au(III) 
models. 
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The products II-5+Sp1 and II-6+Sp1 have almost identical XAS spectra, pointing to 
the formation of identical species (Figure II-2.3B and Figure AII-2.6). Figure AII-2.1 shows 
that these species are, however, different from the purified gold finger, II-5+Sp1(AuF).  
The EXAFS spectra of these two reaction products with Sp1 presented rather poor 
quality, which prevented a complete structural analysis. This was due to the limited achievable 
concentration and sample quantity, which was more critical for II-6+Sp1. Reaction products 
II-5+Sp1 and II-6+Sp1 show experimentally a reduction in white line peak intensity and a 
slight energy shift and appear to result in identical products. For comparison with the 
experimental spectra obtained for II-5+Sp1 and II-6+Sp1, the theoretical models T-3 (from 
Part I – Chapter 3) and T-5 to T-7 were considered. The Au(III) theoretical models do not 
reproduce the experimental trends observed. For (dien)Au(III)-His (T-6), a white line with 
higher intensity than observed for compounds II-5 and II-6 was obtained. The calculated 
spectrum of model (dien)Au(III)-Cys (T-5) shows a rather small reduction in the peak intensity, 
inconsistent with the ca. 20% reduction observed experimentally. The spectrum of the 
theoretical model Cys2-Au(III)-His2 (T-7) reproduces the observed reduction in intensity. 
However it does not account for the energy shift observed experimentally, which is likely a 
result of Au(III) → Au(I) reduction. The His-Au(I)-His model assumes that the two Cys 
residues in the Sp1 zinc finger are oxidized to form a disulfide bond and this electronic transfer 
reduces Au(III) to Au(I), resulting in ligand loss and binding to the two remaining His residues 
to Au(I). The calculated XANES spectrum for theoretical model T-3 accounts for both intensity 
reduction with respect to the original compounds II-5 and II-6, and the correct energy shift in 
the white line peak. Moreover, the second feature at about 11928 eV is also present in the 
experimental XAS data of II-5+Sp1 and II-6+Sp1, being slightly broader.  
For II-5+NCp7, the TD-DFT calculations show that both theoretical models Cys-Au(I)-
Cys (theoretical model T-2 from Part I – Chapter 3) and His-Au(I)-Cys (T-4, also from Part I 
– Chapter 3) reproduce the general behavior observed experimentally, i.e., a diminishing of the 
white line intensity and an energy shift of about 1.7 eV in the peak position when compared to 
the spectrum of intact [AuCl(dien)]2+. Both theoretical models indicate that loss of all ligands, 
Au(III) → Au(I) reduction and coordination to either two cysteine residues or one cysteine and 
one histidine have occurred upon interaction of [AuCl(dien)]2+ with NCp7. As discussed for II-
5+Sp1 and II-6+Sp1, if the Au(III) center is reduced, it is likely that two Cys residues will form 
a disulfide bond (which gives off 2 electrons, reducing Au(III) to Au(I)). In the NCp7 case, the 
two remaining residues are one Cys and one His, suggesting that His-Au(I)-Cys is the most 
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likely model. In fact, the calculated spectrum of the His-Au(I)-Cys model gives a slightly higher 
white line peak intensity than compound [Au(N-Ac-Cys)] (M-5), which is consistent with the 
experimental observation of II-5+NCp7 having slightly higher intensity than compound [Au(N-
Ac-Cys)].  
Compound II-6 differs from the other Au(III) model compounds in the sense that it 
retains its oxidation state and the square-planar geometry upon interaction with NCp7. 
Moreover, MS studies show that the Zn(II) ion is indeed ejected in the interaction product II-
6+NCp7.145 This result suggests two possibilities: one is the non-covalent interaction between 
[Au(dien)(dmap)]3+ and NCp7, with II-6 behaving as the class of ZnF inhibitors proposed by 
Garg and Torbett,12 with a mechanism of zinc displacement other than the electrophilic attack 
observed for most Au(I,III) compounds. Since [Au(dien)(dmap)]3+ is a potent π-stacker (as 
indicated by tryptophan fluorescence quenching), we can hypothesize that compound II-6 may 
disrupt the structure of the target ZnF, causing zinc displacement by π-stacking with neighbor 
aromatic residues (Phe16 and Try37). We were also able to identify the non-covalent adduct 
between compound II-6 with the dinuclear NCp7 complete ZnF by MS (Figure AII-2.7), further 
supporting the importance of an initially π-stacked species in the recognition of 
[Au(dien)(dmap)]3+ by NCp7. The second hypothesis is the selective electrophilic attack on the 
histidine residue followed by replacement of the dmap ligand and maintenance of the (dien)Au-
N coordination sphere. The possible mechanisms of zinc displacement caused by compound II-
6 are shown in Scheme II-2.1.  
We recently demonstrated that [Au(dien)(9-ethylguanine)]3+, an analog of compound 
II-6 where dmap is replaced by the nucleobase 9-ethylguanige, is capable of binding to NCp7 
dinuclear “full” zinc finger as demonstrated by MS and circular dichroism, with zinc 
displacement and gold incorporation into the protein structure with loss of all ligands.39 
[Au(dien)(9-ethylguanine)]3+ is also capable of inhibiting the interaction of the full-length 
NCp7 zinc finger with a small model for its natural substrate, SL2 RNA. The inhibition was 
demonstrated by MS, gel shift assay and fluorescence polarization, all of which show the release 
of SL2 DNA from the full-length NCp7 zinc finger once the system is treated with the Au(III) 
compound. Here we demonstrated that compound II-6 was even more redox stable than 
[Au(dien)(9-ethylguanine)]3+, and our previous MS works145 also indicate that II-6 remains 
stable after interaction with NCp7 (ZnF2), with no signs of AuF being formed. Furthermore, 
compound II-6 was also assayed as an inhibitor of the full-length NCp7 ZnF – SL2 RNA 
interaction by fluorescence polarization and was shown to be a potent inhibitor (IC50 = 29 μmol 
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L-1). Combined with the XAS data discussed in this paper, the unique behavior of II-6 points 
towards Zn displacement and inhibition of full-length NCp7 ZnF – SL2 RNA interaction based 
on a non-covalent mechanism. 
 
 
Scheme II-2.1. Proposed mechanisms of Zn(II) displacement caused by [Au(dien)Cl]2+ (II-5) and 
[Au(dien)(dmap)]3+ (II-6) upon interaction with NCp7 and Sp1. The final coordination sphere of Au is 
highlighted in each case. 
 
Comparing the final species formed for interaction of Au(III) compound (Scheme II-
2.1) with those formed by reacting Au(I) compounds (Part I – Chapter 3, Scheme I-3.1) with 
the selected ZnF protein, it is possible to observe that they are not the same. Reduction vs. 
oxidation is a hot topic in Au chemistry and it has been studied extensively by van Eldilk.147,148 
In general, for Au(III) complexes reduction is really fast, to the point that ligand replacement 
cannot be observed experimentally. On the other hand, with the proper ligands (chelators, strong 
σ-donors), the redox process can be slowed down and ligand replacement will start to be 
relevant. For the Au(III) compounds studied here (II-5 and II-6), the fact that the final 
interaction products with NCp7 and Sp1 are not the same observed for the Au(I) compounds is 
indicative of an important ligand-replacement step. Furthermore, the harder Lewis acid 
character of Au(III) vs. Au(I) can play an important role in the His selectivity observed for 
Au(III) compounds. 
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Zinc K-edge 
The zinc K-edge XAS can be a powerful tool to get insights about the mechanism of 
zinc displacement from ZnFs, as differences in geometry and coordination sphere arise as 
consequence of the interaction with Zn ejectors, including the gold complexes evaluated here. 
K-edge EXAFS has been previously used to structurally characterize zinc finger binding sites 
in NCp7.149 The Zn K-edge XANES of the free zinc finger proteins NCp7 and Sp1 are shown 
in Figure II-2.5, together with those from the reaction products obtained from the interaction 
with the Au(I) and Au(III) model compounds [AuCl(Et3P)] (I-1, from Part I – Chapter 3), II-5 
and II-6, respectively. In the case of Au(I), only data of the reaction with [AuCl(Et3P)]+NCp7 
was acquired. In all cases, the EXAFS data quality does not allow a complete structural 
determination of the ejected zinc species.  
 
Figure II-2.5. Zinc K-edge XANES spectra of the pure NCp7 (ZnF2) and Sp1 (ZnF3) proteins, and the 
interaction products with Au(I) compound [AuCl(Et3P)] and Au(III) compounds 2 and 3. 
 
 A correlation between white line intensity and the coordination number of zinc in a 
metalloprotein is well documented: the white line intensity increases with the coordination 
Zn foil
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number.150,151 Furthermore,  it has been noted that the presence of Cys residues in the first 
coordination sphere of Zn diminishes the intensity of the white line, while the presence of 
carboxylate ligands such as Glu and Asp lead to an increase in intensity.151 A theoretical and 
experimental trend was established by Ginchini et al.150, which says that white line intensities 
< 1.5 correspond to coordination numbers of 3 and 4, while a white line intensity of 1.6 and 
higher correspond to coordination numbers of 5 and 6.  
Comparing our data to coordination number and donor atoms trends described above, 
we can see that the white line intensity of Sp1 (ZnF3) is indeed slightly higher than that of 
NCp7 (ZnF2), as consequence of the lower Cys count present in the coordination sphere of 
Zn(II) in Sp1. As for the interaction products, we can see that all Au+ZnF products led to a Zn 
K-edge white line intensity of 1.6, while the free ZnFs have white line intensities of 1.4 or 
lower. This increase suggests an expansion of the coordination number of zinc upon interaction 
with the target protein. Regarding the first coordination sphere of Zn after interaction with the 
ZnFs, we can see two different behaviors depending of the oxidation state of the Au complexes 
tested. Au(III) complexes led to spectra with two features in the XANES region, while the Au(I) 
complex [AuCl(Et3P)] led to a spectrum with a broad and slightly more intense signal in the 
near-edge region. That is a clear evidence that the coordination sphere in the final Zn species 
depends on the oxidation state of the Au compound. The higher intensity of the Zn K-edge 
white line peak found in the Au(I) case can be due to the presence of carboxylates, such as the 
residues Glu and Asp, in the coordination sphere of the final Zn species. 
Conclusions 
While the case of Au(I) compounds interacting with zinc fingers represents a relatively 
straightforward case of electrophilic attack of the zinc core, as discussed in Part I - Chapter 3, 
different mechanisms were clearly identified for Au(III) compounds when interacting with the 
ZnF proteins NCP7 and Sp1. Previous spectroscopic studies on the interaction of Au(III) 
complexes with ZnF proteins indicated final products being pure Au(I) species with loss of all 
ancillary ligands (dien, bipyridine and others). However, we have already observed different 
degrees of reduction of gold and maintenance of (most of) the coordination environment in 
some systems previously investigated.35,54,145 The XAS experiments, combined with TD-DFT 
calculations, confirm the ability to modulate the Au(III)-ZnF reaction by a suitable choice of 
ligands. Moreover, it is presented for the first time, structural-sensitive information on these 
reaction products.  
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Specifically, we showed that compound II-1 suffers different degrees of reduction when 
interacting with the model S-donor N-Ac-Cys or with NCp7. With N-Ac-Cys, the interaction 
product has Au(III) in a coordination sphere consistent with replacement of the chlorides by a 
better donor, thiolate. On the other hand, when interacting with NCp7 a mixed population of 
Au(I,III) was observed, possibly as consequence of reductive elimination step that leads to a C-
S coupling between the ligand bnpy and a Cys residue from the protein. 
Regarding the Au(dien) complexes, II-5 (AuClN3 coordination sphere) reacts promptly 
with NCp7 (Cys3His) and Sp1(Cys2His2) producing interaction products with different degrees 
of reduction in the gold site and different final geometries. The reduction in the white line 
intensity observed from the pure compound II-5, to the interaction II-5+Sp1 and finally II-
5+NCp7, reflects the respective decrease in the number of 5d empty orbitals in this series and 
thus an increased reduction in the gold center. The final compounds were found to change from 
square-planar to linear geometry, with Cys-Au-Cys and His-Au-His coordination in the case of 
interaction of II-5 with NCp7 and Sp1, respectively. In contrast, compound II-6 (AuN4 
coordination sphere) is found to initially maintain the oxidation state and coordination geometry 
after zinc displacement in NCp7, with a final (dien)Au-N, coordination sphere where the N-
donor is dmap or a histidine residue from the protein. To our knowledge, this is the first example 
of stabilization of a square-planar Au(III)-ligand moiety on a ZnF. It suggests an interaction 
relying on a mechanism other than a direct electrophilic attack as commonly observed in Au(I) 
compounds, with the initial gold species possibly being stacked with the tryptophan residue in 
NCp7. Furthermore, upon reaction with Sp1 compound II-6 undergoes a marked reduction of 
the Au center, resulting in a final product identical to II-5+Sp1, i.e., His-Au-His in linear 
geometry. This suggests that the probable mechanism for the integration of Sp1 with gold(III) 
compounds is the usual electrophilic attack to the cysteines, causing zinc displacement and 
followed by reduction of gold (possibly via oxidative disulfide bond formation). These 
differences allow specific ZnF targeting considering the ZnF core intrinsic reactivity and also 
the gold coordination sphere. The Zn K-edge XAS spectra of the free ZnFs confirmed the trend 
between higher white line intensities and lower Cys count in the coordination sphere of Zn. 
Regarding the interaction products, zinc displacement is confirmed for both Au(I) and Au(III) 
cases, with expansion of the coordination number from 4 in the free ZnFs to 5 or 6 upon 
interaction with the Au complexes. The coordination sphere of the displaced Zn species depends 
on the oxidation state of the Au. Further studies are still needed to provide a detailed picture of 
the structure of the final Zn(II) species. 
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Appendix 
XAS of Au(III) model compounds and TD-DFT calculations 
The spectra in Figure II-2.1 show distinguishing features in the white line region, which 
originate from dipole-allowed 2p3/2 → 5d transitions, containing both metal-centered 5d3/2 and 
5d5/2 final states.  
 
Figure AII-2.1. Gold L3 XANES spectra of the Au(III) complexes evaluated here. The spectrum 
obtained for a Au(0) foil is also shown and the vertical line indicates its edge position (19919 eV).  
The Au(III) compounds ([5d86s0] electronic configuration) have white line peaks with 
high intensity (Figure AII-2.1) in comparison to the Au(I) model compounds discussed earlier 
(Part I – Chapter 3, Figure AI-3.1), as consequence of empty d orbitals promoting the allowed 
2p3/2 → 5d transitions in the L3-edge XAS. In principle, the intensity of the white line can be 
used as a fingerprint of the d- electron count in these cases; however, in some cases the standard 
relationships between experimental Au L3-edge white line intensities and oxidation state does 
not hold.152 The XANES spectrum of compound [AuCl4]
- contains a sharp peak in the white 
line region and presents a distinct XANES spectrum when compared to compounds II-5 and 
II-6, [AuCl(dien)]2+ and [Au(dien)(dmap)]3+, respectively. Compounds II-5 and II-6 have their 
white line maxima shifted by 0.8 and 1.0 eV respectively, in comparison to compound    
[AuCl4]
-, indicating that the dien ligand has an oxidizing effect on the Au center (higher count 
of d holes on Au). That suggests a higher stability of the Au(III) species bound to chelating N- 
donor ligands, which directly translates into higher stability under biological reducing media. 
Au
[AuCl4]
-
II-5
II-6
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Point symmetry also contributes to the intensity of the white line in the gold L3 XAS. When 
coordinated, dien leads to non-centrosymmetric groups. The p-d hybridization is enhanced 
reducing the effective d electron count in gold, thus increasing the intensity of the white line.  
 
Figure AII-2.2. A. Experimental Au L3-edge spectra Au(III) compounds II-5 and II-6 in comparison to 
[AuCl4]-. B. TD-DFT-calculated Au L3-edge spectra, shifted by 465 eV to lower energies. The DFT-
optimized structures of teh experimental model compounds are also shown (bottom).  
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Table AII-2.1. Edge position, oxidation state and approximated site symmetry from studied compounds 
and gold(0) reference. 
Compound 
Edge position 
/ eV 
Oxid. 
St. 
Site Symmetry 
(around Au Atom) 
# Name 
II-1 [Au(bnpy)Cl2] 11918.9 3+ C1 
II-3 [AuCl2(dmbipy)]1+ 11918.5 3+ C2v 
 [AuCl4]- 11917.6 3+ D4h 
II-5 [AuCl(dien)]2+ 11918.1 3+ C2v 
II-6 [Au(dien)(dmap)]3+ 11918.5 3+ C2v 
Reaction Name 
Edge position 
/ eV 
Oxid. 
St. 
Coordination sphere 
II-1+NCp7 [Au(bnpy)Cl2] + NCp7 ZnF2 11919.7 1+ L-Au-L 
II-1+N-Ac-Cys [Au(bnpy)Cl2] + N-Ac-Cys 11919.9 3+ (bnpy- κ2C,N)-Au-S 
II-5+NCp7 [AuCl(dien)]2+ + NCp7 ZnF2 11919.7 1+ (Cys)S-Au-N(His) 
II-6+NCp7 [Au(dien)(dmap)]3+ + NCp7 ZnF2 11918.9 3+ (dien-κ3N,N’,N’’)-Au-N  
II-5+Sp1 [AuCl(dien)]2+ + Sp1 ZnF3 11919.2 1+ (His)N-Au-N(His) 
II-6+Sp1 [Au(dien)(dmap)]3+ + Sp1 ZnF3 11919.8 1+ (His)N-Au-N(His) 
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EXAFS 
 
 
Figure AII-2.3. Comparison of the k2-weighted EXAFS of model compound [Au(N-Ac-Cys)] (M-5), 
with coordination sphere S-Au-S, compound [AuCl(dien)]2+ (II-5) and the reaction product II-5+NCp7. 
 
 
 
Figure AII-2.4. A. The AuF obtained when interacting II-5+NCp7 is expected to have a similar S-Au-
S coordination as observed for the compound [Au(N-Ac-Cys)] (M-5). B. DFT-optimized structure of 
[Au(N-Ac-Cys)2], highlighting the Au-S distance of about 2.30 Å. 
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Figure AII-2.5. Comparison of the k2-weighted EXAFS of model compound [Au(dien)(dmap)]3+ and 
the reaction products II-6+NCp7 and II-6+Sp1. 
 
Figure AII-2.6. Experimental Au L3-edge spectra of A. II-5+Sp1 and II-6+Sp1 and C. II-5+NCp7 and 
II-6+NCp7. The near-edge regions are shown in B and D. 
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Mass Spectrometry 
 
 
Figure AII-2.7. Non-covalent adduct identified between compound II-6 ([Au(dien)(dmap)]3+ and the 
dinuclear full-length NCp7 ZnF. 
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